and ELI LILLY CANADA INC.
Plaintiff by Counterclaim
- and -
ELI LILLY AND COMPANY
and ELI LILLY CANADA INC.
Defendants by Counterclaim
SHIONOGI & CO. LTD.
Defendant by Counterclaim
REASONS FOR JUDGMENT AND JUDGMENT
 The plaintiffs in this action claim that their rights under eight Canadian patents were infringed when Apotex Inc. (Apotex) imported bulk cefaclor into Canada for use in the various Apo-cefaclor dosage forms they sold after January, 1997. The plaintiff Eli Lilly and Company (Lilly U.S.) is the owner of these eight patents. Eli Lilly Canada Inc. (Lilly Canada) is a wholly owned subsidiary of Lilly U.S. incorporated under the laws of Ontario and it alleges that it has rights under the patentee, which is contested by Apotex. These plaintiffs will collectively be referred to as “Lilly”.
 Lilly sold dosage forms of cefaclor in Canada under the registered name of Ceclor®. This medicine was put on the market in 1980.
 The following four patents, all filed on February 1, 1979, were issued to, and were continuously owned by, Lilly U.S. (the Lilly patents):
Letters Patent No. 1,133,007 (“the ‘007 Patent”), issued October 5, 1982,
expired October 5, 1999;
Letters Patent No. 1,146,536 (“the ‘536 Patent”), issued May 17, 1983, expired
May 17, 2000;
Letters Patent No. 1,133,468 (“the ‘468 Patent”), issued October 12, 1982,
expired October 12, 1999; and,
d. Canadian Letters Patent No. 1,150,725 (“the ‘725 Patent”), issued July 26, 1983, expired July 26, 2000.
The patents referred to in paras. b, c and d will collectively be referred to as “the Lilly process patents”.
 The other four relevant patents were issued to Shionogi & Co. Ltd., a Japanese pharmaceutical company, (Shionogi) on the dates indicated below:
Letters Patent No. 1,095,026 (“the ‘026 Patent”), issued February 3, 1981,
expired February 3, 1998;
Letters Patent No. 1,132,547 (“the ‘547 Patent”), issued September 28, 1982,
expired September 28, 1999;
Letters Patent No. 1,136,132 (“the ‘132 Patent”), issued November 23, 1982,
expired November 23, 1999; and,
d. Canadian Letters Patent No. 1,144,924 (“the ‘924 Patent”), issued April 19, 1983, expired April 19, 2000.
While all have the same filing date of February, 1976 (when the original application was filed in Canada), three of these patents resulted from the filing of divisional applications, which will be further discussed below. These patents will be collectively referred to as the “Shionogi patents”. Lilly U.S. became the owner of the Shionogi patents by way of assignment dated April 27, 1995 which was registered in Canada on August 24, 1995.
 Although this action was instituted nearly twelve years ago, the dispute between the parties as to whether or not the sale by Apotex of a generic version of Ceclor® in Canada would infringe the patents at issue started earlier, with the filing of an application under the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133 (PM (NOC) Regulations) by Lilly and Shionogi on June 23, 1993. Earlier, the issue had also been raised when Apotex sought a compulsory licence with respect to cefaclor and certain Lilly patents related thereto in 1986.
 Despite the fact that for the most part of this period, the parties have been intensively litigating the matter, neither the discovery process nor any other steps taken in this long period of time succeeded in significantly reducing the number of issues involved or to focus the debate at trial.
 Given the amount of evidence filed and the many issues involved, the parties’ counsel made a real effort in attempting to consign all their arguments in writing. This entails that they filed nearly one thousand pages of submissions (including those filed with respect to the counterclaim), not counting the various submissions filed in respect of a number of objections which had to be taken under reserve to avoid delaying the trial. The Court thanks each counsel involved for their effort in reducing the number of those objections that remained outstanding in the end.
all this goodwill, the Court was left with a daunting task. This is only partially
reflected in these reasons which are, unfortunately, too long despite the fact
that the Court could not really do justice to all the issues raised. It was simply
not possible or even desirable to refer to all the evidence and the hundreds of
cases put forth by the parties.
 At the end of the process, one must wonder where the system failed for the Court is convinced that there has to be a better way to achieve the objectives set out in section 3 of the Federal Court Rules, SOR/98-106 (the Rules), which seeks to achieve the just, most expeditious and least expensive determination of every proceeding on its merits.
1. General Background 10
2. The Evidence 16
3. Lilly Canada’s Lack of Standing 75
4. Patent Construction 87
4.1. Person Skilled in the Art 91
4.2. Common General Knowledge (Principles) 95
4.3. The ‘007 Patent 106
4.4. The Lilly Process Patents 144
4.4.1. The ‘536 Patent 145
4.4.2. The ‘725 Patent 164
4.4.3. The ‘468 Patent 170
4.5. The Shionogi Patents 175
4.5.1. Common Disclosure 177
4.5.2. The ‘547 Patent 184
4.5.3. The ‘924 Patent 188
4.5.4. The ‘132 Patent 192
4.5.5. The ‘026 Patent 199
5.1. Burden 211
5.2. Statutory and Common Law Presumptions 212
5.3. Lupin Process 224
5.4. Kyong Bo Process 257
5.4.1. Existence of a License 263
5.5. Importation 270
5.6. The Exception Under Subsection 55.2(1) of the Patent Act 342
6. Invalidity 347
6.1. Standard of Review and Burden of Proof 348
7. Inherency and Lack of Subject Matter
7.1. Shionogi Patents 371
7.2. Lilly Patents 380
8.1. The Legal Test 391
8.2. The ‘007 Patent 399
8.3. The Lilly Process Patents 409
8.4. The Shionogi Patents 411
9.1. The Legal Test 412
9.2. The ‘007 Patent (Claim 17) 426
9.2.1. The Person Skilled in the Art 428
9.2.2. Relevant Common General Knowledge 429
9.2.3. Rydon, Coe and Ramirez 432
9.2.4. The Inventive Concept 438
9.2.5. The Difference Between the Common General Knowledge and
the Above-mentioned Publications and the Inventive Concept 439
9.2.6. Would these differences be obvious to the person skilled in
the art? 441
9.3. The Lilly Process Patents
9.3.1. Identify the Skilled Addressee 476
9.3.2. The Relevant Common General Knowledge 477
9.3.3. The Dreux Article and Other Prior Art 484
9.3.4. The Inventive Concept 489
9.3.5. The Differences between the Prior Art Including Common
General Knowledge and the Inventive Concept of the Claims 491
9.3.6. Do these differences constitute steps which would have been
obvious or do they require any degree of invention? 496
9.4. The Shionogi Patents 512
9.4.1. The Person Skilled in the Art 515
9.4.2. Common General Knowledge 516
9.4.3. Contested Art 532
22.214.171.124. Cocker 533
126.96.36.199. Chauvette Application 538
188.8.131.52. Kishi 539
9.4.4. The Inventive Concept 544
9.4.5. The Differences between the Prior Art and the Inventive
184.108.40.206. The ‘547 Patent 547
220.127.116.11. The ‘924 Patent 549
18.104.22.168. The ‘132 Patent 552
22.214.171.124. The ‘026 Patent 554
9.4.6. Are these differences inventive? 557
10. Lack of Utility – Sound Prediction – Inoperability 583
10.1. The Lilly Patents 585
10.2. The Shionogi Patents 604
10.3. Deficiency of Specification and Ambiguity 613
11. Remedies and Costs
11.1. Disentitlement and Set-off 626
11.2. Remedies 646
11.3. Exemplary/Punitive Damages 657
11.4. Interest 665
11.5. Costs 676
12. Apotex’s Counterclaim 683
12.1. Relevant Statutory Provisions 718
12.2. The Framework of Inquiry into Apotex’s Counterclaim 720
12.3. Is Apotex’s Counterclaim Time-Barred? 728
12.4. Apotex’s Claim for Damages 754
12.5. The Applicable Evidentiary Standard 757
12.6. Background 771
12.7. Apotex’s “But For” Scenarios with Respect to Causation 793
12.7.1. Scenarios 1 and 2: Apotex Obtains a Licence from
Shionogi or Lilly 803
12.7.2. Scenario 3: Apotex Practices the Shionogi Process and
is not sued 835
12.7.3. Scenarios 4 and 5: Apotex Practices the Shionogi and
Lilly Processes and is Sued by Shionogi and Lilly 840
12.8. Is there a loss resulting from the assignment under the most
likely “but for” world scenario? 842
12.9. Increased Cost of Legal Bulk Cefaclor 849
12.10. Infringement Liability 853
12.10.1. The Lilly Patents 855
12.10.2. The Shionogi Patents 861
12.11. Costs 882
1. General Background
 It is not disputed that penicillin is the oldest of the β-lactam compounds, having first been discovered in 1928. Semi-synthetic penicillin came later. The β-lactam molecule per se is a small square molecule that is highly reactive, to which, in penicillin, a five-membered ring is attached, whereas in cephalosporin (which includes cefaclor) the β-lactam is attached to a six-membered ring containing sulfur. There are different types of β-lactam depending on their side-chain, such as penicillin V (Pen V) and penicillin G (Pen G).
 Cephalosporins were first discovered in 1948. Semi-synthetic cephalosporins were prepared by altering the naturally produced compounds for greater anti-bacterial activity. Like penicillins, cephalosporins are bactericidal and exhibit similar modes of action. Cephalosporins are classified based on their generation. First generation cephalosporins, such as cephalexin (another Lilly product), have good activity against gram positive bacteria and more modest activity against gram negative. Second generation cephalosporins, such as cefaclor, have better activity against gram negative bacteria. Third generation cephalosporins, such as cephotaxim, ceftazidine and ceftriaxone, were less active than the first generation but have good activity against Enterobacteriaceae.
 Shortly after it was introduced in the market by Lilly, Ceclor® was a very successful drug. It remained so for several years, however, by 1997, when Apotex came to market, it was definitely in decline, having been overtaken by other antibiotics.
 The basic patent on the compound Cefaclor or the class of second generation cephalosporins to which it belongs (7-χ-aminoacyl-3-halo-3-cephem carboxylic acid or ester compound) is patent 1,016,537 (the ‘537 patent) filed on February 22, 1974 and issued in Canada on August 30, 1977. It expired August 30, 1994. It was also owned by Lilly U.S., having been discovered by Dr. Chauvette, a member of its β-lactam research team. Cefaclor was specifically disclosed in an example and the process to prepare it, or an obvious chemical equivalent, was claimed. Other claims dealt with other 7-χ-acylamino-3-chloro-3-cephem compounds prepared by those processes.
 It is not disputed that although the disclosure of the ‘007 patent directly refers to the preparation of a cephalosporin compound using the kinetically controlled complexes claimed in the patent, the claims do not expressly refer to such use. Also, none of the claims in the Lilly process patents or the Shionogi patents are directly claiming a process to make cefaclor itself. As a matter of fact, and as will be explained in more detail later on, these patents more generally relate to the making of what all experts agree was a key intermediate compound (the 3-hydroxy-3-cephem compound) if one were to make cefaclor. The steps required to make cefaclor from this key intermediate were disclosed in the ‘537 patent.
 An important part of the debate relates to processes involved in the transformation of a penicillin molecule into a cephalosporin molecule. Penicillin molecules could be synthetically produced at very low cost whereas the original starting material used by Dr. Chauvette to make cefaclor or other second generation cephalosporins described in his patent was very expensive.
2. The Evidence
 An important part of the evidence in this trial is a long list of facts agreed to by the parties that are applicable both to the main action and the counterclaim. To avoid excessive duplication, the Court will attempt to avoid repeating those admitted facts which are relevant to both actions, with the understanding that the totality of said facts were considered in the course of the determination of both actions.
 In the infringement action Lilly produced six factual witnesses: Dr. Stephanie Parra, Mr. Thomas Lee Pytynia, Ms. Debbie Rassos, Dr. Larry Blaszczak, Dr. Robin Cooper and Mr. John Gardner.
 Dr. Parra is acting manager of the general direct quality division one at Health Canada. Her division is responsible for evaluating data submitted to support the quality of drug submissions made to the department including chemistry and manufacturing data. Her testimony mainly served the purpose of entering into evidence, as well as offering a brief explanation of, documents filed in relation to Apotex’s submission for its Apo-cefaclor product. This included particularly the “open” and “closed” portions of the relevant Drug Master Files (DMFs) submitted by Apotex’s suppliers, Lupin Laboratories Ltd. of India (Lupin) and Kyong Bo Chemical Ltd. of South Korea (Kyong Bo).
 Various important exhibits discussed throughout the trial were put into evidence in the course of Dr. Parra’s testimony, such as the Comprehensive Summary regarding Apo-cefaclor (TX-124), the open and closed portions of Kyong Bo’s DMF (TX-126; TX-129), Apotex’s notifiable change for new source (TX-157) and letters from the Department of Justice to Gowlings Lafleur Henderson LLP with information provided by Lupin attached (TX-167; TX-168).
 Dr. Parra also explained the meaning of a “notifiable change” and the various levels ascribed thereto, which correspond to greater or lesser regulatory filing requirements. A change of supplier for example is classified as a level 2 notifiable change and will receive an objection letter if Health Canada has an objection to the proposed change. In this matter, before approving the change of supplier notified by Apotex (from Kyong Bo to Lupin), Health Canada requested additional information by way of a document called a “Clarifax” (TX-152) to which Apotex replied by a letter dated June 21, 1997 with an attachment explaining the source of the starting material and a full diagram representing the synthetic route used to make 7-amino-3-chloro-3-cephem-4-carboxylic acid esters (7-ACCA) (TX-150).
 Mr. Pytynia was in-house counsel for Lilly U.S. between May 1977 and December 31, 2007. He testified mainly about the relationship between Lilly U.S. and Lilly Canada, including particularly their licensing and distribution agreements. He introduced various documents which will be referred to later on, such as the 1991 licensing agreement between Lilly U.S. and Lilly Canada (TX-109), the 1995 patent and trademark licence amendment (TX-110), the Master Supply and Distribution Agreement between the said two companies (TX-112) as well as the Authorization to grant sub-licences from Lilly U.S. to Lilly Canada (TX-113).
 Ms. Rassos is the senior regulatory affairs manager at Lilly Canada, a position she has held for two and a half years. She had no direct knowledge of any of the events relevant to the proceedings and testified only to the documentation she found in Lilly Canada’s regulatory records concerning cefaclor. She introduced in evidence, among other things, Lilly Canada’s process information filed in relation to its New Drug Submission (NDS) (TX-208; TX-209) for Ceclor® as well as a portion of its 1979 NDS (TX-115). It was made clear during her cross-examination that her testimony with respect to the identity of Lilly Canada’s supplier during the 1979 and 2000 period is solely based on the said documentation for she had no independent knowledge of such matters.
 Dr. Blaszczak is one of the inventors listed in the Lilly patents in suit, with the exception of the ‘536 patent. However, he did not testify in this capacity but rather to explain his relationship with a graduate student in chemistry from the University of Modena, Alberto Spaggiari. This student had solicited Dr. Blaszczak’s supervision in conducting research in β-lactam chemistry with the view of preparing dual action cephalosporins. This led to Dr. Blaszczak collaborating with Mr. Spaggiari as a co-author for a scientific article referred to here as the Spaggiari paper published in 2004. In the course of his testimony on this issue, Apotex formulated a number of objections to hearsay evidence. While the objections were largely justified in this regard, none of this evidence is relevant to the issues upon which this judgment turns.
 On cross-examination, Dr. Blaszczak was referred to a 1978 cefaclor progress report (TX-211) and questioned as to his role in relation with it. He was also probed as to the process used by Lilly in the late 1970’s, particularly the transition to triphenyl phosphite (TPP) chloride (Cl) complex and the comparative yields achieved. Finally, Dr. Blaszczak offered evidence as to how Lilly structured its research operations with regard to cefaclor, particularly the de facto merging of the process research and development and discovery groups (he was part of the latter) when Lilly requested that the discovery chemists thoroughly consider the problem posed by the production of cefaclor on a commercial scale.
 Dr. Cooper was working with Lilly’s research team at the relevant time. He was already a world-renowned expert in cephalosporin chemistry. He was presented as a factual witness to relate any attempts he made back in the early 1970’s to cyclicize the thiazoline azetidinone compound he discovered (Cooper compound), which is used as starting material in the process described in the Shionogi patents. The content of his testimony will be discussed in more detail when assessing the allegations of invalidity of the Shionogi patents.
 Mr. Gardner is a chemist who performed the experiment described in example nine of the ‘007 patent (characterised as a side chain cleavage using the tri-p-chloro phenyl phosphite chlorine complex) while at Lilly in the late summer, early fall of 1978. Although Lilly produced a copy of his thirty-year-old lab notebook (TX-1799), Apotex objected to this evidence being used to counter the arguments of Apotex’s experts with regard to invalidity. Mainly, Apotex argues that Rule 248 of the Federal Courts Rules precludes this evidence from being introduced as Apotex sought to obtain all these lab notebooks during the discovery and its requests went unheeded. However, I fail to see how Rule 248 can apply when it is the Court which determined that the requested documents were not relevant. That said, in order to avoid further peripheral debates, the Court does not consider this evidence to be necessary to reach its findings.
 Subject to what I said about Ms. Rassos and my further comments in respect of Dr. Cooper, I accepted as credible the evidence of these witnesses.
 Apotex presented eight fact witnesses in the main action: Ms. Julie Carrière, Mr. Donald Barber, Mr. Gordon Fahner, Dr. Bernard Sherman, Mr. John Hems, Mr. Rajeev Patil, Mr. Vilas Satpute and Mr. Haracharan (Harry) Singh.
 Ms. Carrière is Apotex’s director of quality assurance and she testified about the regulatory context which requires Apotex to conduct tests and analyses of the bulk chemicals it uses in making pharmaceutical formulations. Her testimony was put forth in support of Apotex’s defence pursuant to s. 55.2 of the Patent Act, R.S.C. 1985, c. P-4. In cross-examination, she explained that the related compounds which must be tested referred to the synthetic or degradation impurities which have been previously identified in the New Drug Submission or Notifiable Change. She also agreed that these related compounds may change from supplier to supplier, depending upon the processes used, which may create a need for different analytical techniques. Finally, Ms. Carrière agreed that apart from the regulatory obligation, testing is beneficial to Apotex for it must ensure that the products it puts on the market are safe and of good quality, otherwise its sales might suffer.
 Mr. Barber has been the formulation development manager at Apotex since 1998. He provided testimony on product development at Apotex. He explained in detail the various testing required to develop a commercially viable product, which includes the formulation stages, the scaling up of a process or formulation that is thought to be workable on an industrial scale and the testing or evaluation of the formulation so produced. The raw material testing is ongoing throughout the process.
 He noted that whenever Apotex switches to a different supplier for an active pharmaceutical ingredient (API), evaluations, both chemical and physical, are repeated and a “good amount” of the formulation development work must also be repeated. Mr. Barber discussed how, with regard to cefaclor, such work started as early as 1991. He identified several exhibits relating to quantities of cefaclor which have not been sold or used for commercial purposes. Again, this testimony was offered in support of Apotex’s defence pursuant to s. 55.2 of the Patent Act. On cross-examination, Lilly’s counsel focused on the accuracy of records which are not relevant to the issues the Court must decide today, given that if infringement is established, the damages will be assessed by reference. The accuracy of Apotex’s records in this regard can be contested at the reference stage, in accordance with the Court’s reasons below on the proper scope of the exemption.
 Mr. Fahner has been Apotex’s Vice-President of Finance since 2003, having held the position of Director of Finance at the relevant period. He testified twice in the course of the main action. Firstly, Mr. Fahner testified as to the inventory tracking system at Apotex and the gradual evolution of this system from a paper-based system to an electronic SAP system in the 1999 to 2001 timeframe. The main purpose of Mr. Fahner’s testimony was to introduce in evidence, and explain the significance of, spreadsheets (TX-1559; TX-1560; TX-1561) he prepared representing compilations of quantities of cefaclor which Apotex claims is covered by the defence provided for at s. 55.2 of the Patent Act. Also, Mr. Fahner explained the significance of another spreadsheet he prepared (TX-1759) which represents a summary of raw cefaclor quantities purchased by Apotex primarily for commercial use as well as prices paid for said cefaclor.
 On cross-examination it became apparent that some of the material included in the spreadsheets was in fact material that had been acquired post-patent expiry and thus is not relevant for the purposes of this proceeding. On this basis, Apotex undertook to have Mr. Fahner revise said spreadsheets to ensure that they only include quantities relevant to the allegation of infringement. This was provided by Apotex on May 12, 2008. Inconsistencies were also identified with regards to the summary of raw cefaclor quantities (TX-1759) and various purchase orders, which again, in a context where a reference will take place, are not germane to the issues presently at hand. Finally, Mr. Fahner also identified a spreadsheet representing international sales of Apo-cefaclor (TX-1747) and confirmed that no sales had occurred in the United States.
 Following the testimony of Mr. Singh, which will be discussed below, Apotex re-called Mr. Fahner to testify with regard to certain invoices emanating from Tektrade Ltd. (contained in Glopec-36) which called into question Mr. Fahner’s earlier testimony. Mr. Fahner testified that the relevant invoices (# TTL-981006-02 and TTL-981006-3) were not in Apotex’s records, that the cefaclor quantities represented therein had not been received by Apotex and that no payment had been made to Tektrade Ltd. in relation thereto. Lilly objected to Mr. Fahner being called back to testify, but on June 17, 2008, the Court ruled that it would exercise its discretion and allow said testimony, noting that Lilly did not suffer any prejudice in light of the bifurcation order for the issue of the quantum of damages, save perhaps in losing what was indeed a very able cross-examination of Mr. Singh by counsel for Lilly.
 Mr. Hems is the Director of Regulatory Affairs at Apotex. He testified as to the regulatory requirements which Apotex must meet in order to offer a drug on the market and the process used to meet these requirements. He oversaw the process for seeking approval for cefaclor, which began in 1993 with the filing of the original drug submission (TX-1761; TX-1762) and explained the analysis of the API which is necessary for such submissions. Mr. Hems also explained what a DMF contains and the portions of said files which Apotex may gain access to and how it may gain access to them.
 Except for the issue relating to the Tektrade invoices in respect of which the Court will make no finding, the evidence of the aforementioned witnesses was accepted.
 Dr. Sherman is the Chairman and Chief Executive Officer of Apotex. In this phase of the trial, he testified as to Apotex’s practices with regard to the sourcing of APIs, particularly cefaclor. He explained that, around the time where Apotex received its NOC for cefaclor, it hired an in house lawyer named Brigitte Fouillade, who has since passed away. Her role was to advise Dr. Sherman as to intellectual property issues. Referring to correspondence addressed to Ms. Fouillade from Kyong Bo dated October 10, 1997 (TX-662), Dr. Sherman explained that Kyong Bo represented to Apotex that it had rights to use the Shionogi process.
 With regard to Lupin, Dr. Sherman testified that while no formal agreement was entered into at first, it is his understanding that Ms. Fouillade attempted to ensure that the material supplied was not infringing. Ms. Fouillade developed a flow sheet for such a non-infringing process and, relying on correspondence between Ms. Fouillade and Mr. Singh (TX-679), explained that she was to ensure that this process was followed even if the cefaclor so produced was more costly, which is why Apotex then entered into a formal agreement.
 On cross-examination, Dr. Sherman was led to explain the reasons for which Apotex limited its choice of Lilly patents in its compulsory licence application (TX-265) and the reason which led him to terminate said licence (TX-267). He was also questioned as to why the agreement with Lupin (TX-1656) was not in the original affidavit of documents he signed (TX-327) and why no Notifiable Change had been filed by Apotex for this new process. He was also thoroughly questioned with regard to his answers on discovery pertaining to Lupin process information and communications between Lupin and Apotex. Finally, he also attempted to explain price variations for bulk cefaclor purchased, from Lupin and Kyong Bo.
 Generally, the Court has no problem with the credibility of Dr. Sherman’s testimony in respect of matters where he was directly involved as opposed to those where others were directly involved such as Ms. Fouillade. It is obvious and understandable that Dr. Sherman did not recall factual details and appeared sometimes to be offering explanations based on common sense and written documentation. The Court was certainly surprised by his candour when he noted that he did not read correspondence from his lawyers (there was simply too much of it) and he entirely relied on them when signing affidavits (it is not clear if he even read them all).
 The testimonies of Mr. Singh, Mr. Patil and Mr. Satpute were heard under reserve of general objections (generally referred to as voir dire by the parties) which will be discussed in the section regarding infringement. Still, it is useful to briefly note what their testimonies relate to.
 Mr. Singh is the owner of Glopec International Inc. (Glopec), a company which imports and distributes raw pharmaceutical ingredients in both Canada and the United States. Glopec represents Indian manufacturers, such as Lupin, taking care not only of selling their products in Canada but also filing their regulatory materials with Health Canada. With regard to cefaclor, a certain amount of such correspondence related thereto was introduced in the course of his testimony (Glopec 1-14; 28-33). Also, Mr. Singh had in his files a certain amount of correspondence between Glopec and Apotex (addressed to Ms. Fouillade) regarding the process used by Lupin in the summer of 1997 and the subsequent development with Lupin of a non-infringing process (Glopec 16-26), as well as related correspondence with Lupin (Glopec 27; 35).
 Mr. Singh also testified as to a big order of 7,500 kg of cefaclor passed by Apotex to be manufactured using the so-developed process. When Apotex was invoiced for bulk cefaclor manufactured by Lupin, these invoices were issued by Tektrade Ltd. (Glopec 36), a trading company owned by his in-laws in India and which Mr. Singh represents in Canada. Mr. Singh explained how the prices represented in these invoices were set and how payments are processed from Apotex through Tektrade Ltd. and finally to Lupin. While much of his cross-examination focused on these same points, counsel for Lilly was able to identify a rather large discrepancy between Tektrade Ltd. invoices and the data compiled by Apotex as to quantities received, which, as mentioned above, prompted Apotex to recall Mr. Fahner to testify on this point.
 Mr. Patil is the Vice-President of Regulatory Affairs at Lupin. At the relevant period, he was a senior manager within the same department. He was tasked with the registration of the companies’ products (DMFs), which include dosage form and API (bulk), the study of regulatory requirements in countries to which Lupin exports and compliance with these requirements. Mr. Patil testified as to how the registration and other requirements were performed at Lupin as well as what they generally entailed, with a particular focus on communications with Health Canada concerning cefaclor both directly from Lupin and via Glopec (which were tendered as Patil 1-6; TX-337; Glopec 4-5; 10). These documents came into the possession of Mr. Patil following a request made to Health Canada in 2008 to provide them as Lupin’s records had been largely lost in a flood in 2005 (some files still existed at the Bombay office while others were salvaged).
 Mr. Patil also testified as to the locations where cefaclor and 7-ACCA are manufactured. Correspondence between Lupin and Glopec was also tendered, for example Patil 8 (but also Patil 9; TX-158), which contained Mr. Patil’s handwriting in the margins and which prompted testimony about the interaction Mr. Patil had with the research and development (R&D) department (the letter was addressed to Dr. Gutpa, the chief of the R&D department) of Lupin regarding Apotex’s request for cefaclor produced using a third process. Concerning this third process, Mr. Patil testified as to a mix up in the correspondence in 1999, specifically an incorrect flow sheet depicting the manufacture of 7-ACCA appended thereto (see, for example, Patil 10).
 Mr. Satpute is the Vice-President of API manufacturing at Lupin’s Mandideep facilities. At the relevant period (1996-1999), he was the senior manager of Lupin’s Ankleshwai facility, which manufactured ethambutol, vitamin B-6 and two intermediates, 7-ADCA and 7-ACCA. After 1999, he took up this same role but at the Mandideep facilities where cephalexin, cefadroxil, cefaclor, ceftriaxone and cefatoxime are manufactured. Mr. Satpute testified as to the process used at the Ankleshwai facility to manufacture 7-ACCA and its subsequent transformation to cefaclor at Mandideep and the delay this entails.
 He testified that initially, in 1996, Lupin used a process which began with Pen V acid. Sometime in 1997, Lupin did trial batches and a few commercial ones to validate a new process starting with Pen G before reverting in 1998 to Pen V acid but using a third process which was slightly different from the one used in 1996 (particularly at what is described as step V in some of Lupin’s documents) to fulfill what he qualified as a “one of the biggest orders we received”. Mr. Satpute explained the implementation of this third process, the fact that it produced substantially lower yields (about 60 percent of the yields of the previous Pen V acid process used) and the use of chlorine (Cl) gas and TPP. Also when he was asked to find batch records for the 7-ACCA so produced, for which the plant manager and the R&D department would have created a template a few weeks before coming to Canada, he found that these documents no longer existed. It is not clear if anybody verified the files of the R&D department for the data relating to this process.
 Once this order was filled, Mr. Satpute testified that Lupin reverted to the Pen G process validated in the latter part of 1997. Documents referred to in the course of Mr. Satpute’s cross-examination were marked Satpute 1-3.
 Finally, the parties filed by consent an affidavit of Leslie Sands, Director of regulatory affairs at Lupin Pharmaceuticals Inc., a subsidiary of Lupin operating in the United States (TX-340). This filing was made under reserve of an objection that the documents therein are not proof of their contents but rather only of the existence of such communications with the U.S. Food and Drug Administration. The Court agrees with Apotex in this respect.
 In the main action, the parties filed 33 expert reports dealing with the infringement and invalidity allegations. They are listed in Chart A attached hereto with the names of the experts, dates, subject matter and exhibit numbers, together with their area of expertise and a brief summary of their qualifications.
 On the question of infringement of the Shionogi patents by the use of the Kyong Bo process, Lilly called Dr. Anthony Barrett while Apotex responded with the evidence of Dr. Stephen Hanessian who touches on the issue of infringement of all the patents in issue mostly to support Apotex’s arguments with regard to importation (A-10). Both experts were properly qualified to opine on these issues. Their evidence in that respect was not contradicted. The Court accepts the evidence of Dr. Barrett in respect of the Kyong Bo process. While the relevance of Dr. Hanessian’s evidence will be discussed in the section dealing with importation.
 A much more contentious issue concerns the infringement of the Lilly patents, particularly whether the Lupin process described in the Health Canada file fell within the scope of the monopoly of the plaintiffs. Lilly’s main expert witnesses in this respect were Drs. Miller and Baldwin. While Dr. Hunter and Mr. Moraski reported and commented on the results of numerous experiments conducted by both sides in relation to this question, particularly with the use of 31P Nuclear Magnetic Resonance (31P NMR) Spectroscopy. Apotex’s experts on this question were Drs. Modro, McClelland and Cowley. Dr. Chase also testified about the tests he performed.
inordinate amount of time was spent discussing the results of the various
experiments performed by both sides as well as their respective alleged flaws.
It is clear that most of these experiments involved a certain amount of
subjectivity (for example, what is yellow vs. light or faint yellow, or what is
cooled vs. ice cooled or cooled with ice salt, what is room temperature, etc.)
and that really none of the tests performed were perfect. For various reasons,
choices were made with respect to temperature and equipment. Many things can
and do go wrong in laboratories (broken valves, etc.). The Court used considerable
caution in assessing the weight to be given to this evidence, but in the end,
considering the construction of the claims at issue adopted, most of these
experiments and the comments relating thereto became somewhat irrelevant. With
respect to those that remain relevant, such as reactions carried out on
cephalosporin substrate with or without a halogen scavenger, individual tests
were not considered in isolation, in the sense that the Court always looked to
confirm if the results were supported by other evidence on the record.
one positive aspect of the testing is that it led to the abandon of some of the
arguments and helped focus the debate.
was a lengthy debate about the admissibility of tests performed ex parte
and how tests must be introduced in the evidence. In the end, these issues were
settled without the need for a ruling. Nevertheless, it is important to note
that pre-trial scheduling orders setting deadlines for the reporting of test
results, absent an express indication to the contrary, must not be construed to
constitute a waiver of any requirement that may exist regarding notice of
testing to be performed pre-trial.
 Also, with respect to the infringement of the Lilly process patents, the Court granted leave to both parties to file expert evidence on issues arising from the testimony of Mr. Satpute. Dr. Barrett (E-15), who had only previously been dealing with the Shionogi patents, and Dr. Hanessian (A-20) testified in respect of the various processes allegedly used by Lupin.
 Turning now to the validity phase of the trial, Apotex relied on the evidence of Drs. McClelland, Hanessian and Martin in respect of the Shionogi patents while Lilly responded with the evidence of Dr. Barrett and that of Mr. Murphy, who focused on the prosecution of the Shionogi patents and the unity of invention practice of the Canadian Patent Office.
 In respect of the Lilly patents, Drs. Modro, Chivers, Olah and McClelland discussed the validity of the ‘007 patent while Dr. McClelland also addressed issues relating to all the Lilly process patents and Dr. Olah opined in respect of the ‘536 patent. In response, Lilly relied upon the evidence of Dr. Baldwin who discussed all of the Lilly patents and Dr. Hunter who focussed on certain allegations in respect of the ‘007 patent. Mr. Murphy also discussed the prosecution of the Lilly patents and the unity of invention practice in relation thereto.
 In respect of infringement by the Lupin process, the Court found the evidence of Dr. Baldwin and Dr. Miller particularly helpful. Despite Apotex’s attempts to challenge their credibility on the basis that they had worked as a consultants for Lilly from time to time and the university where Dr. Miller teaches received some grants from Lilly, the Court is satisfied that they gave their evidence in a straightforward, unbiased manner. In that respect, the Court notes that early in his testimony, Dr. Baldwin readily admitted that the kinetic complex must have formed when one carried out some of the experiments in the prior art.
 In respect of the validity of the Lilly patents, like the House of Lords in Synthon BV v. Smithkline Beecham plc,  UKHL 59,  1 All ER 685 (Synthon), who described him as one of the foremost organic chemists in the world, the Court found Dr. Baldwin to be particularly well qualified to opine on the issues of fact covered in his report. In fact, he was the only expert witness that was properly qualified to opine on the common general knowledge of the posita to whom the Lilly process patents were addressed and how said posita would read those patents or the relevant prior art.
 Drs. Modro, Olah and McClelland were all properly qualified to opine in respect of the ‘007 patent. Generally the Court had no difficulties with their credibility although, the Court was more cautious with the evidence of Dr. McClelland because of his vast experience acting as an expert in patent cases he was somewhat less spontaneous than other Apotex experts.
 It is obvious, and Drs. Modro and Martin readily admitted it, that Ivor Hughes and Dr. Stewart from his office played a very significant role in the drafting of the reports (presumably all of them except maybe for that of Dr. McClelland). Normally there is nothing wrong with being assisted by one’s lawyer in drafting one’s report but despite the Court’s flexibility in that respect, one must not lose sight of the principle expressed in National Justice Compania Riviera S.A. v. Prudential Assurance Co. (“the Ikarian Reefer”),  2 Lloyd’s Rep. 68 to the effect that “expert evidence should be seen as the independent product of the expert uninfluenced as to form or content by the exigencies of litigation: Whitehouse v Jordan  1 WLR 246 at 256, per Lord Wilberforce” (emphasis added). Certainly the more the lawyers are involved the more careful an expert must be in reviewing the text proposed to ensure that it truly reflects his or her views. There was some evidence in this case that the review, by Apotex’s experts particularly, was not as careful as one would expect.
 Although the Court generally accepted the evidence of Dr. Hunter in respect of the testing performed and found his evidence credible in respect of the common general knowledge about 31P NMR and the impact of various factors on the ppm chemical shift at the relevant time, his evidence was not as useful considering the construction of the claims at issue adopted by the Court. With respect to the validity of the ‘007 patent (E-18), the Court notes that Dr. Hunter’s PhD is in inorganic chemistry. His evidence was given the same weight as that of Dr. Chivers’ in respect of the said patent.
 Again, in view of the construction of the claims at issue, most of the evidence of Dr. Cowley was not particularly useful. In respect of the view he expressed in para. 27 of his report (A-9), the Court preferred the opinion of Dr. Hunter which was corroborated by the tests performed, including those of Dr. Chase. The Court was unimpressed by his evidence with respect to the Spaggiari article.
 As mentioned, Dr. Chivers, like Dr. Hunter, has a PhD in inorganic chemistry with particular expertise in chemistry involving various elements including phosphorus. He testified in a straightforward, clear and credible manner. It is evident that he had initially also been asked to comment on the validity of the ‘536 patent, a matter in respect of which he was clearly not qualified, but the report he filed when he took the stand was heavily redacted, probably in response to Lilly’s objection that there was duplication. Only paragraph 6 now deals with the ‘536 patent, it describes the characteristics of the addressee of the patent. His evidence, in respect of the ‘007 patent, like that of Dr. Hunter, did not add much to that of the well-qualified organic or medicinal chemists relied upon by Apotex and Lilly.
Barrett and Dr. Hanessian are both well-qualified and have expertise in
β-lactams, particularly cephalosporin chemistry, even if the details as to
exactly what Dr. Hanessian was doing in the late 1970s in respect of β-lactams
or cephalosporins are not as clear.
These two experts were equally credible which made the task of the Court
particularly difficult considering that their evidence is often contradictory.
further comments in respect of Drs. Olah, McClelland and Martin’s evidence in
respect of the Lilly process patents and the Shionogi patents illustrate
difficulties the Court faced in this case and which are unfortunately not
Olah is an imminent scientist. Among his many outstanding achievements, he has
won a Nobel Prize in 1994 for his work on positively charged compounds of
carbons. However, he has no experience whatsoever with respect to
β-lactams or cephalosporin chemistry. Despite this, he was asked to opine
on the validity of the ‘536 patent on the basis of publications provided to him
by Ivor Hughes, one of Apotex’s counsel at the time. Like other experts acting
for Apotex, his report includes a description of the addressee of these patents
which appear to be meant to fit his credentials.
cross-examination, he could not name a reagent used in cephalosporin chemistry
– the type of chemistry discussed in the ‘536 patent. This may explain why he
appeared as a reluctant witness who even refused to answer some questions
during his cross-examination until offered a choice between withdrawing his
report and answering the questions put to him. It may also explain comments
such as: “I wouldn’t stick out my reputation one way or another to argue that
the few ppm one way or the other is a fundamentally different situation.”
such a case, it is easy to understand why the Court preferred Dr. Baldwin’s evidence
in respect of the ‘536 patent to that of Dr. Olah, and why time spent on
examination and cross-examination of a witness that is not “the right expert
for the job” is almost always time lost for all concerned.
McClelland’s evidence in respect of the Lilly process patents and the Shionogi
patents falls pretty much in the same category especially when one considers
that he should know better given his vast experience in litigation.
is a problem because one’s willingness to offer an opinion without an
appropriate basis to do so can impact on the overall credibility of a witness
otherwise qualified to opine on another issue for it can raise some doubt as to
the existence of a proper basis for the other portion of his opinion or as to
whether the expert really understood his role.
 Dr. Martin is another distinguished organic chemist expert in his field which includes lactams but he has no experience whatsoever in β-lactam chemistry let alone cephalosporin chemistry – a prerequisite of the posita to whom the Shionogi patents are addressed according to para. 12 of his report. In an attempt to compensate for his “obvious” inability to see through the eyes of such posita, Dr. Martin testified that in the claimed reactions in fact the β-lactam molecule remains a spectator. The Court cannot agree and as argued by Lilly, this is a clear use of hindsight. This puts in question Dr. Martin’s understanding of his role particularly as he also offered comments on other issues that appear to go beyond his expertise and personal knowledge (conferences given by Kishi and the invention not claimed in the Shionogi patents).
 Another issue on which the parties presented expert evidence was on pharmaceutical regulatory affairs, particularly the filing of NDSs and DMFs and the requirements for keeping these filings up to date. For this purpose, Lilly called upon Ms. Azzarello who filed one report (E-7) and Apotex relied on the testimony of Ms. Wehner, who did likewise (A-11). This evidence provided some background for the debate on the evidentiary value of the information provided to Health Canada by the foreign suppliers of Apotex. It also brought to light that there may be a loophole in the regulations or at least in how they are applied. According to Ms. Wehner, it is known that foreign suppliers do not always abide by the regulations and file up-to-date information about their processes. Also changes are sometimes implemented before receiving Health Canada approval. I understand that this may have an impact on the ultimate safety of the product because the testing performed on the API by the Canadian sponsor may need to be adapted to the process used to manufacture it. Clearly this is a matter for the regulator, not a Court dealing with an infringement action. That said, in the end, this evidence was not particularly useful.
3. Lilly Canada’s Lack of Standing
 Apotex argues that Lilly Canada has not proven its standing to sue. It alleges that a bare assertion of a corporate relationship is not sufficient. In that respect, it relies on two statements made by Justice Judith Snider in Laboratoires Servier v. Apotex Inc., 2008 FC 825, 67 C.P.R. (4th) 241 (Laboratoires Servier) that read as follows:
The test for who qualifies as a person claiming under a patentee is not simply whether the patentee has consented to the person being joined as a plaintiff in an action; nor is it enough to demonstrate that two parties are related. In each case, the facts must demonstrate a credible and legally sufficient basis for claiming under a patentee
As noted above, the mere existence of a corporate affiliation is not conclusive evidence of a right under s. 55(1) of the Patent Act. There must be something more. That something more has consistently been described in the jurisprudence as a license or some other arrangement (for example, a lease, an assignment, or a sale) that would give the affiliate the right to use the patent.
[paras. 70 and 82]
 Lilly Canada does not disagree with the above-noted statements, it simply says that in this case it has not only established, through the testimony of Mr. Pytynia (Transcript Volume 7, pp. 56-63; 83-84) that Lilly Canada is a wholly owned subsidiary, but also that it had an express licence to both the Lilly and Shionogi Patents at issue in this case. It has also been admitted that Lilly Canada has been selling Ceclor® (cefaclor) in Canada since 1980. Lilly Canada made specific references to various exhibits filed during the hearing to support its position, particularly an agreement executed and effective as of January 1, 1991 between Lilly U.S. and Lilly Canada (TX-109) where:
Lilly represents and warrants that for Canada, it has the exclusive right to grant licenses to enable the licensee to make, have made, use and sell certain products, including the right to use within Canada, certain patents, trademarks
relating to such products and to their preparation, manufacture, processing and packaging.
 In the said agreement, Lilly U.S. appoints Lilly Canada as its authorized distributor of all Lilly U.S. products in Canada (which includes Ceclor®) and at s. 1.2:
Lilly further grants to Lilly Canada a non-exclusive sublicense (without right of further sublicense except as further granted in writing by Lilly) under the Canadian patent applications and patents listed in Schedule “A”
to make, have made, use or sell, and/or import Lilly Products whose preparation is covered by the patent applications and patents.
 At pp. 8 and 9 of Schedule A, the four Lilly patents at issue here are listed. Normally, it should thus not be contentious that Lilly Canada has proper standing pursuant to subs. 55(1) of the Patent Act, at least in respect of those patents.
 Apotex, however, says that on January 1, 1995, the 1991 agreement was amended (TX-110) to delete the various schedules which, according to Mr. Pytynia, was done to avoid having to keep them up to date which was found to be difficult. According to Apotex, the result of this amendment is simply that licences to the Lilly or Shionogi patents were no longer granted to Lilly Canada.
 This, according to Apotex, makes particular sense in respect of the Shionogi patents, given that none of the material purchased by Lilly Canada was made by the processes protected thereunder and that Lilly Canada never actually made, purchased or sold any of the actual compounds claimed in the patents in suit. Apotex also discards the impact of the General Supply and Distribution Agreement, filed as TX-112, on the basis that Lilly Canada’s role as distributor appears to be based on an agreement that says nothing about patent rights, nor does it characterize Lilly Canada as an agent and expressly disclaims any other rights flowing between the parties.
 The Court agrees with the plaintiff that such an interpretation of the 1991 agreement as amended through time leads to an absurd result and is simply incorrect. The January 1, 1995 agreement expressly states:
WHEREAS the parties desire to maintain the rights, licenses and sublicenses granted by the AGREEMENT while also recognizing that the parties will receive full compensation under the Master Supply and Distribution and Manufacturing or other Agreements.
 It is also worth noting that the 1991 agreement was further amended on April 9, 1998 (TX-113) giving Lilly Canada the right to further sub-licence a third party under some of the patents covered by the agreement, in conformity with s. 1.2 of the 1991 agreement. More particularly, the amendment refers to the licence granted under the 1991 agreement for cefaclor and:
grants to Lilly Canada the right to sub-license the following licenses granted to it under the  License Agreement (collectively, the “Licenses”) for cefaclor: (i) licenses granted under patent rights of Lilly U.S. (including, without limitation, the patents listed in Schedule A hereto).
Said schedule made specific reference to three of the Lilly Patents in suit (the only ones missing are the ‘007 and ‘026, the latter having expired by that time).
considered all of the evidence, the Court is satisfied that Lilly Canada has
properly established its standing based on an express licence from the
 Before concluding on this issue, it is worth quoting a passage from the decision of the Federal Court of Appeal in Apotex Inc. v. Wellcome Foundation Ltd.,  1 F.C. 495 (2000), 262 N.R. 137 (Apotex (2000)), where, after observing that the trial judge, Justice Howard Wetston, had committed no error in his analysis and conclusion, and that based on the unwritten licensing practices of the Glaxo Wellcome Inc. group of companies, Glaxo Wellcome Inc. had an unwritten licence to all the patents held by companies under the control of Glaxo Wellcome Inc. of the United Kingdom, Justice Marshall Rothstein noted, at para. 99, that:
It is perhaps not uncalled for to observe that this is not a case in which the alleged licensee is alone in advancing its claim for the patent infringement. Here, the patentee is also before the Court as a co-Plaintiff supporting the claim of GWI. It is difficult to conceive of what more is necessary to prove the existence of a licence than to have the licensor and licensee both attesting to the validity of the license. Where both the patentee and the person claiming under the patentee are before the Court, are affiliated as being owned by the same parent and have an identity of interest in the litigation – with the patentee supporting the person claiming under the patentee – it is, to say the least, surprising that technical questions of status to sue would be advanced as a defence to infringement.
 In fact, Lilly Canada argues that in the past, the Federal Court of Appeal has accepted less than an exclusive or non-exclusive licence as evidence of a right to claim under the patentee. For example, in Signalisation de Montreal Inc. v. Services de Béton Universels Ltée (1992),  1 F.C. 341 p, 147 N.R. 241, the Court accepted that the plaintiff whose standing was contested was a sales representative of the patentee’s product in Canada. The agreement between it and the patentee did not make any specific reference to the patents or rights of any kind thereunder, leading Justice Paul Rouleau to conclude that the plaintiff had no standing to sue for infringement. In reversing the decision of the trial judge, the Court of Appeal said, among other things, that:
In my view, a person ‘claiming under’ the patentee is a person who derives his rights to use the patented invention, at whatever degree, from the patentee. The right to use an invention is one of the monopoly to which is conferred by a patent. When a breach of that right is asserted by a person who can trace his title in direct line back to the patentee that person is ‘claiming under’ the patentee. It matters not by what technical means the acquisition of the right to use may have taken place. It may be a straightforward assignment or a license. It may, as I have indicated, be a sale of an article embodying the invention. It may also be a lease thereof. What matters is that the claimant asserts a right in the monopoly in that the source of that right may be traced back to the patentee. This is the case with the appellant here.
[Footnotes omitted, para. 24]
is no doubt here that Lilly Canada derives its rights from the patentee, Lilly U.S.
4. Patent Construction
considering the allegations of infringement and invalidity, the Court must
construe the claims at issue in this proceeding. The principles of construction
are well-established. They are set out in Free World Trust v. Electro Santé
Inc. 2000 SCC 66,  2 S.C.R. 1024 (Free World Trust), and Whirlpool
Corp. v. Camco Inc. 2000 SCC 67,  2 S.C.R. 1067 (Whirlpool).
Since those decisions were issued, much has been written by this Court on this
topic. Be it sufficient to say that “[t]he key to purposive construction is
therefore the identification by the court, with the assistance of the skilled
reader, of the particular words and phrases in the claims that describe what
the inventor considered to be the “essential” elements of his invention.” As to
the further details of what date the claims are to be construed, using what
criteria, what resources, through whose eyes and what is made of the resulting
construction, the Court adopts and refers to paras. 32-48 of Justice Roger
Hughes’ decision in Pfizer Canada Inc. v. Canada (Minister of
FC 1725, 285 F.T.R. 1.
 As noted in Shire Biochem Inc. v. Canada (Minister of Health), 2008 FC 538, 328 F.T.R. 123, at para. 21 (Shire), the Court “is not to construe a claim without knowing where disputes between the parties lie.” This is particularly important in cases such as this one, where a large number of claims in eight distinct patents are at issue. As previously noted, all of the patents in this case were issued before October 1, 1989 and are thus subject to the pre October 1, 1989 version of the Patent Act (s. 29 of the post October 1, 1989 version of the Patent Act). They are to be construed as of their respective dates of issuance.
 To these more general principles, one should also add that the Court adopts and will apply Justice Denis Pelletier’s statement regarding claim differentiation in Halford v. Seed Hawks Inc., 2004 FC 88, 246 F.T.R. 1 (Halford), affirmed, 2006 FCA 275, 275 D.L.R. (4th) 556 at para. 110, where he quoted the following passage from D.M.I., Inc. v. Deere & Co., 755 F. 2d 1570, 225 U.S.P.Q. (BNA) 236 (U.S. Cir.):
The district Court said ‘As a general rule a limitation cannot be read into a claim to avoid infringement’…Where, as here, the limitation sought to be ‘read into’ a claim already appears in another claim, the rule is far more than ‘general.’ It is fixed. It is long and well established. It enjoys an immutable and universally applicable status comparatively rare among rules of Law.
 The Court will also rely on the following passage from The Canadian Law and Practice Relating to Letters Patent for Inventions by Harold G. Fox (Fox) , which was recently quoted by Justice Snider in Hoffmann-Laroche Ltd. v. Mayne Pharma (Canada) Inc., 2005 FC 814, 41 C.P.R. (4th) 505 (Hoffmann (2005)), at para. 43:
Each part of the specification must be effectively construed and, if it is at all possible, each claim must be construed independently of the others and be given an effective and distinct meaning. The court will not be inclined to construe two claims in a specification as identical, for if one claim bears the same meaning as another it does not bear an effective meaning.
[Emphasis is in the original.]
4.1. Person Skilled in the Art
 With respect to the ‘007 patent, although the disclosure discusses, among other things, the utility of the new class of halogenating compounds in the chemistry of cephalosporins, the Court is satisfied that the art to which the patent relates is wider than the chemistry of cephalosporins for the patent covers the kinetic complexes (compound by process claims) and processes to make them. Thus, the Court accepts Apotex’s view that the addressee of the patent would have a Ph.D. in organic or medicinal chemistry with 3-5 years experience in carrying out organic transformations and knowledge of organophosphorus compounds as well as the use of 31P NMR (see para. 119 of Apotex’s memorandum on infringement).
 That said, with respect to the Shionogi patents and the Lilly process patents, the Court finds that the addressee is a person with a Ph.D. in organic or medicinal chemistry, with 3-5 years experience in organic synthesis and heterocyclic chemistry, particularly in β-lactam chemistry and penicillin or cephalosporin compounds.
 Insofar as the Shionogi patents are concerned, there is little dispute between the parties in that respect even if Dr. Hanessian appears to prefer the word “focus” to describe the experience of the person skilled in the art in the β-lactam antibiotic field. It is apparent that at the relevant time, this kind of chemistry was only conducted by, and of interest to, very specialized research teams. Dr. Baldwin, who was actively working in that field at the time, described those researchers in his testimony.
 The views of Apotex’s experts such as Dr. Olah (with respect to the ‘536 patent) and Dr. McClelland (who deals with the Lilly process patents as well as the Shionogi patents) regarding the particular addressee of the process patents appear to be designed to suit the particular characteristics of their own expertise, rather than that of the true addressee. The Court cannot accept the view that the addressee of the Lilly process patents is the same person to whom the ‘007 patent is addressed, but who “would in addition likely be interested in cephalosporin compounds.” That said, this finding will have little impact on the evaluation of their evidence, given that, as mentioned when discussing the weight given to the expert evidence, Apotex’s experts who commented on the Lilly process patents would not meet either description as there is no evidence that any of them had a particular interest in cephalosporins prior to their involvement in this litigation. They have failed to establish in their affidavit the basis on which they are qualified to comment on how a person skilled in the art (hereinafter posita) at the relevant time would construe the patents and what common general knowledge these persons would possess.
4.2. Common General Knowledge (Principles)
 During the trial, the Court noted on several occasions that there was little evidence to establish that the numerous publications, patents, applications relied upon by various experts were part of the common general knowledge of the posita at the relevant time. While this was to a certain extent cured through the cross-examinations, it remains that too little attention was given to such matters which are of prime importance, not only to construe the claims, but also to assess the prior art put forth to establish invalidity. This is particularly significant when, like in this case, one is considering older patents issued at a time when a posita did not have the benefit of electronic versions of scientific publications and could not use the internet or other sophisticated research tools to locate relevant information.
 The very general statements made recently by the Supreme Court of Canada that “[c]ommon general knowledge means knowledge generally known by persons skilled in the relevant art at the relevant time” (Apotex Inc. v. Sanofi-Synthelabo Canada Inc., 2008 SCC 61,  3 S.C.R. 265 (Sanofi)) or that a posita is expected to be “reasonably diligent in keeping up with advances in the field to which the patent relates” and that their common knowledge “undergoes continuous evolution and growth” (Whirlpool, para. 74) must be read together with other classic comments that are still applicable.
 As noted in General Tire & Rubber Co. v. Firestone Tyre & Rubber Co. Ltd,  RPC 457,  FSR 417 (U.K.C.A.) (General Tire) at pp. 482-483 (of the RPC):
The common general knowledge imputed to such an addressee must, of course, be carefully distinguished from what in patent law is regarded as public knowledge. This distinction is well explained in Halsbury's Law of England, Vol. 29, para. 63. As regards patent specifications it is the somewhat artificial (see per Lord Reid in the Technograph case  F.S.R. 188 at 193) concept of patent law that each and every specification, of the last 50 years, however unlikely to be looked at and in whatever language written, is part of the relevant public knowledge if it is resting anywhere in the shelves of the Patent Office. On the other hand, common general knowledge is a different concept derived from a commonsense approach to the practical question of what would in fact be known to an appropriately skilled addressee – the sort of man, good at his job, that could be found in real life.
The two classes of documents which call for consideration in relation to common general knowledge in the instant case were individual patent specifications and “widely read publications”.
As to the former, it is clear that individual patent specifications and their contents do not normally form part of the relevant common general knowledge, though there may be specifications which are so well known amongst those versed in the art that upon evidence of that state of affairs they form part of such knowledge, and also there may occasionally be particular industries (such as that of colour photography) in which the evidence may show that all specifications form part of the relevant knowledge.
As regards scientific papers generally, it was said by Luxmoore, J. in British Acoustic Films (53 R.P.C. 221 at 250):
“In my judgment it is not sufficient to prove common general knowledge that a particular disclosure is made in an article, or series of articles, in a scientific journal, no matter how wide the circulation of that journal may be, in the absence of any evidence that the disclosure is accepted generally by those who are engaged in the art to which the disclosure relates. A piece of particular knowledge as disclosed in a scientific paper does not become common general knowledge merely because it is widely read, and still less because it is widely circulated. Such a piece of knowledge only becomes general knowledge when it is generally known and accepted without question by the bulk of those who are engaged in the particular art; in other words, when it becomes part of their common stock of knowledge relating to the art.” And a little later, distinguishing between what has been written and what has been used, he said:
"It is certainly difficult to appreciate how the use of something which has in fact never been used in a particular art can ever be held to be common general knowledge in the art."
Those passages have often been quoted, and there has not been cited to us any case in which they have been criticised. We accept them as correctly stating in general the law on this point, though reserving for further consideration whether the words “accepted without question” may not be putting the position rather high: for the purposes of this case we are disposed, without wishing to put forward any full definition, to substitute the words “generally regarded as a good basis for further action.”
 In Mahurkar v. Vas-Cath of Canada Ltd. (1988), 16 F.T.R. 48, 18 C.P.R. (3d) 417, Justice Barry Strayer noted, at para. 27:
In reviewing the prior art I have also been persuaded by counsel for the plaintiff that an objective test should be applied to determine whether the hypothetical skilled workman in the art could be reasonably assumed to have knowledge of such prior art. There appears to be adequate authority in the jurisprudence for such a test. No evidence was produced by the defendants to show that the ordinary skilled workman should be assumed to have been aware of all of this prior art. Frankly I find it difficult to believe that several of the items of prior art would have been present to the mind of the ordinary skilled workman in 1981.
 Furthermore, as noted by Justice Karen Sharlow in Janssen-Ortho Inc. v. Novopharm Ltd., 2007 FCA 217, 366 N.R. 290, at para. 25 (citing factors developed by Justice Hughes in Janssen-Ortho Inc. v. Novopharm Ltd., 2006 FC 1234, 301 F.T.R. 166 (Janssen-Ortho (2006)):
Not all knowledge is found in print form. On the other hand, not all knowledge that has been written down becomes part of the knowledge that a person of ordinary skill in the art is expected to know or find.
 With respect to the proof required to establish common general knowledge, this passage from Simon Thorley et al., Terrell on the Law of Patents, 16th ed. (London: Sweet & Maxwell, 2006) (Terrell), at 6-39 is relevant:
Proof of common knowledge is given by witnesses competent to speak upon the matter, who, to supplement their own recollections, may refer to standard works upon the subject which were published at the time and which were known to them. In order to establish whether something is common general knowledge, the first and most important step is to look at the sources from which the skilled addressee could acquire his information.
The publication at or before the relevant date of other documents such as patent specifications may be to some extent prima facie evidence tending to show that the statements contained in them were part of the common knowledge, but is far from complete proof, as the statements may well have been discredited or forgotten or merely
ignored. Evidence may, however, be given to prove that such statements did become part of the common knowledge.
 In the present case, most of the printed information cited by Apotex’s experts was provided to them by the office of Ivor Hughes, one of Apotex’s counsel. Originally, Dr. Sarkis from that office was scheduled to appear as a witness. However, he did not testify and no evidence was given as to how the search for this literature was conducted. With the exception of one answer, given during Dr. Barrett’s testimony, that Chemical Abstracts were not available in electronic form at the relevant time, the Court still does not know what research tools, if any, would have been available. This is particularly important when one considers that this information was used by experts, such as Drs. McClelland, Olah and Martin, who did not work in the area relevant to the process patents at the relevant time, nor did they have a particular interest or focus on β-lactam, let alone cephalosporin compounds. Such experts could not rely on their own experience and memories of these publications and they opined on the validity of various process patents at issue simply on the basis of the written material provided to them.
 Even Dr. Hanessian, who was, to some extent, working in that field in the late 1970’s, does not properly address the notion of common general knowledge and what search would normally be done at the time by the skilled addressee. He noted during one of his cross-examinations that he was aware of some of the materials given to him but did not specify when he had become aware of this material during his career. Was it only in the 1980’s when he got more deeply involved with cephalosporins?
 Certainly none of these experts describe the beliefs and biases commonly held by such an addressee at the relevant time that could not be expressed in printed form.
 The distinction between common general knowledge and prior art which is part of the state of the art for the purpose of assessing anticipation and obviousness tends to diminish in modern times because of the sophistication of search engines and the availability of electronic publications and databases. Nevertheless, the degree to which a particular publication was “generally regarded as a good basis for further action” (General Tire, at p. 483) is still very relevant when one considers issues such as obviousness, where mosaicing is permitted in certain circumstances.
 That said, the Court will now turn to the immediate task at hand, which is the construction of the individual patents.
4.3. The ‘007 Patent
 The claims of the ‘007 patent that remain at issue are claims 1, 4 (dependent on claims 1, 2 or 3), 13 (dependent on claims 8, 9 or 10), 17 (dependent on claims 8, 9 or 10) and 18 (dependent on claims 8, 9 or 10). Claims 1 and 4 are compound claims, whereas claims 13, 17 and 18 are process claims. It is not necessary to reproduce all of these claims here; an example of each type will suffice.
 The Court will use claims 1 and 17, as their construction has been a subject of dispute between the parties. These claims read as follows:
1. A halogenating compound of the general formula
which is the kinetically controlled product of the reaction of equivalent amounts of a triaryl phosphite of the formula
and chlorine or bromine in a
substantially anhydrous inert organic solvent wherein in the above formulas Z
is hydrogen, halo, C1-C4 alkyl or C1-C4
alkoxy, and X is Cl or Br.
17. The process of claim 8, 9 or 10 wherein the solvent is an aromatic hydrocarbon or halogenated hydrocarbon.
However, to better understand claim 17, one must look, for example, as to how it would read if one used the process described in claim 8. It would cover a process for preparing a halogenating compound of the general formula:
which is the kinetically controlled product of the reaction of equivalent amounts of a triaryl phosphite of the formula:
and chlorine or bromine in substantially anhydrous inert [aromatic hydrocarbon or halogenated hydrocarbon] wherein the above formulas Z is hydrogen, halo, C1-C4 alkyl or C1-C4 alkoxy, and X is Cl or Br.
 It is also useful to reproduce claim 6 which, although not at issue, has been referred to by all parties when discussing the essential elements of claims 1 and 4 in particular.
6. A compound having the empirical formula
(a) has a 31P nuclear magnetic resonance signal in methylene chloride at -3.7 ppm relative to that of phosphoric acid;
(b) has in, methylene chloride, an infrared spectrum which exhibits the following characteristic absorptions: 1120-1190 (very strong), 1070 (very strong), 1035 (strong), 1010 (very strong), 990 (very strong), 640 (medium), 625 (medium) , 580 (weak), 510 (strong) and 465 (weak)
(c) reacts with water to give HCl and triphenyl
(d) reacts with n-butanol to give HCl n-butyl
chloride, and triphenyl phosphate.
 The common elements of claims 1, 4, 13, 17 and 18 are (1) a halogenating compound of the general formula described therein; (2) which is the kinetically controlled product; (3) of the reaction; (4) of equivalent amounts; (5) of triaryl phosphite; (6) and Cl or bromine (Br); (7) in a substantially anhydrous inert organic solvent. It is not disputed that these seven elements (in the form covered by each claim) are essential elements of these claims.
 The parties disagree, however, on whether or not the specific solvent described in claim 17 is an essential element of that claim. This will be discussed later. They also disagree as to the impact of the words “[a] halogenating compound” at the beginning of claim 1, for example. Is claim 1 a Shell Oil type claim (Shell Oil Co. v. Canada (Commissioner of Patents),  2 S.C.R. 536, 142 D.L.R. (3d) 117), i.e. a claim for a new use of the kinetically controlled product of the reaction described therein, or is the reference to halogenating compounds simply a description of the nature or class of the compound described by formula I per se? There is also a dispute as to whether or not the term “kinetically controlled product” necessarily and implicitly includes the properties described in Table 1 (p. 8 of the disclosure) as an essential element when the reaction is between TPP and Cl (i.e. where Z and X of the formula in claim 1 is H and Cl respectively).
 It is undisputed that “substantially anhydrous inert organic solvent” means a solvent that is not going to react with the compound and that is substantially water-free or contains
little water. The term substantially anhydrous, as used in the disclosure and the patent, is also defined at p. 14 to mean that:
although anhydrous organic solvents are
generally preferred, trace amounts of water, such as that often found in
commercially available solvents, can be tolerated. Although the kinetic products
described herein will react with any water present in the solvent medium,
additional amounts of reagents can easily be added to compensate for the loss.
It is preferred that conventional laboratory techniques be employed to dry the
solvents employed and to exclude moisture from the reaction mixtures.
 Although the
disclosure describes suitable solvents that can be used in great detail at pp.
14 and 15 it is also stated that the “[p]referred solvents for the preparation
of the [claimed] compounds are hydrocarbons, especially aromatic hydrocarbons,
and halogenated hydrocarbon solvents”, such as those specifically referred to
in claim 17. In addition, “[t]he particular inert organic solvent employed as a
medium for the preparation of the […] triaryl phosphite-chlorine complex or as
a medium for its use in halogenation processes is not critical”.
 With respect to the nature of the invention, the disclosure states, at p. 1, that it is “directed to a novel class of halogenating agents which are useful in preparing 3-halo-3-cephems.” The said halogenating agents are described as “highly reactive halogenating compounds, having the structural formula [I]” and “derived from the reaction of a triaryl phosphite and chlorine or bromine respectively.” It then states that “[a] number of
halogenating agents derived from halogens and phosphorus or phosphorus containing compounds have been described” in the prior art and that:
[o]f those prior art compounds, those most closely related to the present compounds are the triphenyl phosphite dihalides which have an empirical formula identical to that of the present compounds. See, for example, D. G. Coe, S. R. Landauer, and H. N. Rydon, J. Chem. Soc., 2021 (1954) and H. N. Rydon and B. L. Tonge, J. Chem. Soc., 3043 (1956).[]
 At p. 3, the disclosure acknowledges that “the present halogenating compounds can be described as intermediates, previously unrecognized, in the preparation of the prior art triaryl phosphite dihalides from triaryl phosphites and chlorine or bromine.” (Emphasis added.)
 The disclosure also states that, although the prior art triaryl phosphite dihalide and the claimed triaryl phosphite-halogen compound have two discrete molecular forms (i.e. a kinetic form and a thermodynamically stable form described in the prior art), their exact molecular forms have not been established definitively. Therefore, the dot (●) in the general formula used for example in claims 1 and 17 (dependent on claim 8, 9, or 10):
is used simply to designate that equivalent amounts of halogen and phosphite reagent are combined chemically and in a way that can be distinguished from that in the prior art compounds which typically have been drawn without the dot.
[p. 4 of the disclosure]
The only further information with respect to the molecular form of the claimed compounds is that “physical-chemical data do indicate that the kinetic product is one wherein the phosphorus center acquires some cationic character.”
 At p. 15, the specification also states that:
the triaryl phosphite-halogen complexes of the present invention are potent halogenating agents. Like the prior art thermodynamically stable triaryl phosphite dihalide compounds, the present kinetic complexes react with aliphatic alcohols to provide the corresponding alkyl halides (with different by-products). Unlike the prior art triaryl phosphite dichlorides, however, the present compounds efficiently halogenate under mild conditions both enolic groups to form the corresponding vinyl halides and, in the presence of base, amido functions to form the corresponding imino halides.
More particularly the present halogenating complexes can be used in preparing known 3-halo-cephem antibiotics of the formula [V].
[Emphasis and footnote added; emphasis in the original omitted.]
 However, as mentioned earlier, there is no specific reference to this use of the claimed compounds or processes in any of the claims.
 The disclosure discusses in some detail how the reaction should be carried out to maximize the formation of the kinetically controlled products and means for stabilizing those products. However, except for claims 18 and 8, where the reaction temperature for carrying out the process of the claims described therein is stated as “about -70 to about 0º C” and, to some extent, claims 17 and 27, which specifically refer to the solvent being an aromatic hydrocarbon or halogenated hydrocarbon, none of the claims include elements directed to stabilizing or improving the formation of the kinetically controlled product of the reaction described in the claims.
 The disclosure describes in some detail how the kinetically controlled product converts to a corresponding thermodynamically stable prior art form at varying rates, depending on, among other things, the nature of the triaryl phosphite, the halogen, the solvent and the solution temperature (see pp. 6-11) and discusses the half-life of the kinetically controlled product as well as how to use 31P NMR to determine the half-life of the product or its presence in solution. It also lists in Table 1 on p. 8 five indicia, or properties, differentiating the kinetically controlled product and the thermodynamically controlled product of the reaction of TPP and Cl. These are 1) a 31P NMR shift in CH2Cl2; 2) the half-life in CH2Cl2; 3) infrared data; 4) the reaction products obtained when each compound is hydrolyzed; and, 5) the reaction products with N-Butanol (See also p. 7, lines 18 to 21; p. 2, line 20 to p. 3, line 3; p. 9, lines 1 to 8). Again, except for claims 6 and 7, there is no express reference to such characteristics in the claims.
 The disclosure of the ‘007 patent includes 10 examples and only examples 1 and 2 provide corresponding 31P NMR data to identify the kinetically controlled product obtained in methylene chloride from the reaction of TPP with Br (example 1) and TPP with Cl (example 2). In both instances, it appears that a +3.7 ppm shift was observed./ The 31P NMR for the thermodynamic product was described as -22.7 ppm.
 As noted, claim 6 (an independent claim) expressly refers to four properties of the product from the reaction of TPP and Cl listed in Table 1. This includes a 31P NMR shift at +3.7 ppm (in CH2Cl2), IR data, by-products of hydrolysis and reaction with N-Butanol. Claim 7 covers the kinetically controlled product of the reaction of TPP with Br in methylene chloride and only refers to the 31P NMR resonant signal at +3.7 ppm. Although these two claims are not at issue, as mentioned in Hoffmann (2005) and Halford, they can be useful in construing the claims at issue.
 Each claim is generally to be given a distinct and effective meaning. It is clear that claim 6 is more limited in scope than claim 1 because it covers only a subset of the compound, i.e. when Z = H and X = Cl. In my view, it is also evident that they have different essential elements given that these claims adopt a very different approach to delineate the monopoly they cover. In claim 1, the general formula representing the halogenating compound is only particularized by reference to the kinetically controlled nature of the product and the main features of the reaction producing it (i.e. how it can be obtained). Conversely, claim 6 defines its monopoly by reference to the empirical formula of the compound and the properties that further distinguish it from the prior art dihalides having a similar empirical formula (Table 1, p. 8).
 Inasmuch as one could not construe claim 6 as including, as essential elements of the claim, the reaction of equivalent amounts of the materials described in claim 1 without rewriting the claim, one could not construe claim 1 as including as its essential elements the properties described in claim 6. If, by construing the claim, one were to limit or incorporate the elements of one independent claim into the elements of another independent claim, one would disregard the right of the inventors to adopt different ways of defining their monopoly and describing different aspects of an invention, which may or may not be too limited or too wide.
 Having considered the specification as a whole, the Court can now address the main issues raised by the parties (see para. 110, above).
 The Court cannot accept Apotex’s argument (summarized at paras. 151-160 of its memorandum on infringement) that the expression “kinetically controlled product” in claim 1 would be read and understood by a posita as including as one of its essential elements, a 31P NMR shift of +3.7 ppm (or any other data included in claim 6) when applied to the kinetically controlled product of the reaction between TPP and Cl.
 Among other things, the Court notes that the disclosure, at pp. 4 and 5, is quite specific as to the meaning of this term:
[H]erein, the terms “kinetic compound,” “kinetic complex,” “triaryl phosphite-halogen complex (compound)”, “kinetically controlled halogenating compounds,” and “kinetically controlled product (compound)” are used synonymously and likewise are to be distinguished from those triaryl phosphite dihalides of the prior art.
The term kinetically controlled product is a term of art which, when used in reference to reactions yielding two (or more) products, refers to the product formed faster, regardless of its thermodynamic stability.
 There is evidence from Dr. McClelland that a skilled person would understand the meaning of “kinetically controlled product” without even consulting the disclosure preceding the claims. In any event, after discussing various criteria contained in the disclosure, such as half-life and reactivity, which distinguish the claimed compound from the thermodynamic product, Dr. McClelland states that:
This is criteria, but the basic term, “kinetic complex,” as used in the patent, indicates that it’s not stable in regards to what its half-life is, and that it would convert to the thermodynamic complex with time.[]
 This is perfectly in line with the Court’s understanding of the patent.
 Given the uncertainty as to the molecular structure, Apotex’s experts appear to focus on the need to better understand and identify the claimed compounds. For this purpose they use the properties described in Table 1 which in fact concern only one such compound.  The inventors did not wish to be tied down to a particular molecular structure and they used the formula with a dot (●) only to distinguish the claimed compounds from the thermodynamic compounds described in the prior art. It is evident that the information given in Table 1 and elsewhere in the disclosure will enable the posita to more easily identify and use the claimed compounds and processes. This does not however answer the question of law as to whether these elements are included in claim 1 as essential elements of the monopoly described therein.
 Also, Dr. McClelland clearly adds words to the disclosure when, in para. 15 of his affidavit (TX-1764) he states that:
[t]he skilled chemist would understand from the patent that these criteria such as the 31P NMR chemical shift and the IR are to be employed to distinguish the novel kinetic product […] claimed in the Patent from the prior art, i.e. from the thermodynamic product […] and other previously unrecognized halogenating compounds with the same empirical formula.”[]
In fact, there is no mention in the specification that the inventors are trying to distinguish their claimed kinetic product from previously unrecognized intermediates made using Rydon. On the contrary, they clearly focus on distinguishing the kinetic products from the prior art dihalides, i.e. the thermodynamic form of the compounds disclosed in the prior art.
 The idea that a posita would try to determine what novel compound was claimed, meaning according to Dr. McClelland, what differentiated the previously made and unrecognized compound in Rydon versus the claimed compound, is not acceptable. Even the Courts had not specified that previously made but unrecognized compounds could prevent Lilly from claiming novelty in the ‘007 patent until the decision of the House of Lords in Merrell Dow Pharmaceuticals Inc. and another v. HN Norton & Co. Ltd. and others,  BMLR 201,  RPC 76 (Merrell Dow Pharmaceuticals Inc.) in 1995 and in Canada until the decision of the Federal Court of Appeal in Abbott Laboratories v. Canada (Minister of Health), 2006 FCA 187, 350 N.R. 242 (Abbott (2006)).
 The Court is not convinced that Apotex has established that Tseng and Michalski’s articles, particularly the information the authors give about 31P NMR shift of the substances discussed therein, were part of the common general knowledge available to the addressee of the patent at the date of issuance. That said, to avoid any collateral debate, the Court did in fact consider this information to determine if it would have any impact on the construction at issue and concluded that it would not. It is therefore not useful to elaborate further on this.
 Also in respect of common general knowledge, the Court agrees with Apotex that Dr. Gorenstein’s evidence, to the effect that it was well-known and part of the general common knowledge at the relevant time, that 31P NMR shifts were susceptible to variations of several ppm (more than the ±1 ppm advanced by some of Apotex’s experts) for a given compound as a result of very many variables, was not proper reply evidence because Dr. Hunter had already addressed this very issue in a prior affidavit. But this conclusion is of no moment, given that the Court found Dr. Hunter’s evidence credible in that respect and gave it much weight, but more importantly because this evidence has little impact, if any, on the Court’s conclusion in respect of the construction of claims 1 and 4. Again, like the Tseng and Michalski articles, it may well have an impact on the construction of claim 6 but this claim is not at issue and the Court certainly does not need to decide what variant, if any, would be covered by the express reference to a shift of +3.7 ppm.
 Turning now to the second element in dispute, the Court must also reject Lilly’s argument that claim 1 is a Shell Oil-type claim, where the invention is a new use of a previously unrecognized compound as opposed to a classic compound claim.
 There is no mention in the patent that the previously unrecognized intermediate discussed in the disclosure was not a halogenating compound and should be distinguished in any way from the claimed compound on that basis.
 However, as mentioned earlier, it is clearly stated in the disclosure that both the thermodynamic products and the kinetically controlled products of the reactions described in the claims are halogenating compounds. The only discussion of a new or distinct use of the kinetically controlled compound is in contradistinction with the prior art triaryl phosphite dihalides and it concerns their ability to efficiently halogenate under mild conditions both enolic groups and their “utility” in preparing known 3-halocephem antibiotics of the formula described on p. 15 of the patent. The words “a halogenating compound” cannot be meant to infer those distinctions. The Court is thus satisfied that the reference to “halogenating compounds” is simply descriptive of the class of compounds to which the claimed compounds pertain. The invention as described and claimed is thus the compounds themselves and the processes to produce these compounds.
 With respect to claim 17, the Court must determine whether or not the particular solvent (an aromatic or halogenated hydrocarbon) is an essential element of the claim. As noted earlier, the disclosure states that the particular inert organic solvent employed is not critical to the making of the claimed compounds so long as it is substantially anhydrous. On the other hand, it is undisputed that an anhydrous solvent is essential for the process to work and the only solvents in claim 17 are the preferred solvents described on p. 15 of the patent.
 As a dependent claim, it covers a particular embodiment of the invention described in claim 8, 9 or 10. The solvent is its only distinguishing feature. Here it is worth pointing out again that one of the main purposes of establishing what is essential in that claim is to determine what element cannot be varied in an allegedly infringing product. In other words, could one infringe claim 17 without using an aromatic or halogenated hydrocarbon. To ask the question is to answer it, which answer is obviously no.
 To say otherwise would mean that this claim is not distinct at all from claim 8, 9 or 10. As described in Whirlpool and Free World Trust, there are limits to how the Court may use the disclosure to construe the claims. The disclosure cannot be used to rewrite a claim. If an inventor has clearly limited his or her monopoly by making essential what is clearly not necessary to the proper working of the invention, he will suffer the consequences and will not be able to prevent a third party from using his invention for it will be able, with a simple variation, to avoid infringement.
 To adopt Apotex’s position that the solvent in claim 17 is a non-essential element would mean that this claim is essentially read out of the patent and has absolutely no meaning.
 It may well be that the claim is invalid for lack of novelty or inventiveness or that it is not patentably distinct but that is not to be decided at this stage.
4.4. The Lilly Process Patents
 It is not disputed that the applications for these three process patents were filed on the same day as the ‘007 patent.
 The Lilly process patents relate to the use of the kinetically controlled product discussed in the ‘007 patent, to effect, either alone or in any combination, the following steps: cephalosporin sulfoxide reduction, enol chlorination and imino halide formation. The schematic depictions of these steps are described in para. 18 or Dr. Baldwin’s report (E-6) as follows:
 Optionally, included within some of the claims of each of the Lilly process patents, is a subsequent alcoholysis (converting the imino halide intermediate to an amine) and salt formation steps. That said, and given that the construction of the claims in the patents raises no substantial issue, the Court will only discuss the ‘536 patent in some detail, for this is the most comprehensive, and will briefly deal with the other two patents.
4.4.1. The ‘536 Patent
 The following are the claims being pursued at trial: 4-6, 8, 11, 14-18, 20-22, 27 and 30-34. They are all dependent claims.
 The ‘536 patent is entitled “Cephalosporin reduction process”. The specification starts by disclosing that “[c]ephalosporin sulfoxides are widely used intermediates in the synthesis of cephalosporin antibiotics.” Several examples are provided and relevant prior art, such as two patents by Dr. Douglas C. Spry, one by Dr. Stjepan Kukolja and a couple of patents by Dr. Robert R. Chauvette. It states in particular at p. 2 that the “3-exomethylenecepham sulfoxides are useful intermediates in the preparation of the 3-halo substituted cephalosporins described by Chauvette […] and in the synthesis of the 3-methoxy-3-cephem antibiotic compounds described by Chauvette […].”
 At p. 3, it is noted that “[p]rior to this invention one preferred method for reducing cephalosporin sulfoxide was that of Murphy et al., U.S. Pat. No. 3,641,014.” It also deals with other reduction methods, disclosed by Drs. Lowell D. Hatfield, Kukolja and Spry in other patents. It continues by saying, at pp. 3-4, that:
In view of the usefulness of cephalosporin sulfoxides in the synthesis of cephalosporin antibiotics, more efficient and more economical methods for sulfoxide reduction, have been the object of extensive research efforts. This invention provides a process for the reduction of cephalosporin sulfoxides. More particularly this invention is directed to a process for reducing cephalosporin sulfoxides using a recently discovered class of triaryl phosphite-halogen compounds, derived from the kinetically controlled reaction of equivalent amounts of triaryl phosphites and chlorine or bromine. The triaryl phosphite-halogen reducing compounds employed the present reduction process are useful for effecting other desirable chemical modifications (halogenation) of cephalosporin compounds. It is therefore another object of the present invention to provide processes for one step reduction/halogenation conversions of C-7 acylamino cephalosporin sulfoxides to 7-amino cephalosporins or depending on the cephalosporin starting materials and the amounts of reagents employed C-7 acylamino halogenated cephalosporins or C-7 amino halogenated cephalosporins.
Further, the invention is said to “also be directed to processes wherein the triaryl phosphite-halogen complex is utilized to effect multiple chemical conversions of the cephalosporin sulfoxide starting materials in one reaction mixture.”
 On p. 5, the disclosure says that the “products formed in the present process are known antibiotic compounds or intermediates thereto.”
 As in the ‘007 patent, at p. 9 one can read that:
The dot (●) in the general formula used to represent the kinetically controlled products employed in the present processes is used simply to designate that equivalent amounts of halogen and triaryl phosphite are combined chemically and in a way that can be distinguished from that in the thermodynamically stable derivatives that have been known in the art and which typically have been drawn without the dot [e.g. (PHO)3PCl2]. The exact molecular form of the triaryl phosphite-halogen kinetic complexes […] has not been established definitively […].
 The specification then discusses in detail the preparation of the kinetically controlled products, the solvents to be used, the reaction conditions, some properties distinguishing the kinetic product and the thermodynamic product when TPP and Cl are reacted in methylene chloride, including the data found in Table 1 of the patent which is identical to the one discussed earlier in respect of the ‘007 patent. It deals with temperatures and preferred conditions for the formation of the kinetically controlled products and their stabilization in a tertiary amine base as well as details of temperatures for carrying out the processes and chemical reactions claimed in the patent. At p. 17, it also mentions that, because the reduction process claimed produces Cl or Br as a by-product, “[i]n order to prevent undesirable side reactions between the halogen by-product and the cephalosporin product, a halogen scavenger is used in the reaction mixture to react with or inactivate the chlorine or bromine as it is formed.” The term “halogen scavenger” is defined and various such scavengers are discussed. Further details (such as quantities, etc.) as to how to use the kinetic product to effect one or a combination of the reactions claimed are also given.
 On p. 35, there is a discussion of how “[t]he triaryl phosphite-halogen complexes utilized as reducing agents in the present process are also potent halogenating agents” and how “[t]he multiple reactivity of the triaryl phosphite-halogen kinetic complexes is exploited in each of several alternate embodiments of the present invention.” At pp. 46-47, the inventor particularly mentions that:
combining the […] reduction/-enol-imino halogenation (Scheme III above [found on p. 36 of the patent]), using a triaryl phosphite-chlorine complex, with subsequent alcoholysis of the resulting imino chloride constitutes an improved method of preparation of 7-amino-3-chloro-3-cephem-4-carboxylic acid esters [7-ACCA] from the corresponding 7-acylamino-3-hydroxy-3-cephem-4-carboxylic acid ester sulfoxides. Prior to this invention the total 3-function conversion was effected either in 3 separate steps, that is reduction, chlorination and side chain cleavage or in two steps, either combining reduction and chlorination (see U.S. Patent No. 4,115,643) with subsequent side chain cleavage or by combining chlorination and side chain cleavage after reduction of the sulfoxide entity, for example, using the method disclosed in U.S. Patent No. 4,044,002. With the discovery of the present process the reduction, chlorination and cleavage conversion can be executed in excellent yields in one reaction vessel without isolation of intermediates.
 This is said to be of particular significance, given that the 3-halocephem nucleus ester “can be acylated using conventional acylation techniques and subsequently deesterified to provide known antibiotic compounds [particularly cefaclor]” (p. 47, lines 6-14).
 After providing 96 examples, the 70-page disclosure concludes with a list of 52 claims.
 For the purpose of considering what aspects of the construction of the claims are at issue here, it is sufficient to reproduce claims, 1, 9, 10 and 11.
 Claim 1:
A process for reducing a cephalosporin sulfoxide to the corresponding cephalosporin which comprises reacting said cephalosporin sulfoxide with a triaryl phosphite-halogen complex of the formula
wherein X is Cl or Br, and Z is hydrogen, halo, C1-C4 alkyl or C1-C4 alkoxy, which is the kinetically controlled product of the reaction of equivalent amounts of a triaryl phosphite of the formula
and chlorine or bromine in an inert organic solvent,
in the presence of at least 1 equivalent of a halogen scavenger per equivalent of cephalosporin sulfoxide in a substantially anhydrous inert organic solvent at a temperature of about 30°C. or below;
(a) about 1.0 to about 1.3 equivalents of the triarylphosphite-halogen complex per equivalent of cephalosporin sulfoxide are employed when the reduction of the sulfoxide group is the only reaction desired,
(b) about 2 to about 3 equivalents of the triarylphosphite-halogen complex per equivalent of cephalosporin sulfoxide are employed when the cephalosporin sulfoxide is a 3-hydroxy cephalosporin sulfoxide and it is desired to simultaneously reduce the sulfoxide and halogenate the 3-position, or the cephalosporin sulfoxide is a 7-acylamino cephalosporin sulfoxide and it is desired to simultaneously reduce the sulfoxide group and convert the acylamino group to an imino halide group, and
(c) about 3 to about 5 equivalents of the
triaryl phosphite-halogen complex per equivalent of cephalosporin sulfoxide are
employed when the cephalosporin sulfoxide is a 3-hydroxy-7-acylamino
cephalosporin sulfoxide and it is desired to simultaneously reduce the
sulfoxide group, halogenate the 3-position, and convert the acylamino group to
an imino halide group; and further provided that when the cephalosporin
sulfoxide has a free amino, hydroxy or carboxy group on the C-7 substituent,
those groups are first protected by conventional amino, hydroxy or carboxy
 There is no dispute as to the meaning of this claim and no issue as to whether or not certain elements described therein are essential. What is clear is that the claim requires the following elements: (i) cephalosporin sulfoxide; (ii) kinetic complex as defined by the formula and the reaction of equivalent amounts of the components described therein; (iii) at least one equivalent of halogen scavenger per equivalent of cephalosporin sulfoxide; (iv) an anhydrous inert organic solvent; (v) a temperature of 30º C or below; and, (vi) that certain quantities of kinetic complex be used depending on how many steps one wishes to perform.
 Claim 4 is dependent on claims 1 and 3 and specifies the various substituents on the cephalosporin sulfoxide starting material involved in the reaction. Claim 5 is dependent on claims 1, 2 and 3 and limits the starting material to 3-cephem sulfoxide or 3-exomethylene cepham sulfoxide. Claim 6 is dependent on claim 1 but includes specific halogen scavengers. Claim 8 is dependent on claims 1 or 2 with a more specific temperature range.
 Claims 9, 10 and 11 read as follows:
9. The process of claim 1 wherein X is Br.
10. The process of claim 9 wherein Z is hydrogen.
11. The process of claims 1, 2 or 10 wherein X is Cl.
 There was an
argument raised by Apotex as to how one could construe claim 11, given its
reference to claim 10, which itself refers to claim 9, wherein X is Br, whereas
according to claim 11, X is Cl. There is little doubt that a person skilled in
the art with a mind willing to understand would simply disregard this
apparent contradiction and would understand claim 11 to apply only to processes
wherein X is Cl. The reference to claim 10 being understood to refer to the
process where Z is hydrogen.
 Claim 14 is dependent on claims 1, 12, and 13 “wherein the tertiary amine base is pyridine.” Claim 15 is the process of claim 1 where the “solvent is an aromatic or halogenated hydrocarbon.” Claim 16 is dependent on claims 1 and 15 but further limits the solvent to methylene chloride. Claim 17 is dependent on claims 1 and 3 but limits the acyl group R3. Claim 18 covers a one step reduction process only using a TPP and Cl complex having the characteristic of +3.7 ppm signal (again, as per the new convention) and specific infrared data described in the claim. While claim 20 (dependent on claims 1 and 19) covers a two step process (reduction of sulfoxide/halogenation of the enol chlorination) using a TPP and Cl complex as a reagent, claim 21 (dependent on claims 1, 19 or 20) deals again with the two steps described above using the TPP and Cl complex but in the presence of a tertiary base. Claim 22 is another claim dependent on claims 1 and 19 which covers specific halogen scavengers.
 Claim 27 is dependent on claims 1, 19, 20, or 25, which deals with situations where X is Cl and it appears to be somewhat redundant in respect of claim 20, which already refers to the use of TPP and Cl complexes. Claim 30 is dependent on the process of claim 1 for specific cephalosporins with the use of pyridine as a tertiary amine base. Claim 31 is dependent on claims 1 and 19 for specific cephalosporins wherein the inert organic solvent is an aromatic or halogenated hydrocarbon. Claim 32 (dependent on claims 19, 20, or 31 and thus, claim 1) further limits the solvent to methylene chloride. Claim 33 is dependent on claims 19 or 20 and claim 1, with a specific acyl group. Claim 34, like claim 18, includes a description of the characteristics of the TPP and Cl complex to be used in the process such as infrared data and 31P NMR shift. It applies in the context of a two step process (or imino halide formation process).
 As with the construction of claim 1 in the ‘007 patent, the Court does not find that the 31P NMR shift of +3.7 ppm and presumably the IR data described in Table 1 of the ‘536 patent are essential elements of any of the claims which simply refer to the kinetically controlled product of the reaction of a triaryl phosphite and Cl or Br in an inert organic solvent. This is particularly clear when one considers that claim 18 (dependent on claim 1) only has two distinguishing features – these two properties.
 From all of the above, the Court concludes that the invention is alternative or improved processes as opposed to new processes for transforming cephalosporin sulfoxides. It consists mainly in the use of the kinetically controlled product described therein as the reagent and in the fact that said reagent may be used to make up to three reactions or steps in one pot.
4.4.2. The ‘725 Patent
 The claims at issue here are claims 1 (the only independent claim in the patent), 16, 22 to 27 and 30. The patent is entitled “Process for Halogenation of β-lactam Compounds”. The ‘725 patent claims a process again requiring the use of the kinetically controlled product of the reaction of equivalent amounts of defined triaryl phosphite and Cl or Br as halogenating agents to convert the 3-hydroxy group at the 3-position of a cephem ring to a halo group as well as a process using the same kinetic product to convert a class of halides to corresponding amino halides (two of the three steps already described in respect of the ’536 patent). Again, on p. 28, the specification notes that “[c]ombining the aforedescribed enol-halogenation/imino-halogenation process, where X is Cl, with subsequent alcoholysis of the resulting imino chloride constitutes an improved method of preparation of the 7-amino-3-chloro-3-cephem-4-carboxylic acid esters”. It is then mentioned, on p. 29, that this is of particular significance given that the 3-halocephem nucleus esters “can be acylated using conventional acylation techniques and subsequently deesterified to provide known antibiotic[s]”, such as cefaclor.
 Forty-eight examples are then provided and the patent ends with 30 claims, some of which include the alcoholysis step after the formation of the imino chloride products is complete (see for example claim 27, a process claim dependent on claim 16). There is only one claim at issue (claim 30) that includes a reference to the various characteristics of the specific kinetically controlled product described therein (all the characteristics found in Table 1, reproduced at p. 8, except the half-life).
 Claim 1 covers the process described previously using the kinetic complex made in a substantially anhydrous inert organic solvent at a temperature below about 30º C in a prescribed ratio depending if one desires to simply halogenate the enol of formula V (about 1.0 to about 1.3 equivalents of triarylphosphite-halogen complex per equivalent of cephalosporin starting material) or to also carry out imino-halogenation (about 2.0 to about 3.0 equivalents of triarylphosphite-halogen complex per equivalent of cephalosporin starting material). The imino-halogenation must also be carried out “in the presence of about 1.0 to about 1.2 equivalents of a tertiary amine base per equivalent of [kinetic complex].”
 Claim 16 is dependent on claim 15 which covers the process of claim 1 for preparing 7-imino halide-3-halo-3-cephem from 7-acylamino-3-hydroxy-3-cephem. Claim 16 covers said process where the kinetic complex is TPP and Cl.
 Claim 22 covers the process of claim 15 where X is Cl while claim 23 covers the same process but where Z is hydrogen and X can be either Cl or Br. Claims 24 and 25 depend on claim 15 but limit the type of solvents (aromatic or halogenated hydrocarbon and methylene chloride respectively). Claim 26 is dependent on claim 15 or 16 and specifies the acyl group.
 For reasons already given in respect of claims 18 and 34 of the ‘536 patent, the Court does not need to determine the essential elements of claim 30, given that it will not deal with the issue of infringement for such claim. Furthermore, as there are no other disagreements as to the construction of any of the other claims at issue, there is little more to say other than this patent also relates to an alternative or improved process (one or two steps in one pot) where the key feature is the use of the kinetically controlled product of the reaction described therein as reagent.
4.4.3. The ‘468 Patent
 This process patent is entitled “Process for Preparation of Penicillin and Cephalosporin Imino-Halides”. The patent contains only two independent
claims, i.e. claims 1 and 8. The claims at
issue are dependent claims 2, 7 and 17-20, as well as claim 8.
 The disclosure starts by making it clear that the process for “the cleavage of the C-6 or C-7 acylamino group to provide the corresponding C-6 or C-7 amino compounds which are reacylated […]” is known. Thus, the specification states on p. 2 that “an object of the present invention [is] to provide a new process for preparing penicillin and cephalosporin imino halides”, more precisely “to provide a high yielding method of preparing C-6 and C-7 imino halides of penicillin and cephalosporin respectively using novel triaryl phosphite-halogen kinetic complexes”. As this is the last of the three steps covered in the ‘536 patent and of the two steps covered in the ‘725 patent, it contains many similar details about the process itself and about the reagent and its preparation. The disclosure gives thirty examples and ends with 20 claims. The Court will not review the specific wording of any of those claims as there is no dispute between the parties as to their construction.
 Here again, and for reasons similar to those expressed in respect of the ‘007 patent, the Court does not consider the 31P NMR shift of the TPP and Cl complex (and the other properties described in Table 1) to be an essential element of claim 1 or its dependent claims that make no reference to such properties when describing the kinetic product to be used in the claimed processes. The only claims at issue that specifically referred to such properties are claim 8 and its dependent claims (one alternative in claims 17-20). As was noted in respect of claims 18 and 34 of the ‘536 patent, even if it is likely that these elements are essential elements of those claims, there was no argument presented in that respect. There is no need to make a judicial determination of this issue.
 Claim 7 is dependent on claim 5 or 6 and includes the optional alcoholysis step discussed earlier. Claims 17-20 are all dependent on claim 1 or 8. Claim 17 specifies a particular range of temperature, while claim 18 includes specific types of solvents. Claim 19 is limited to certain types of cephalosporins and claim 20 specifies that the halogenating compound in claim 1 or 8 is stabilized by a tertiary amine base.
 Once again, it is quite clear that the invention is an alternative or improved process, whose key feature is the use of the triaryl phosphite-halogen kinetic complex.
4.5. The Shionogi Patents
 Initially, Shionogi filed an application on February 9, 1976 to obtain a patent covering all the processes described therein, including the compounds obtained from some of these processes. This first application claimed a priority date based on the filing of the Japanese applications (February/March, 1975).
 During the patent examination process, the Patent Examiner noted that the application contained more than one invention. He identified four distinct groups of claims and requested amendments. Thereafter, four divisional applications were filed on October 19 and 22, 1979, resulting in the issuance of the four patents at issue. Thus, they all have an identical disclosure; only their claims vary as each now covers a separate portion of the overall synthetic pathway described in the specification which deals with the overall cyclization of the 6-membered ring structure with the concurrent introduction of an OH substituent at the 3-position of the ring that allows for the subsequent conversion of the substituent to Cl. Except in respect of the ‘026 patent where an issue of construction is raised, the content of such disclosure will only be discussed once. Also, because the construction of the claims at issue in each of these patents raises little dispute, my review will be brief.
4.5.1. Common Disclosure
 The disclosure starts with the following: “[t]his invention relates to the cyclization to form cephem ring, and the intermediates therefore. More specifically, it relates to a compound” of the formula:
where “the substituents can be combined to form an azetidinothiazoline bicyclic ring; and their enamine derivatives, and to the processes for the cyclization to form cephem ring
through the said intermediates shown above by the reactions representable by the following reaction scheme”:
 At p. 2 it is noted that:
Many trials for synthesizing 3-cephem ring in large scale have been reported, but no factory produce cephalosporins by synthesizing nucleus except for cephalexin.[] This invention provides mild cyclization to form 3-hydroxy-3-cephem compounds through 4-mercaptoazetidinone derivatives.
Efforts to cyclize a type of compounds of the formula (2) or (3) where Y is other than hydroxy or a substituted amino resulted in unsatisfactory results. However, when Y is a group which promotes enolization to form a double bond toward the exo-position, the cyclization took place smoothly to form the objective 3-hydroxy-3-cephem compound (4).
The 3-hydroxy-3-cephem compound (4) is a useful intermediates for synthesizing useful cephem compounds (e.g. recently developed 3-methoxy-7-(α-phenylglycinamido)-3-cephem-4-carboxylic acid [this is cefaclor], 3-chloro-7-(α-phenylglycinamido)-3-cephem-4-carboxylic acid, 3-bromo-7-(2-thienylacetamido)-3-cephem-4-carboxylic acid).
 On p. 17, line 23 to p. 18, line 14 of the disclosure, one finds that:
Halogenation of compounds representable by the formula (1) provided Y is other than amino took place smoothly in some cases and with difficulty in other cases. Main difficulty was the position where the halogen atoms was introduced. In other words, the priority of the desired position to other position in the molecule for halogenation was rather small, and it differs from a compound to other. Another factor which restrict Y to the scope given above is found not in the halogenation but in the following reactions, i.e. i) ease of deprotection to give a compound (I) where Y is hydroxy; and ii) ability to cyclize giving the desired cephem compound (4). The compounds representable by formula (1) provided Y is other than hydroxy cyclized unefficiently or insignificantly. From these observations, Y is restricted to include a hydroxy and substituted amino, as is explained above.
The deprotection 2) of the compound (2) can be carried out by treating the compound (2) with aqueous acid for the thiazolino-azetidine compound, and by treating the compound (2) where R is a carbonic acyl, with a Lewis acid.
The decomposition of the azetidinothiazoline compound with an aqueous acid is a new generic reaction for obtaining the 4-mercapto-3-carboxylic acylamino-2-oxoazetidine derivatives according to the reaction scheme
[Depicted on the said page.]
 On p. 22 of the disclosure after discussing the reactions claimed in the ‘026 patent, one finds that:
[t]he final product is a 3-hydroxy-3-cephem-4-carboxylic acid or 3-oxocepham-4-carboxylic acid (4). In some instances, the substituents at position 3 or 7 on the cephem ring change during the reaction or working up, and as a result, the corresponding substituents in the starting and produced materials differ each other. If desired, such substituents can be recovered or transformed into other required one by conventional methods. Such cases are also included in the scope of the present invention.
 And at p. 23, also concerning the ‘026 patent, that:
The halogenation 1), deprotection 2). and cyclization 3) can be carried out in one pot, namely without isolating intermediates, and even without removing each reaction solvents. Therefore, the reactions practically be done as simply as one step reaction (see Examples 2(2) and (3), and Examples 9 to 17 of Part III Cyclization).
[See also p. 33, lines 6-12.]
 The disclosure further indicates that the products of the claimed reactions (except for the 3-hydroxy or 3-oxo) are novel. The lengthy disclosure includes various details relevant to the carrying out of these processes and the preferred modes particularly the
reasoning behind the choice of
substituents and other products to be used such as acids, solvents, etc.
 One also finds the following statement at p. 33: “this invention provides the higher yielding and simpler process from less expensive penicillins to give valuable key intermediates, the 3-hydroxy-3-cephem-compounds.” Numerous examples are given in respect of each of the processes claimed in the individual patents. As mentioned, given that sufficiency was not an issue in respect of these patents. It is not useful to discuss further these examples or the details given.
4.5.2. The ‘547 Patent
 This patent, like the other three Shionogi patents, is entitled “Cyclization to Form Cephem Ring and Intermediates Therefore” and the disclosure ends with eight claims. The claims being pursued at trial are claims 1 (independent claim), 3, 5 and 7-8 (dependent claims).
 Those claims are directed to processes for preparing hydroxylated compounds from exomethylene compounds (penicillin derived compound, including the Cooper compound), via oxidative cleavage of the unsaturated bond of the exomethylene group and to the resulting compounds.
 Claim 1 can be summarized as follows:
A process for preparing
To oxidation followed by cleavage of the thus produced ozonide.
 The target compound of claim 1 is the compound claimed in claim 8. Claim 3 is dependent on claims 2 and 1 and relates to the specific use of ozone as the oxidizing material. Claim 5 is dependent on claims 1 and 4, and covers the reduction of the ozonide using specific reducing agents described therein. Claim 7 is dependent on claims 6 and 1 and covers the process of claim 1 in the presence of the specific solvents described therein.
4.5.3. The ‘924 Patent
 The claims at issue are 3-4, 8-9, 12, 27, 31 and 37. These claims are generally directed to processes for acylating azetidinone compounds and subsequently forming an enamine azetidinone.
 Claim 1 can be simplified as follows. A process for preparing:
(Enol form) (Keto form)
with an acylating agent to introduce the C2-12 carbonic acyl, the C1-20 sulfonyl group, and if required, subjecting such compound to a C2-20 disubstituted amine to give the amine compound.
 Claim 3 is dependent on claims 2 and 1 and covers the process where the selected compound is treated with the sulfonylating reagent mentioned therein. Claim 4 (dependent on claims 2 and 1) covers the process for preparing an acylated or sulfonylated azetidinothiazoline. Claim 8 claims a process of further reacting the acylated or sulfonylated compound of claim 1 with dialkylamine, including piperidino and morpholino. Claim 9 is dependent on claim 8 and deals with a specific substituted amino. Claim 12 (dependent on claims 10, 8 and 1) claims the same process wherein R’ is benzyl, X includes the carboxy protecting group benzyhydryloxy and the substituted amine is morpholino.
 Claim 27 covers a compound prepared by the process in claim 1 where specific functional groups are as defined in claim 1, whereas claim 31 covers a compound prepared by the process in claim 4 (which is dependent on claims 2 and 1) where specific functional groups are as defined in claim 4. Claim 37 covers a compound prepared by the process in claim 35 (which is dependent on claims 10, 8 and 1) wherein R’ is benzyl; Y” is a morpholino and, when prepared by the process of claim 12 (dependent on claims 10, 8 and 1), X is a p-nitrobenzyloxy, 2,2,2-trichloroethoxy, benzyloxy.
4.5.4. The ‘132 Patent
 The parties
have agreed that the halogenation described in the ‘132 patent can generally be
referred to as an allylic halogenation.
 Of the 76 claims in this patent, only claims 15, 22, 29, 34, 38 and 58 are at issue. Claims 15 and 22 are dependent on claim 1. Claim 15 specifies that the halogenating reagent is Cl, Br or iodine, whereas claim 22 is the process of claim 1 but for preparing specific compounds described therein.
 Claim 29 is a compound claim dependent on independent claim 24, which generally describes the compounds made using the process claimed in the previous claims (the formula in claim 24 is the same formula as in claim 1) with the same substituents. Claim 34 is another dependent claim, and, like claim 29, it claims a compound with specific substituents described therein.
 Claim 38, which is dependent upon claim 36 (and claim 1), covers a specific process involving treating a compound shown in claim 36 with particular substituents with a halogenating reagent which includes Br. The said compound includes a thiazoline β-lactam, in which the Y is a morpholino, the group R is benzyl and the group X may be benzhydryloxy.
 Finally, claim 58 covers the compound according to claim 56 prepared by the process of claim 38, where Y is a morpholino, Hal is a Br and X is one of three compounds listed therein, which includes benzhydryloxy.
 There was some dispute between the parties as to the meaning of “Hal” in the two independent claims, 1 and 24. Although this is not determinative in any way, given the specific wording of claims 29 and 58, which restrict the definition of “Hal” to a specific halogen other than fluorine, the issue is whether or not claims 1 and 24 would include fluorine as “Hal” in the formula described in the said claims. The disclosure is quite clear at p. 8 that “[h]alogen which may be represented by Hal in the formulae can be a chlorine, bromine, iodine, or fluorine, in which chlorine and bromine are most preferable.”
 Having considered the specification as a whole, including the various claims which specify which Hal is covered, the Court concludes that fluorine is included in the halogen (Hal) described in the formulas in claims 1 and 24, although it is evident that this is not the preferred halogen and would be so understood by a posita.
4.5.5. The ‘026 Patent
 The ‘026 patent has five claims. Generally, the claims of this patent relate to the two steps described in the disclosure as the deprotection and cyclization. The claims being pursued at trial were claims 1, 2 and 4. Claim 1 covers a process for preparing a 3-hydroxy-3-cephem (or its keto tautomer) (A and B below) and an azetidinone enol (or its keto tautomer) (C and D below).
 Claim 1 reads as follows:
1. A process for preparing a compound represented by the following formulas:
Wherein A and B are, independently, hydrogen, substituted or unsubstituted alkanoyl, substituted or unsubstituted aralkanoyl or substituted or unsubstituted aroyl, which substituents are such as to not affect the cephem ring formation ability of the compound;
X is a hydroxy or carboxy-protecting group;
Hal is halogen; and R is hydrogen, alkoxycarbonyl, cycloalkyl-methoxycarbonyl, aralkoxycarbonyl, aryl-, benzothiazolyl-, furyl-, thienyl-, pyrryl-, oxazolyl-, isoxazolyl-, oxadiazolyl-, oxatriazolyl-, pyrazolyl-, imidazolyl-, triazolyl-, tetrazolyl-, pyridyl-, pyrimidyl-, pyrazinyl-, pyridazinyl-, or triazinylthio each being optionally substituted by halogen, alkyl containing from 1 to 3 carbon atoms, hydroxy, aminomethyl or alkoxy containing from 1 to 3 carbon atoms, which comprises:
1) treating an enamine of a compound represented by the formula:
wherein A, B, R, X and Hal are defined above and the broken line between A and R constitutes a combining together of A, B and R when R and B are hydrogens and A is a carboxylic acyl with a disbustituted amino containing from 2 to 20 carbon atoms, with the action of an aqueous acid.
2) cyclizing a compound of the formula:
wherein, A and B are as defined above by treating a selected compound of above formula x with an acid, base, or solvent, if required in the presence of a catalizer to prepare selected compounds of formulas (A) or (B).
 The starting compound described therein (keto compound) can have a thiazoline ring present or not. In the absence of the thiazoline ring, the sulfur group is independently protected with a thiol substituent (R). In the disclosure, at p. 8, R is described as a thiol substituent which is “easily removable without adverse effect on the other part of the molecule prior or during cyclization reaction” (emphasis added). “It is needless to use the isolated starting material (3) for the reaction” (p. 20, lines 27-28, see also p. 33, lines 6-18).
 As a first step, the enamine of the keto compound is treated with an aqueous acid, the result of which is the hydrolysis of the disubstituted enamine group (which is in effect the only reaction expressly described therein). Where a thiazoline ring is present, the experts are in agreement that the first step will also open the thiazoline ring leading to the formation of the compounds represented by C or D where R = H. When a thiazoline ring is not present, depending on the substituent used to independently protect the sulfur group, the first step may or may not result in the deprotection of the sulfur substituent. Where it does, the result is the same as above, that is compound C or D where R = H. Where it does not, R is unchanged.
 The step described in para. 2 of claim 1 is the cyclization of the compound described therein (C or D where R=H). This takes place by reacting the said compound with either an acid, a base or a solvent (and optionally, a catalyst) to produce the key intermediate described in the disclosure, that is the 3-hydroxy-3-cephem (represented as A or B).
 Dr. Hanessian, who is the only expert for Apotex qualified to opine on how a posita would read this claim, simply describes this as reacting an azetidinone-thiazoline with an aqueous acid to form an azetidinone enol, which is further reacted with an acid, base or solvent (with an optional catalyst) to give the 3-hydroxy-3-cephem compound. He does not raise any difficulty or issue with the construction of this claim.
 Dr. McClelland, whom has no relevant experience with cephem compounds and cephalosporins, noted that Dr. Hanessian’s was the literal interpretation he had first adopted but he felt this was not accurate on closer examination of the substances. Dr. McClelland testified to the effect that this cyclization step, on his interpretation of the claim, would not take place when R is a group that cannot be removed through treatment with an aqueous acid. This would mean that for such compound the ending material of the claimed process would be the compounds represented as C or D.
 Dr. Barrett, in the course of his cross-examination, agreed that in order to cyclize (second reaction covered in claim 1), R had to equal H. However, he noted that the disclosure contains examples where the R substituent in C or D does not equal H but can be removed effectively in a “one pot” or “two pot” operation through treatment with acid for the purpose of cyclization. This would, as shown in example 2. – III, deprotect the sulfur group (with R becoming H) and allow for cyclization to take place (see also p. 18, lines 7-10, p. 19, line 28 to p. 21, line 19 of the disclosure).
 There is no evidence of any allowed R substituent that would not permit cyclization when one considers the “one pot” or “two pot” method or the fact that the removal of the thiol substituent can be done during cyclization as a preliminary reaction that will enable the R substituent to become H and thus arriving at compounds A or B.
 Based on the evidentiary record before me and on my review of the patent, I conclude that a posita would understand that in all cases the processes claimed in the ‘026 patent can lead to compounds A or B.
 In any event, this particular issue of whether or not the product of the reaction will be compounds A or B need only be determined in relation to Apotex’s argument that the Shionogi patents lack subject matter and constitute improper divisional, which for the reasons described below, are rejected.
 Like the ‘132 patent, the “Hal” is halogen in claim 1 and would be understood by a person skilled in the art to include fluorine because of the definition on p. 8 of the disclosure. Although again it would be readily appreciated by such a person that this is not the preferred halogen to be used (leaving group in the reaction).
 It is not disputed that the Plaintiff must establish on a balance of probabilities that the processes used by Apotex’s suppliers included all of the essential elements of one or more claims of the patents at issue.
5.2. Statutory and Common Law Presumptions
 Lilly argues that in this particular case, they have the benefit of two presumptions. First, the presumption of infringement arising under s. 55.1 of the Patent Act, which reads as follows:
55.1 In an action for infringement of a patent granted for a process for obtaining a new product, any product that is the same as the new product shall, in the absence of proof to the contrary, be considered to have been produced by the patented process.
55.1 Dans une action en contrefaçon d’un brevet accordé pour un procédé relatif à un nouveau produit, tout produit qui est identique au nouveau produit est, en l’absence de preuve contraire, réputé avoir été produit par le procédé breveté.
 According to Lilly, the word “product” (« produit ») was substituted with the word “substance” (same in French) as a result of an amendment in 1993 in order to give effect to para. 1709(11)(a) of the North American Free Trade Agreement Between the Government of Canada, the Government of Mexico and the Government of the United States, 17 December 1992, Can.T.S. 1994 No. 2, 32 I.L.M 289 (NAFTA). Lilly says that the Courts have yet to interpret the meaning of “new product” and it submits that it is a product that has not been sold on the market before. To that end, it refers to various dictionary definitions of the word “product.” According to Lilly, cefaclor, which was first sold in Canada in 1980, was thus not even a product when the Lilly and Shionogi patent applications were filed and they relate to processes for the production of such new products.
 The Court cannot accept this argument. As noted by Apotex, the words “product” and “substance” were used interchangeably by the Supreme Court of Canada in (Harvard College v. Canada (Commissioner of Patents), 2002 SCC 76,  4 S.C.R. 45 (Harvard College (2002)). The word “product” must be given the same meaning as it received throughout the Patent Act. It is used in the definition of “invention.”
 In my view, by changing “substance” to “product”, the legislator was simply ensuring that the Canadian provision would be applied in accordance with its obligations pursuant to NAFTA. “Substance” appears to be a more restrictive expression that could, for example, hardly apply to a new hairdryer, whereas the presumption is meant to apply to any new product.
 None of the patents at issue are processes to make cefaclor per se. Thus, the Court could only apply the presumption to the making of the new compounds covered in the Shionogi patents or to the products claimed in the ‘007 patent.
 As will be discussed, there is no need to apply this presumption to determine the merits of the infringement allegations in respect of the Kyong Bo process and the Shionogi patents. With respect to the ‘007 patent, for reasons given below under anticipation, the Court finds that these compounds are not new products.
 Lilly also asked the Court to apply the common law presumption discussed in Hoffmann-La Roche Ltd. v. Apotex Inc. (1983), 41 O.R. (2d) 84, 145 D.L.R. (3d) 270 (H.C.) (aff’d (1984), 47 O.R. (2d) 287, 11 D.L.R. (4th) 320 (C.A.)), in which Justice Walsh confirmed Hoffmann-La Roche Ltd.’s assertion that the burden of proving what process was used by its supplier was on Apotex, as:
at common law the rule has always been that when the subject matter of an allegation lies particularly within the knowledge of one of the parties that party must prove it, whether it be an affirmative or negative character.
 In that case, there was evidence that Apotex had written to its supplier, asking it not to voluntarily give information to the plaintiff. Also, it had manoeuvred to ensure that all process information would be sent to its counsel directly with no copy being sent to Apotex.
 According to Lilly, Lupin was actually willing to cooperate in this case and Apotex knew this, but did not disclose it to the plaintiffs or to the Court. Moreover, given the special contractual undertaking of Lupin to assist Apotex (see TX-1656), Apotex was in a much better position to provide admissible and credible evidence as to the process actually used by Lupin.
 Had I been satisfied that Lilly had taken reasonable steps to obtain this information, for example by pursuing a motion to obtain further information about the process actually used once TX-1656 was produced (after the filing of their initial motion), rather than relying on an undertaking from Apotex to look through their file, the Court would have been willing to apply this presumption given the particular circumstances of this case. Contrary to what was argued by Apotex, the Court does not believe that it is necessary for a plaintiff to go around the world using means available under various foreign legal systems to obtain the information it can use in a case in order to benefit from the presumption.
 Apotex’s failure to advise Lilly and the Court that Lupin was willing to disclose the details of its process subject to proper protection of the confidentiality of the information contained in the said documentation will be discussed further when assessing costs and the admissibility of certain evidence produced to defend the allegation of infringement.
 Needless to say, even if Lilly cannot benefit from this common law presumption, it can still rely on inferences that can reasonably be made based on the evidence produced to establish certain facts. This is perfectly in line with the statement made in Whirlpool.
5.3. Lupin Process
 Apotex received cefaclor made by Lupin from about May 23, 1997 until at least October, 1998. Although the exact amount of material received from that supplier will be ascertained through the reference, it appears that Apotex imported at least 8,650kg and maybe as much as 10,000kg of cefaclor made by Lupin.
 Apotex admitted that in respect of at least the receiving lot numbers described in the Request to admit, and except for the quantities used for testing and other regulatory purposes pursuant to subs. 55.2(1) of the Patent Act, the bulk cefaclor imported from Lupin was used in the manufacture of its Apo-cefaclor product.
 In light of the Confidentiality Order issued in this matter, the Court will give few details of the processes used by Apotex’s suppliers.
 In his report (E-15), Dr. Barrett summarizes the various processes described in the evidence filed by the parties. I will use his nomenclature:
Process “A” – Process described in Lupin’s filing with Health Canada. It is also described in the material filed by Lupin in 1996 with the Federal Drug Administration (FDA) (U.S. health authority). It is a process whereby cefaclor is synthesized from Pen V acid. The manufacturing process described in letters dated June 21, 1997 and August, 20, 1997 (TX-150; TX-158-TX-159) filed in response to a Health Canada request for clarification in respect of the process used by Lupin to make its 7-ACCA, is similar if not identical to the manufacturing process described by Lupin in its FDA filings in 1996. [Omitted.]
Process “B” – A process
described in an update filed by Lupin with the FDA in November, 1997. It is a process
whereby cefaclor is synthesized from Pen [omitted]. It appears from TX-167 and
TX-168 filed by Dr. Parra of Health Canada, that in June, 1999, Lupin updated
its DMF disclosing a process which is similar (if not identical) to the one
described in the FDA filing of 1997. According to Dr. Barrett, this process
infringes the Shionogi patents.
Process “C” – Another
process described in a further update filed by Lupin with the FDA in 2000,
which, according to Dr. Barrett uses both the Shionogi and the Lilly processes
(a mixture). However, there is no indication that it was used at any time
before the expiration of all the patents at issue.
Process “D” – Another process starting from Pen [omitted].
Whereas all those reactions were described simply as step V of Process “A” – they are now shown as step V(a) and step V(b). [Omitted.]
described in a document allegedly attached to various versions of a letter
dated October 27, 1997 from Mr. Patil to Mr. Singh which was never filed by Mr.
Singh with Health Canada. This letter and other documents similar to it
were all produced under reserve of Lilly’s objection (voir dire).
According to Mr. Satpute, this process (or at least the new process used in
1998) was only used to produce one very large order sometime early in 1998.
Process “E” – A process described in the appendix to the contract for the sale and manufacture of cefaclor between Apotex and Lupin, dated March 15, 1998 (TX-1656). According to this schematic outline, it starts from Pen [omitted].
 For reasons that follow, the Court has come to the conclusion that Lilly has established on a balance of probabilities that the cefaclor received by Apotex between May 23, 1997 and June 3, 1998 infringes the following claims in the Lilly patents:
1. The ‘007 patent: claims 1, 4, 8-13, and 17-18.
2. The ‘536 patent: claims 1, 4, 11, 14 and 16.
3. The ‘728 patent: claims 1, 15, 16, 20, and 25-27.
4. The ‘468 patent: claims 1, 2 and 7.
 However, the plaintiffs have not met their burden in respect of the cefaclor shipped to Apotex as of June 4, 1998.
 In respect of the period ending on June 3, 1998, the Court is satisfied that the plaintiffs have established that Lupin was using Process “A”, described above. Having carefully examined the arguments and the evidence referred to in Apotex’s memorandum on infringement (part V) and considering its construction of the claims at issue, the Court is convinced (as was, apparently, Apotex’s in-house counsel back in 1997) that Process “A” infringes the claims referred to above. The Court accepts and prefers the evidence of Drs. Baldwin and Miller who both concluded that Lupin was using a kinetic complex covered by the Lilly patents (as opposed to the thermodynamic product of the reactions between TPP and Cl in dichloromethane (methylene chloride)) to perform the reactions described in the Lupin process.
TX-150, TX-158 and TX-159 do not specifically refer to the use of a halogen
scavenger, the Court is persuaded that, as explained by Dr. Baldwin, without
such scavenger, the reactions in step V of Process “A” could not be
successfully performed. As mentioned, the correspondence filed by Lupin with
the FDA is not proof that what is represented to be used was effectively used
to make the cefaclor shipped to Apotex. The Court notes, however, that what was
represented to the FDA corroborates at least to some extent the evidence of
Lilly’s experts. Also, once the evidence of Mr. Satpute is considered, it
becomes clear that except for the special order made in 1998, there was only one
process which started from Pen V acid used at Lupin’s plant in 1997. The Court
understands from Mr. Satpute’s evidence that apart from the special order
referred to above, the plant used the same processes to fulfill all its orders.
 With respect
to Process “B” and Process “C”, there is insufficient evidence for the Court to
conclude that either was used to produce the cefaclor shipped to Apotex during
the period between May 23, 1997 and October, 1998. The arguments presented by
Lilly in that respect are purely speculative.
conclusion remains true whether or not the Court accepts or rejects all or any
of the evidence presented under reserve of Lilly’s objections (voir dire).
 It is clear
that as of March 15, 1998, Lupin had agreed to change the process it had used
until then to make cefaclor for Apotex. Apotex’s position has always been that
it presumed that Process “E” was used at least after that date.
 I do not
intend to refer to all the circumstances referred to in the parties’
submissions. I will simply mention some salient points of the background
relevant to this debate (voir dire).
 On March 10,
2000, Lilly obtained an Order
from Justice James Hugessen enjoining Apotex to request from its suppliers and
the Minister of Health copies of its suppliers’ DMFs in support of its NDS for
Apo-cefaclor and to provide an affidavit stating that it had made such
requests. After writing to the Minister and to Lupin, Dr. Sherman swore such an
affidavit stating that the Minister had refused to disclose the closed portion
of the DMF, that he had received no response from Lupin and that Apotex did not
have the ability to compel its suppliers to provide the said information.
thereafter, Lilly received an amended affidavit of documents from Apotex which
included the 1998 agreement between Apotex and Lupin which expressly stipulates
that the said supplier would assist Apotex in providing “information and
evidence necessary to show that it has used the process of appendix A”.
 On May 4,
2000, Lilly filed another motion seeking an order compelling the Minister of
Health to produce all portions of Apotex’s NDS relating to Apo-cefaclor
including any DMFs relating to Apotex’s suppliers’ processes for preparing
cefaclor. Although Lilly specifically refers to Lupin’s undertaking to provide
Apotex with information and evidence in respect of the contract process
(Process “E”), Lilly did not seek an order compelling Apotex to obtain such
information on the basis that they were, as they now argue, under their
possession and control.
confirmation that no response had been obtained from Lupin, on July 5, 2000,
Justice Hugessen issued an order enjoining the Minister to produce the
materials sought by Lilly. As a result, Lilly became aware of the details of
Process “A” and of the fact that no update had been filed by Lupin until 1999
Lilly asked at each new session
of its examination for discovery whether Apotex had received any reply to its
letter to Lupin and whether it had any information or documentation regarding
the process they used. Dr. Sherman continued to say that he had received no
response from Lupin and essentially that he assumed that they were using the
contract process (Process “E”).
 In 2006 and
thereafter, Apotex indicated in their trial chart(s) that they expected to
present witnesses from Lupin. Lilly raised no particular issue or objection in
that respect. However, it appears that at some stage, it took legal steps in
to obtain about the Lupin process from Lupin’s American subsidiary. As a
result, and among other things, it obtained copy of a letter from Lupin
Laboratories to Ivor Hughes dated July 4, 2000 which indicates that Lupin knew
of Lilly’s motion which was set to be heard on July 5, 2000 and
understood that Lilly was seeking information concerning the process they used
to make cefaclor. It also appears that Lupin thought that Apotex was already in
possession of the closed portion of their DMF as well as the information
exchanged in 1997 about the manufacture of the 7-ACCA (presumably TX-150;
TX-158; TX-159). Thus the letter only enclosed information about the process
developed by Lupin pursuant to the March 15, 1998 agreement. The letter also
includes an authorization to use the said information upon certain conditions
which included ensuring that it would be protected by a confidentiality order.
This letter and its attachments never found their way into Apotex’s affidavit
of documents. They were not filed as exhibits in the trial, although a copy was
shown to the Court and Lilly included the letter itself in its written
submissions on the voir dire.
 It is in this
context that Lilly raised their objections in respect of the admissibility of
any viva voce evidence and documentary evidence presented to establish
what process was actually used by Lupin after March, 1998 or failed attempts by
Lupin to update their Health Canada DMF. Essentially, Lilly relies on paras.
232 and 248 of the Federal Courts Rules as well as on the evidentiary
principle of spoliation because the destruction of Lupin’s manufacturing
and of the files of Mr. Patil which were lost in a flood in 2005.
 As mentioned,
the parties filed extensive submissions in respect of these objections. When
the Court pointed out that Apotex could seek leave pursuant to Rule 232 to file
the documents that according to Lilly were under its possession and control,
Apotex indicated that it felt no need to do so.
 On the other
hand, the Court offered
to Lilly to suspend the trial so that steps could be taken to obtain evidence
in India if
necessary. According to Lilly, this would be useless given that the best
evidence – the documentation on the manufacturing of individual batches – were
destroyed. Both parties thus remain entrenched in their initial position. It is
in that context that leave was granted to file additional expert evidence from
Dr. Barrett (E-15) and Dr. Hanessian (A-20).
 The absence
of evidence establishing that either Process “D” or Process “E” infringes on
any of the patents at issue means that prior to gaining any knowledge of the
July 4 letter or of the evidence presented under reserve, Lilly’s only
argument, with respect to the period after the signing of the March, 1998
contract, was that Process “E” was too inefficient to be commercially viable.
Also, it appears that Lilly thought that the Health Canada filing would provide
sufficient evidence in this case given that there were, according to them, only
two commercially viable processes (the Shionogi and the Lilly patented processes)
and Lupin had filed no updates with Health Canada. However,
prior to trial, Lilly had not served on Apotex any expert report supporting
this position including the inefficiency of Process “E”.
learning of Process “D” Lilly’s position remained that Process “E” and Process
“D” were inefficient and not commercially viable and that there was no time to
implement either processes in the timeframe discussed in TX-1671.
 Thus, in my opinion, the main difference for Lilly between the case it thought it had to meet before trial and after it learned of the July 4, 2000 letter and the evidence taken under reserve is that, with respect to Process “D”, which Dr. Barrett described as different from Process “E” while Dr. Hanessian described it simply as an improvement over Process “E”, Apotex could now counter Lilly’s allegations of inefficiencies by referring to Lilly’s own NDS documentation submitted to Health Canada on June 23, 1978 to obtain its NOC for Ceclor® (TX-208).
 Also, because of
Apotex’s failure to disclose the July 4, 2000 letter, Lilly was deprived of an
opportunity to change its tactics and to use whatever means were available to
obtain or verify what process Lupin effectively used after March, 1998. In that
respect, however, the Court notes that given that it had failed to do so after
learning of the contract and the undertaking in it, this remains only a
possibility rather than a probability. Also, there is insufficient evidence
before me to conclude that the manufacturing documentation, which Mr. Satpute
could not find in 2008, would have all been available at that time. Evidently,
the files of Mr. Patil should have remained intact until 2005.
 Had Lilly
lost their action because of this, I would have had no hesitation in awarding
them all their costs on a solicitor-client basis as of July 5, 2000. That said,
this is not what happens here and I do not believe that all the viva voce
evidence objected to is inadmissible.
 In effect,
having carefully examined the relevant extracts from the transcripts of the
examination for discovery, the Court cannot conclude that Rule 248 applies
 In any event,
even if the Court were to apply this rule, it would not mean that all
the viva voce evidence of Mr. Singh, Mr. Satpute and Mr. Patil would become
inadmissible. It could only affect the evidence relating to the details of the
process used after March 15, 1998 that differs from Process “E”.
 In my view,
it could not be used to exclude the evidence of Mr. Satpute that sometime in
early in 1998 Lupin took the necessary steps to adopt a process different from
Process “A” and Process “B”
to fulfill a very large order of the magnitude provided for in the March 15,
1998 contract of which he had no knowledge. It would not exclude his evidence
that such process, although not as efficient as Process “A”, still produced a
yield than enabled them to fulfill this order. When the Court heard and saw
this witness, it found his testimony very credible. The transcript of this
evidence was read several times and this only confirmed my first impression.
This evidence is, in itself, sufficient to convince me that the shipments made
as of June 4, 1998, were not manufactured using Process “A” or Process “B”.
There is no need for the Court to determine which process (Process “D” or
Process “E”) was used.
 Mr. Patil and
Mr. Singh had no personal knowledge of the process actually used by Lupin and
even if the documentary evidence they produced was admissible, it would have no
probative value in respect of the process used by Lupin during that period. In
effect, there is a contradiction between some of the correspondence,
particularly the October 27, 1997 letter and Mr. Satpute’s testimony, which I
prefer. None of this evidence can have, or would have had, an impact on my findings.
 In the
circumstances, there is no need to discuss further the application of paras.
232 and 248 of the Rules.
 Finally, with respect to spoliation and the residual discretion of the Court in such matters, the law is well summarized by the Alberta Court of Appeal in McDougall v. Black & Decker Canada Inc., 2008 ABCA 353, 62 C.P.C. (6th) 293. As noted at para. 18 of the said decision:
Spoliation in law does not occur merely because evidence has been destroyed. Rather, it occurs where a party has intentionally destroyed evidence relevant to ongoing or contemplated litigation in circumstances where a reasonable inference can be drawn that the evidence was destroyed to affect the litigation. Once this is demonstrated, a presumption arises that the evidence would have been unfavourable to the party destroying it. This presumption is rebuttable by other evidence through which the alleged spoliator proves that his actions, although intentional, were not aimed at affecting the litigation, or through which the party either proves his case or repels the case against him.
 First, it is evident that spoliation could not apply to the destruction of the files of Mr. Patil which was clearly an act of God. With respect to the manufacturing data that was destroyed by Lupin (not Apotex), the Court is not persuaded that in the particular circumstances of this case a reasonable inference can be drawn that the destruction was meant to affect the litigation. I have not come to this conclusion lightly for the Court is obviously alive and alert to any tactic meant to revive the old “trial by ambush” concept. However, in this case I truly do not believe that it would be in the best interests of justice to totally put aside the viva voce evidence of Mr. Satpute. I would thus exercise any residual discretion I may have to admit this portion of the evidence if it were necessary.
5.4. Kyong Bo Process
ordered and received cefaclor from Kyong Bo from at least November, 1996 to at
least September, 1997. Once again, there is some discrepancies as to the exact
quantity involved, this will be dealt with in the second phase of the trial
 Also, Apotex
at least in respect of the receiving lot numbers described in the Request to
admit, and except for the quantities used for testing and other regulatory
purposes, pursuant to subs. 55.2(1) of the Patent Act, the bulk cefaclor
imported from Kyong Bo was used by Apotex for the manufacture for its
 Lilly presented expert evidence from Dr. Barrett (A-1) who reviewed in detail the processes described in the closed portion of that manufacturer’s file at Health Canada at the relevant time. In his cross-examination on his reply affidavit, Dr. Hanessian also confirmed that the processes described in that documentation were covered by the Shionogi patents.
 Although there is no direct evidence from a Kyong Bo representative that it indeed used the processes described in Health Canada’s file to produce the material shipped to Apotex at the relevant time, the Court is satisfied that in this case, it can reasonably infer that it was so used. From the correspondence between Ms. Fouillade and Kyong Bo, it is clear that Kyong Bo used the information and the processes it learned from Shionogi to produce the cefaclor sold to Apotex. In fact, this is why they initially alleged that they had been authorized by Shionogi to use the patented processes. It is also the basis of a defence raised by Apotex, which obviously implies that the processes covered by Shionogi patents were used.
 Having carefully considered the evidence, I am satisfied that the cefaclor made by Kyong Bo for use by Apotex in Canada infringes all the claims in issue in the ‘547 patent. I have come to the same conclusion with respect to claims 3-4, 8-9, 12, 27, 31 and 37 of the '924 patent as well as claims 15, 22, 29, 34, 38 and 58 of the '132 patent. There again, not only are the steps in the patented process used but the starting and resulting compounds claimed (compound by process claims), for example, at claim 58 of the ‘132 patent, are necessarily produced during the Kyong Bo process. The Court is also satisfied that Lilly has met its burden on a balance of probabilities that the Kyong Bo process infringes claims 1, 2 and 4 of the ‘026 patent.
 In fact, Apotex only raised two particular defences in respect of Lilly’s allegation of infringement: the first one is based on the existence of a licence from Shionogi, implicit or express, and the second on the fact that Canadian law does not provide for infringement by importation and use in Canada and no infringement acts took place in Canada.
5.4.1. Existence of a Licence
 With respect to the argument that Kyong Bo was licensed, very scant evidence was produced by Apotex. In fact, the Court expressed its surprise during the final argument that Apotex’s counsel insisted on pursuing this issue.
 Apotex relies on the testimony of Dr. Sherman, who said that he was informed by Ms. Fouillade that Kyong Bo’s position was that it had the right to use the processes covered by the Shionogi patents because of a licence obtained from Shionogi itself. In his testimony, Dr. Sherman also noted that he had instructed Ms. Fouillade to obtain clarification and appropriate evidence as to the alleged arrangement.
 The only evidence produced as to how Ms. Fouillade obtained this information, i.e. that Kyong Bo would have been authorized by Shionogi to use their process, is a letter from Kyong Bo Senior Managing Director, Seung-Ho An, dated October 10, 1997 produced as TX-662. But what is more telling here is the answer received from Kyong Bo (TX-664) when Ms. Fouillade requested further details as to the arrangement referred to in that said letter.
We do not have a kind of contract for the technology transfer. I think, a kind of sales contract was made by Mitsubishi with Shionogi in 1992. As a matter of fact, we do not have an authorized document to use specifically CP 1,095,026, CP 1,132,547, CP 1,136,132 and CP 1,144,924.
 Shortly after this exchange, Apotex stopped buying cefaclor from Kyong Bo.
 Furthermore, it is an agreed fact that “Shionogi did not license the Shionogi patents to any non-Lilly entity for the manufacture of cefaclor before April 27, 1995.”
 Without ever explaining or referring to the above admission, Apotex argued that the evidence of Dr. Sherman in TX-662 and TX-664 is sufficient to shift the burden of proof to Lilly who should present cogent evidence that no such licence existed. Apart from being contrary to an admitted fact, such position appears to be based on a misunderstanding of the nature of the present proceedings. This is an infringement action, not a PM (NOC) proceeding where Lilly has to prove that the allegations of Apotex, presumably put into play by means of this evidence, are unjustified. If, in its defence (paras. 15-17), Apotex alleges that it bought material from a licensed source, it must prove that fact on a balance of probabilities. It has failed to do so.
 This is one of many arguments that the Court would have expected counsel to put aside at least in their final presentation of the case. Pursuing arguments that have little or no chance of success unduly lengthens the trial process, places an undue burden on the Court and increases costs for all concerned. More will be said in that respect later on.
 Apotex’s main defence in respect of the allegations of infringement of the Shionogi patents is that the importation and use of products in Canada which one made abroad by a process patented in Canada cannot constitute infringement under the Canadian Patent Act. Apotex recognizes that there is Canadian jurisprudence applying the English doctrine of “infringement by importation”, but it submits that those cases do not bind the Court and should not be followed.
 Not surprisingly, Lilly relies on this Canadian case law, which will be discussed later on, and states that infringement by importation and use in Canada has recently been reinforced by the Supreme Court of Canada’s decision in Monsanto Canada Inc., and that the so-called “Saccharin doctrine” was applied by Justice Snider in Pfizer Canada Inc. v. Canada (Minister of Health), 2007 FC 898, 328 F.T.R. 41 (Pfizer), in respect of product claims (as opposed to process claims).
 The defendant advances two primary arguments as to why the existing case law on “infringement by importation” should be disregarded. First, the Court should conclude that Canadian courts were incorrect in following English precedents such as Elmslie v. Boursier (1869), [L R] 9 Eq 217 (Elmslie), Von Heyden v. Neustadt (1880), 14 Ch D 230 (C.A.) (Von Heyden), Saccharin Corporation Ltd v. Anglo-Continental Chemical Works Ltd (1900), 17 RPC 307 (Saccharin) and Wilderman v. F.W. Berk & Co. Ltd. (1925), 42 R.P.C. 79 (Wilderman), because of material differences between the Canadian Patent Act and the English patent legislation in force until 1977.
 Instead, argues Apotex, given that our Patent Act was modeled on U.S. patent legislation, our Courts should have followed the American case law, which concluded that, in light of the territorial application of patent legislation, an American process patent could not be infringed unless the process was actually used in the U.S. To adopt this approach would also be more in line with the Canadian view of the exclusive rights or the monopoly defined by the claims of a process patent, which do not cover the product made by such process unless so claimed.
 Second, Apotex submits that, should the Court feel compelled to follow the general principles set out in the Canadian case law, it should at least restrict their application to cases that meet the statutory limitations now applicable in the United Kingdom Patents Act 1977 (U.K.), 1977, c. 37, para. 60(1)(c), and the European Economic Community (EEC) as a result of the European Patent Convention (EPC) and in the United States as a result of legislation adopted in 1988.
 This would mean, according to Apotex, that importation and use or sale of cefaclor in Canada could only amount to infringement if cefaclor was a product “obtained directly” by the process covered by the Canadian patents and used overseas or if the chemical compounds made by said patented processes (in this case, the 3-chloro-cephem or the 3-hydroxy-cephem compounds) were not “materially changed” by the subsequent steps used by Apotex’s suppliers to make cefaclor and these compounds had not become a trivial or non-essential component of cefaclor.
 To come to such conclusion, Apotex recognizes that it must also convince the Court that Justice Snider in Pfizer misread Monsanto Canada Inc. and that the “creative compromise” she articulated at para. 90 of her decision was “inadequate and not based upon a sound legal foundation”.
 Given the importance of this issue, and the fact that many of Apotex’s arguments have not been recently canvassed by this Court, I will address the issue of infringement by importation in more detail than may normally be required. Specifically, I will address how existing English and Canadian case law dispose of Apotex’s arguments.
 While there appears to be only a dozen or so Canadian cases dealing with this issue, the concept of infringement of a process patent (or process claims) by importation and use or sale in Canada of a product manufactured abroad was first described as a settled question of law more than a century ago.
 In Auer Incandescent Light Manufacturing Co. v. O'Brien (1897), 5 Ex.C.R. 243 (Auer), the Exchequer Court of Canada, granting an injunction to prevent further infringement of a process patent, noted, at para. 26:
Before leaving this question of infringement I ought, perhaps, to refer to the contention made on behalf of the defendant that under any circumstances he would at least be entitled to import for use or sale illuminant appliances made in a foreign country in accordance with the process protected by the plaintiffs' patent. With that view, however, I cannot agree. I think that the law is well settled to the contrary, and I need only refer for this purpose to the cases cited by Mr. Hellmuth, viz.: Elmslie v. Boursier; Wright v. Hitchcock; Von Heyden v. Neustadt.
 The English cases cited above were again applied two years later by the Divisional Court of the Chancery Division of the Ontario High Court of Justice in Toronto Auer Light Company Limited v. Colling (1899), 31 O.R. 18,  O.J. No. 65 (QL) (Toronto Auer Light). In that case, the Court was also dealing with a patent on a method for making incandescent devices (illuminant appliance). It is relevant here to review what passages of Von Heyden Justice Boyd, speaking for the Court, found to be of particular interest:
In Von Heyden v. Neustadt (1880), 14 Ch. D. 230, James, L.J., said (adopting the conclusion arrived at in Elmslie v. Boursier (1869), L.R. 9 Eq. 217): “That the sole right ... to 'make, use ... and vend the invention' ... includes a monopoly of the sale ... of products made according to the patented process ... A person who ... sells the product here, is surely indirectly making, using, and putting in practice the patented invention. Any other construction,” he adds, “would render ... the whole privilege ... futile,” p. 233.
 Given that Apotex says that this reasoning, if applied in Canada, raises an issue of extraterritorial application of our Patent Act, it is also worth mentioning that this very same issue was considered in England more than a hundred years ago. In Badische Anilin und Soda Fabrik v. Henry Johnson & Co. and Basle Chemical Works, Bindschedler,  2 Ch. 322 , a patent owner had obtained a declaration of infringement against a trader in England who had ordered goods made in Switzerland using a process protected by an English patent, but which were delivered to the Swiss post office (the Buyer) by whom they were then imported into England. The defendant appealed and the English Court of Appeal reversed the decision. The following passage from p. 342 of Lord Justice Lindley’s brief reasons clearly shows that the Court was alert and alive to the argument now raised by Apotex:
[…] the defendant Bindschedler had done nothing which amounts to making, using, exercising, or vending the invention of the plaintiffs in this country. In other words, Bindschedler has not infringed the plaintiffs’ patent. The patent is confined to this country, and does not extend to Basle, where all the acts done by Bindschedler were committed. It is true that […] no one has a right to use [the goods so made] here. But what the defendants did in Basle was lawful and not unlawful; lawful by the law of Switzerland and not unlawful by the law of England, which has no application there.
 But even with territoriality clearly in mind, Lord Justice Smith, with whom Lord Justice Lindley concurred, made it clear, at p. 344, that:
[…] if Bindschedler by himself or his agent had brought the infringing article into this country, or had it received her[e], he would have been liable, for he would then be, in this country, by himself or his agent, using, exercising or vending
the infringing article. The cases of Elmslie v. Boursier and Von Heyden v. Neustadt shew this to be so.
This decision was affirmed by the House of Lords at  AC 200; (see to the same effect Badische Anilin und Soda Fabrik v. Hickson,  2 Ch. 495, affirmed,  AC 419.) 
 As the Saccharin case is at the center of the debate, it is of interest to mention the decision in Saccharin Corporation v. Reitmeyer & Co.,  2 Ch. 659, (1900) 17 R.P.C. 606. There, the patent owner, who had successfully obtained a declaration of infringement against the importer in the first Saccharin case, was seeking a similar declaration against the English commission merchant who had originally bought the saccharin in Germany and sold it to the English importer. The Court refused to do so, on the basis that the principles laid down in Elmslie and Von Heyden and applied in Saccharin could not be extended to a case where the defendant had neither imported into nor sold in England the product made abroad using the patented process. Justice Cozens-Hardy reached this conclusion on the basis that, “[n]ow, it is plain that a Patent is of local force. It cannot and does not profess to interfere with or control acts done abroad […]” (p. 611, lines 40-41 of the R.P.C.).
 It could not be clearer that English Courts felt bound by the very principle Apotex seeks to now rely upon. Contrary to Apotex’s assertion, however, they focused only on the acts taking place within their jurisdiction to determine if there was any conduct which constituted infringement.
 There are three other English decisions that must be briefly mentioned. The first, Pfizer Corporation v. Ministry of Health,  AC 512,  1 All ER 450 (H.L.), simply because it was referred to in Monsanto Canada Inc. (albeit in a different context) and indicates that Lord Upjohn, after re-examining the validity of the doctrine both “on principle and on authority”, concluded:
[…] where an importer imports into this country, articles manufactured abroad but in accordance with a British patent for the purpose of distributing them and selling them in this country, he quite plainly is using and exercising the patent, and he thereby infringes the appellant’s patent […]
[p. 469(D) of the All ER]
 The other two decisions are Beecham Group Limited v. Bristol Laboratories Limited and another,  RPC 406,  FSR 283 (CA.) and the final decision on the merits rendered nearly ten years later by the House of Lords ( RPC 153) (Beecham Group). The latter is probably the last decision to apply the principles at issue given that, shortly after it was rendered, the Patents Act, 1977 was adopted.
 The English Court of Appeal (Lord Justice Alfred Thompson Denning writing the main reasons) reversed the decision of the High Court judge and issued an interlocutory injunction to prevent the importation of hetacillin. In the Court of Appeal’s view, the plaintiff had established a prima facie case of infringement of his English patents protecting, in particular, the process for making ampicillin, an intermediate compound which was then transformed into hetacillin by the addition of acetone (see particularly the concurring reasons of Lord Justice Russell, at p. 417 of the RPC).
 The reasoning in this case is, in my view, particularly instructive because the defendants vigorously contested that the Saccharin case was still good law in light of the amendments to the Patents Act, 1949 (U.K.), 12, 13 & 14 Geo. VI, c. 87, which clearly required that the claims define the scope of the invention. Thus, the defendants argued, only patents claiming a product could be infringed by importation of such products into England. As in the present case, it was also argued that the “Saccharin doctrine”, if followed, had the potential to yield extraordinary results and uncertainty, leaving competitors uncertain as to what they are entitled to do.
 These arguments are remarkably similar to those made before me by Apotex; they were ultimately rejected on the merits, by Justice Falconer in the first instance, by the Court of Appeal and by the House of Lords.
 Apotex noted that this case is not helpful because the Courts were really dealing with a colourable imitation of the patented product, ampicillin. That is true. The plaintiffs in Beecham Group also raised an argument based on the fact that hetacillin was a colourable imitation because once it was used by a potential patient as an antibiotic it reverted to ampicillin in the stomach. However, this was treated by all judges as a separate ground. In the decision of the House of Lords, Lord Diplock also made it clear that the doctrine of infringement by importation, applied in Saccharin, was not an extension of the pith and marrow doctrine. It was a distinct concept standing on its own (see p. 200-201).
 The House of Lords also confirmed that the Patents Act, 1949 did not contain any changes that justified setting aside the principles applied in Saccharin and Wilderman. Lord Diplock noted that the need to describe and ascertain the nature of the invention in the letters patent was made a condition of the grant from 1700 onwards. To end the specification with a distinct statement of the invention claimed was made statutory in 1883, at which point Lord Diplock noted the practice to have already become widespread (p.198).
 Lord Diplock describes the reasoning behind Elmslie and Von Heyden as follows at p. 199:
The monopoly granted by a patent is limited territorially to the United Kingdom and the Isle of Man and the corresponding prohibition is limited to acts done within those territorial limits. The wide words of the grant and prohibition[] were, however, treated as entitling the patentee to prohibit the obtaining from abroad and selling in this country an article manufactured abroad by the patented process, even though the article was of a kind that was not new and consequently of itself could not be, and was not, claimed as an invention in the specification.
 With respect to the extraordinary results which would flow from the unbridled application of the “Saccharin doctrine”, it appears that the House of Lords, like Lord Justice Denning in 1967, found comfort in the application of the limitations set out in Wilderman. Lord Diplock explained, at p. 201:
My Lords, if logic were the sole guide to the law of patents such an extension of the doctrine of infringing importation might be difficult to resist. In effect it would mean that in respect of any article sold in this country, anything done in the course of its manufacture which would constitute an infringement of a United Kingdom patent if done in this country would constitute a like infringement if before importation it had been done abroad. This extreme extension of the doctrine was, however, rejected by Tomlin, J. in Wilderman v. F.W. Berk & Co. Ltd. (1925) 42 R.P.C. 79, where in relation to a claim for the infringing importation of an article in the course of whose manufacture abroad a patented apparatus had been used, he expressed the view that the use of the patented process or apparatus must have played an important part in the manufacture of the imported article.
 Finally, it is interesting to note that in that case, the House of Lords refused to decide if the doctrine should also apply to pure product claims, which extension had been accepted by the trial judge and the Court of Appeal. The Court felt that it did not have the benefit of full arguments (see also the reasons of Lord Simon of Glaisdale on this point, p. 204).
 Turning back now to Canadian jurisprudence on the matter. In 1955, in Hoffmann-LaRoche & Co. v. Canada (Commissioner of Patents),  S.C.R. 414; 23 C.P.R. 1 (Hoffmann-LaRoche), the Supreme Court of Canada issued its well-known decision that, contrary to what was then the English practice, no product by process claim could be issued in Canada for a known product, even though the process itself was new. As this involved an appeal in respect of a decision of the Commissioner of Patents refusing to allow the proposed product by process claims, the Supreme Court of Canada was not required to discuss the issue of infringement of a pure process patent or process claims, by the importation of a product (not covered by the patent) made abroad using the patented process. Nevertheless, while dealing with the main issue before it, Chief Justice Patrick Kerwin, writing for the majority, considered the decision of the Court of Appeal of England and Wales in Von Heyden, as well as two Canadian decisions, Auer and Toronto Auer Light and expressly noted that “there seems to be no reason to doubt the correctness of these decisions.”
 While accepting that Canadian patent law differs from British legislation, and that Canadian patent law was originally modeled on U.S. legislation, Apotex’s argument that the distinctions between Canadian and British law should render British jurisprudence of little assistance on this issue is unpersuasive. Put plainly, notwithstanding the differences between Canadian and British patent laws, our Courts continue to look to British jurisprudence to inform the analysis of our intellectual property laws.
 There is also little doubt that the Exchequer Court of Canada and the Supreme Court of Canada were fully aware of these differences between English and Canadian legislation. The best example of this is Union Carbide Canada Ltd. v. Trans-Canadian Feeds Ltd.,  Ex.C.R. 884 (Union Carbide), where President Wilbur Jackett, having reviewed the cases of Elmslie and Von Heyden, said at para. 13:
I have been able to discover no such difference between the ambit of an English patent for an invention and the ambit of the monopoly granted under the Canadian Patent Act as would warrant reaching a conclusion when this question arises under the Canadian Act different from that reached in respect of an English patent.
 The learned judge also noted that he was unable to ascertain any relevant difference between the Canadian legislation that was under consideration in Auer and he concluded based on comity that he should follow Auer, noting that it had also been the subject of the obiter mentioned above in Hoffmann-LaRoche.
 President Jackett appeared unaware of the then recent decision of Justice Noël in Rhone-Poulenc S.A. v. Micro Chemicals Ltd.,  Ex.C.R. 819, 44 C.R.R. 193 (Rhone-Poulenc), where, on the basis of the same authorities, the latter had concluded that the principle was now accepted by our Courts (para. 49). Also, although there is a reference to the Badische Anilin und Soda Fabrik decisions (see above) in the editorial note of the Canadian Patent Reporter for Rhone-Poulenc, at 194, it does not appear that these cases were brought to the attention of the Court.
 The term “Saccharin doctrine” per se came to the forefront in American Cyanamid Co.. In that case, the Court had to determine if the “Saccharin doctrine” should be applied to the importation of tetracycline in Canada. This particular product was not covered by the patent at issue but it was made using a patented process for making chlortetracycline, to which a dechlorination method was then applied to obtain tetracycline. Thus, the patented process was not the last step in making the product ultimately imported and used in Canada. The learned judge does not specifically refer to the decision in Wilderman (he says simply “there are also a number of cases”, para. 41). But having expressed some concern in respect of the application of the doctrine to processes that are merely incidental, the learned judge did apply the “Saccharin doctrine”, as he found that the product used as an intermediary was of importance.
 Between 1966 and 1991, it appears that the Exchequer Court of Canada and the Federal Court of Canada considered the issue quite settled. In Rhone-Poulenc v. Gilbert (1967), 35 Fox Pat. C. 174 (aff’d,  S.C.R. 950, 69 D.L.R. (2d) 353) (Gilbert), Justice Arthur Thurlow, after referring to the decision of President Jackett in Union Carbide, stated that in the absence of any expression of opinion to the contrary by the Supreme Court of Canada, he regarded the point as settled in this Court.
 In Leesona Corp. v. Giltex Hosiery Ltd. (1971), 2 C.P.R. (2d) 211,  F.C.J. No. 1006 (QL), Justice Roderick Kerr followed Justice Thurlow’s decision in Gilbert and even issued an interlocutory injunction to prevent the importation into Canada of certain products made abroad according to patented processes. Reference was also made to the then recent decision of Lord Justice Denning in Beecham Group.
 Nevertheless, three years later in Farbwerke Hoechst Aktiengesellschaft, vormals Meister Lucius & Bruning v. Halocarbon (Ontario) Ltd.,  2 F.C. 266, 15 C.P.R. (2d) 105, Justice Frank Collier again faced the same issue, where the Canadian defendant imported isohalothane, a product made in the United States by a process patented in Canada. It was then used to manufacture another product at the defendant’s plant in Ontario. Although Justice Collier did not go into the details of the arguments presented, he notes in his reasons, at para. 10, that the Court “was invited by Mr. Hughes [as he then was] to distinguish, on a number of grounds, the Union Carbide case and the cases referred to by Jackett P.” but concludes that he does not “see any reasonable grounds for so doing.” It is important to mention that in his decision, Justice Collier specifically echoed the comments of Justice Thurlow in Gilbert and stated that in the absence of any expression of opinion to the contrary by the Supreme Court of Canada, he regarded the point as settled.
 This decision was reversed by the Federal Court of Appeal and the plaintiff appealed to the Supreme Court of Canada, which allowed the appeal ( 2 S.C.R. 929, 104 D.L.R. (3d) 51) and specifically reinstated the decision of Justice Collier in respect of the impugned process claim. At p. 941 (of the S.C.R.), Justice Louis-Philippe Pigeon, who delivered the reasons for the majority, noted:
At the hearing in this Court, counsel for the respondent raised the contention that the importation of a product manufactured outside Canada did not infringe a Canadian patent for the process whereby it is manufactured elsewhere, but counsel for the appellant was informed that no reply to that submission was required. It will therefore not be dealt with.
This strongly suggests that the Supreme Court considered the issue of infringement by importation settled by the existing jurisprudence.
 Undeterred, Apotex mounted a new charge before Justice Andrew MacKay in Wellcome Foundation Ltd. v. Apotex Inc., 47 F.T.R. 81, 39 C.P.R. (3d) 289 (Wellcome (1991)), raising arguments very similar to those discussed at length in its memorandum before this Court. It contested the validity of the “Saccharin doctrine” per se, based among other things on the differences between the English and Canadian patent statutes. It also contested the findings of Justice Noël in American Cyanamid Co., which it found questionable because of the absence of a direct reference to the limitation of the doctrine as set out in Wilderman.
 Prompted by these arguments and the fact that this was indeed only the second reported case involving a process patent for an intermediate compound (B-methoxy-a-(3,4,5-trimethoxybenzylidene) propionitrile, or MTBP and B-anilino-a-(3,4,5-trimethoxybenzyl) acrylonitrile, or TAA), Justice MacKay addressed the point in more detail than his predecessors. Particularly, with respect to the basis of the doctrine in the Canadian legislation, the learned judge stated at para. 59:
I also reject the defendant's submission that the differences in the Canadian Act from the English statute do not support the application of the Saccharin doctrine. The “exclusive right” of “vending” seems to me to be broad enough to encompass situations such as that in this case. This point as well was noted in American Cyanamid, at 168. The effect of the granting provision, now section 44 of the Patent Act, may be summarized, as it was by O'Halloran J.A. in Skelding v. Daly, (1941), 1 C.P.R. 266 at 273 (B.C.C.A.), as intending that “... any act which interferes with the full enjoyment of the monopoly granted to the patentee is an infringement”.
 Applying the “Saccharin doctrine” as qualified by Wilderman, the Court concluded that there was infringement of the process claims by the importation of trimethoprim. As mentioned by Apotex, there was evidence in that case that traces of MTBP and TAA (the intermediate compounds) were found in the final product sold by the defendant in Canada.
 It is worth noting that Apotex appealed the decision of Justice MacKay, which was varied on an unrelated issue ((1995), 100 F.T.R. 320 n, 60 C.P.R. 3(d) 135). Surprisingly, it seems that Apotex did not contest the application of the doctrine by Justice MacKay before the Court of Appeal even though this point was clearly determinative in respect of the findings of infringement.
 These Canadian decisions are, in my view, sufficient for this Court to conclude that the “Saccharin doctrine” as qualified by Wilderman is applicable to the case at bar. However, more recent jurisprudence further undermines the argument advanced by Apotex.
 In Monsanto Canada Inc., the Supreme Court of Canada articulated broad principles related to the interpretation of the rights granted under the Patent Act. At para. 58, Chief Justice Beverly McLachlin and Justice Morris Fish, speaking for the majority, summarize seven such principles:
1. "Use" or "exploiter", in their ordinary dictionary meaning, denote utilization with a view to production or advantage.
2. The basic principle in determining whether the defendant has "used" a patented invention is whether the inventor has been deprived, in whole or in part, directly or indirectly, of the full enjoyment of the monopoly conferred by the patent.
3. If there is a commercial benefit to be derived from the invention, it belongs to the patent holder.
4. It is no bar to a finding of infringement that the patented object or process is a part of or composes a broader unpatented structure or process, provided the patented invention is significant or important to the defendant's activities that involve the unpatented structure.
5. Possession of a patented object or an object incorporating a patented feature may constitute "use" of the object's stand-by or insurance utility and thus constitute infringement.
6. Possession, at least in commercial circumstances, raises a rebuttable presumption of "use".
7. While intention is generally irrelevant to determining whether there has been "use" and hence infringement, the absence of intention to employ or gain any advantage from the invention may be relevant to rebutting the presumption of use raised by possession.
 Several of these principles are relevant to the issue of infringement by importation. First, with regards to the question of “use”, the Court must ask itself: “did the defendant’s activity deprive the inventor in whole or in part, directly or indirectly, of full enjoyment of the monopoly conferred by law?” (Emphasis omitted, Monsanto Canada Inc., para. 35; see also Free World Trust, para. 43). This is exactly the question all the British cases cited above, going back to Elmslie, Von Heyden and Saccharin, meant to answer when they concluded that the importation, use or sale of products made abroad by way of the patented process constitutes infringement.
 Moreover, the meaning and purpose of s. 42 of the Patent Act, as described at para. 34 of the Monsanto Canada Inc. decision, is perfectly in line with the views adopted by Justice MacKay in Wellcome (1991):
[t]he purpose of s. 42 is to define the exclusive rights granted to the patent holder. These rights are the rights to full enjoyment of the monopoly granted by the patent. Therefore, what is prohibited is "any act that interferes with the full enjoyment of the monopoly granted to the patentee": H. G. Fox, The Canadian Law and Practice Relating to Letters Patent for Inventions (4th ed. 1969), at p. 349;
[Monsanto Canada Inc., para. 34.]
 This approach to a patent’s monopoly was discussed by the majority in Monsanto Canada Inc. with reference to British jurisprudence:
Thus, in Saccharin Corp. v. Anglo-Continental Chemical Works, Ld. (1900), 17 R.P.C. 307 (H.C.J.), the court stated, at p. 319:
By the sale of saccharin, in the course of the production of which the patented process is used, the Patentee is deprived of some part of the whole profit and advantage of the invention, and the importer is indirectly making use of the invention.
 It is also worth nothing that even the minority in Monsanto Canada Inc. appear to be in agreement with the “Saccharin doctrine”. As Justice Louise Arbour stated, at para. 155:
It is well established that the use or sale of unpatented subject matter may still infringe a patent where the unpatented subject matter is made employing a patented process: Saccharin Corp. v. Anglo-Continental Chemical Works, Ld. (1900), 17 R.P.C. 307 (H.C.J.); F. Hoffmann-Laroche, supra, at p. 415; Wellcome Foundation Ltd. v. Apotex Inc. (1991), 39 C.P.R. (3d) 289 (F.C.T.D.); American Cyanamid Co. v. Charles E. Frosst & Co. (1965), 29 Fox Pat. C. 153 (Ex. Ct.). This proposition does not assist the respondent, however. The appellants have not infringed the process claim because they have not used the claimed method to produce their canola crop.
[Emphasis in the original.]
 While mindful that Monsanto Canada Inc. did not specifically address the issue of territoriality, the principles laid out therein are of assistance in evaluating Apotex’s argument.
 Both Lilly and Apotex have raised various policy reasons in support of their respective positions with respect to the question of infringement by importation. There is no need to discuss them here except to say such arguments are matters for Parliament to consider, not this Court.
 Apotex’s argument that the U.S. approach to this issue should be preferred is not convincing. It is worth noting that much of the U.S. jurisprudence regarding this issue (which were considered by the Court), was followed by legislative changes seeking to close significant gaps resulting from these decisions.
 In sum, the Court agrees with Lilly that it is now too late to turn back the clock on the application of the general principles set out in the above-mentioned Canadian case law. Importation of products made abroad that are the subject of patented process claims in Canada is prohibited. This prohibition is widely recognized and is well-settled law in Canada.
 Apotex’s second argument with respect to infringement by importation seeks to limit the application of the “Saccharin doctrine” as qualified by Wilderman based on the U.S. Process Patent Amendment Act and/or the EPC, as well as the jurisprudence that has interpreted these instruments.
 First, it is worth mentioning that even though Parliament has had opportunities to intervene in this respect, it appears never to have felt the need to do so even after Canada became a party to the NAFTA and the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreements.
 In NAFTA, para. 1709(5)(b) reads:
where the subject matter of a patent is a process, the patent shall confer on the patent owner the right to prevent other persons from using that process and from using, selling, or importing at least the product obtained directly by that process, without the patent owner's consent.
Para. 28(1)(b) of TRIPS is nearly identical. It reads:
where the subject matter of a patent is a process,
[a patent shall confer on its owner the exclusive right] to prevent third parties not having the owner’s consent from the act of using the process, and from the acts of: using, offering for sale, selling, or importing for these purposes at least the product obtained directly by that process.
 Parliament adopted two bills with respect to the implementation of these agreements. The first, An Act to Implement the North American Free Trade Agreement, S.C. 1993, c. 44, sets out at s. 189 and following, the changes to the Patent Act made necessary by this agreement. The second, An Act to Implement the Agreement Establishing the World Trade Organization, S.C. 1994, c. 47, deals with necessary modifications to the Patent Act at ss. 141 and 142. None of these changes address the issue before the Court.
 It can be reasonably assumed that the legislator was well aware of the state of patent law in Canada before it presented these bills. The relevant law at that time was summarized in Fox, at pp. 391 and 392, as follows:
In considering infringement it is well to remember that it is not only manufacture that is forbidden to others than the patentee, but use and sale as well. For this reason infringement is committed by the importation of infringing articles made abroad, as well as importation and use in the country of articles or products made abroad on a patented machine or by a patented process. This principle applies also where the process used abroad has not produced the finished product that is imported but an intermediate that falls within the claims of the patent. In other words, it is none the less an infringement that the article or substance produced and sold which is manufactured by the use of the patented process is subjected to certain other processes. But this concept must be considered with care: it does not apply in a case of de minimis. If there is an act committed in Canada by the defendant in derogation of the patentee’s rights there is infringement.
 It is also reasonable to assume that Parliament was well aware of the relevant statutory provisions referred to by Apotex.
 What Apotex seeks in this Court is a re-writing of Canadian patent laws in order to limit the application of over a century’s worth of jurisprudence. While European and U.S. statutory provisions may be of assistance in analyzing Canadian laws, they cannot serve to displace the well-settled jurisprudence on infringement by importation.
 As mentioned earlier, Justice Snider, in Pfizer, made a very useful summary of factors that a Court should consider to determine whether or not the patented process plays an important part in the manufacture of the imported products:
importance of the product or process to the final product sold into Canada. Where
the use is incidental, non-essential or could readily be substituted (such as
the Italian scissors example), a Court might be less inclined to find
- Whether the final product actually
contains all or part of the patented product. Where the patented product can
actually be identified in the product sold into Canada, there
may be a strong case for a finding of infringement.
- The stage at which the patented product
or process is used. For example, use of a process as a preliminary step of a
lengthy production process may lead to a conclusion that the patentee has
suffered little deprivation.
- The number of instances of use made of
the patented product or process. Where the same patented product is used
repetitively through the production of the non-patented end product, there may
be clearer evidence that the advantage of the patentee has been impaired.
- The strength of the evidence demonstrating that, if carried out or used in Canada, the product or process would constitute infringement. On this point, my opinion would be that, where there is ambiguity in the evidence, the benefit of the doubt should go to the party using the product or process. This is, perhaps, simply another way of expressing the established principle that the patentee bears the burden of proving infringement.
Justice Snider concludes that “[i]n sum, there must be a strong link established between the use of the patented process or product and the product sold into Canada.” (para. 91.)
 I do not take Justice Snider’s list to be exhaustive or to limit in any way the test applicable in Canada. There is nothing in what she proposed that prevents the Court from also considering whether the imported product was obtained directly from the patented process or whether the compound made by the patented process was materially changed or has become a trivial or non-essential component of the imported product. In fact, these concepts are very close to those she used, her list is obviously more detailed as our test is more flexible and as mentioned, this is rightly so.
 The value of our approach is that it can be adapted to new circumstances. The Courts in Beecham Group were able to conclude to infringement despite the fact that the final ingredient imported in England no longer contained the compound made using the patented processes. It was the flexibility of the test that enabled them to do so and to look at what happened in the stomachs of the patients who actually bought and used the pills made by the defendant.
 For these
reasons, not only do I conclude that the Court cannot redefine and limit the
test applicable in Canada with respect to infringement by importation and use,
but also that I should not do so. On this basis, I will now proceed to apply
these principles to the facts of this case.
 In respect of the Shionogi patents, it is not disputed that if the Kyong Bo process had been carried out in Canada, it would have infringed the Shionogi patents.
 It was also clear, in my view, that Lupin used the process covered by the Lilly patents until 1998.
 The only real difficulty in applying the test in this case arises from the fact that making cefaclor is a very complex process, involving more steps than what was required to make the various compounds previously discussed in the case law. But this alone should not prevent the application of the doctrine. Certainly technical complexity should not enable a party to deprive in whole or in part, directly or indirectly, of the full enjoyment of the monopoly conferred by a patent.
 It is not disputed that there are other steps (chemical reactions) that take place after Lupin and Kyong Bo obtained either the 3-chloro-cephem or the 3-hydroxy-cephem compounds (which are the end compounds of the patented processes) to make cefaclor. Nor is it contested that the 3-chloro-cephem and the 3-hydroxy-cephem are changed into an ultimately different chemical compound (cefaclor) by these additional steps.
 All the experts agreed that there was no known method to make cefaclor without going through the 3-hydroxy-cephem compound.
 None of the experts opine that either patented process was a trivial or unessential part of the processes used by Kyong Bo or Lupin (Process “A”) to produce the cefaclor used by Apotex in Canada.
 On the whole of the evidence, it is clear that the Shionogi and Lilly processes were more efficient (and therefore less costly) than any other alternative discussed in any of the publications referred to by the experts or used by Lupin.
 In fact, in respect of the Lilly process, there is clear evidence that to change what is described in Lupin’s documentation simply as step V (although it involves three distinct reactions) resulted in an increase of almost 50% of the price of cefaclor.
 As discussed, the disclosure of the Lilly process patents expressly states that the inventions are particularly useful to make cefaclor. This is the very purpose for which their teachings were used here.
 Apotex relied heavily on a 1978 progress report from Lilly’s research team working on cefaclor (TX-211). Interestingly it states, at p. 3 that:
The two most difficult steps in the cefaclor synthesis, in terms of time and effort expended, are the exomethylene ring expansion (Dr. T.S. Chou) and the enol chlorination (79284 → 112069). Very few processes have been as extensively investigated as these two synthetic steps for cefaclor.
 Having considered and weighed all the evidence, I conclude that, as a matter of fact, Lilly’s patented process was an “important” part of the method used by Lupin to make the cefaclor that was used by Apotex in Canada.
 I have also
concluded that the Shionogi process was a crucial, thus obviously important,
part of the Kyong Bo process for making cefaclor. Without it, Kyong Bo could
not have used the total synthetic pathway described in its technical
documentation filed with Health Canada.
5.6. The Exemption Under Subsection 55.2(1) of the Patent Act
 Subsection 55.2(1) provides:
55.2(1) It is not an infringement of a patent for any person to make, construct, use or sell the patented invention solely for uses reasonably related to the development and submission of information required under any law of Canada, a province or a country other than Canada that regulates the manufacture, construction, use or sale of any product.
55.2(1) Il n’y a pas contrefaçon de brevet lorsque l’utilisation, la fabrication, la construction ou la vente d’une invention brevetée se justifie dans la seule mesure nécessaire à la préparation et à la production du dossier d’information qu’oblige à fournir une loi fédérale, provinciale ou étrangère réglementant la fabrication, la construction,
l’utilisation ou la vente d’un produit.
It is admitted that this defence was
included in the particulars filed by Apotex but Lilly argues that the statement
of defence was never amended and thus it was not properly pleaded. There is no
dispute that Lilly was fully aware that Apotex would rely on this exemption. Although
strictly speaking Lilly is correct, it is obvious that in the present circumstances
there is no good reason to deprive Apotex of the right to raise this defence.
 The only substantive
argument advanced by Lilly is that, based on Ms. Carrière’s testimony, the
in-process sampling and the reserve samples were not set aside simply to meet
government requirements but also for internal quality controls (which addresses
business, not regulatory, imperatives). Lilly argues that in light of this dual
purpose, the exemption cannot apply to such material. Lilly also says that
Apotex has not established that its records are consistent and complete and
that the quantities set out in the documentation prepared by Mr. Fahner
were only used for the purposes set out in subs. 55.2(1) of the Patent
 The argument
that this exemption should be strictly construed has been rejected by the
Federal Court of Appeal in Merck & Co. v. Apotex Inc., 2006
FCA 323,  3 F.C.R. 588 (Merck & Co. (FCA)) (paras. 103-104).
In that decision and in Laboratoires Servier the Courts did not limit
the exemption solely to material actually provided to a regulator. What is
critical here is that the Court is satisfied that the materials purported to
have been used for research and development formulation, reserve samples and
in-process sampling were not sold or used for any similar purpose. The
fact that these quantities could serve a dual purpose is, in my view,
 As for the
actual amount of bulk cefaclor covered by the exemption, the Court agrees that
the exact quantities described in the document prepared by Mr. Fahner as a result
of his cross-examination and attached to a letter from counsel for Apotex dated
May 12, 2008, shall be the subject of the reference in order to determine what
quantities properly fall under the above-mentioned categories. This being, the
amounts described in this document represent the maximum quantities which can
be considered for the purpose of the exemption (187 kilos).
 Both parties recognize that this is not a major issue in this case and thus there is nothing more to say.
 It has been agreed that as all of the patents in suit have now expired, there is no need to deal with the portion of the counter-claim seeking a declaration that said patents are void. All findings concerning invalidity are thus made in the context of the main action.
6.1. Standard of Review and Burden of Proof
 It is common ground between the parties that Apotex, as the party attacking the validity of Lilly’s patents, bears the burden of proof with respect to invalidity. Such is the effect of subs. 43(2) and s. 59 of the Patent Act.
 Nor do the parties disagree on the applicable standard of proof. As the Supreme Court of Canada recently confirmed, “there is only one civil standard of proof at common law and that is proof on a balance of probabilities.” (F.H. v. McDougall, 2008 SCC 53,  3 S.C.R. 41, at para. 40).
 While agreeing on the onus and the standard of proof with respect to invalidity, Lilly and Apotex disagree on what a party asserting invalidity must prove. Lilly argues that Apotex must prove that the decision of the Commissioner of Patents to approve the patents at issue was unreasonable. In support of this proposition, Lilly relies on the following passage from Apotex Inc. v. Wellcome Foundation Ltd., 2002 SCC 77,  4 S.C.R. 153 (Wellcome (2002)):
Unlike the Harvard Mouse case (Harvard College v. Canada (Commissioner of Patents),  4 S.C.R. 45, 2002 SCC 76), released concurrently, these appeals are not limited to a question of law (i.e., the statutory limits of patentable subject matter). On that issue, the standard is correctness. The issue here is one of mixed fact and law, namely, was the Commissioner properly satisfied the claimed invention met the statutory test of utility? Fact finding generally commands deference, but here Parliament has provided an unfettered right of appeal to the Federal Court (Patent Act, s. 42).
In the circumstances, I think the appropriate standard of review of these issues, which largely raise mixed questions of law and fact, is reasonableness simpliciter, i.e., that the Commissioner's decision must withstand a somewhat probing examination (Canada (Director of Investigation and Research) v. Southam Inc.,  1 S.C.R. 748, at para. 56).
[Emphasis added. Paras. 42 and 44.]
 In effect, relying on Wellcome (2002), Lilly argues that s. 59 of the Patent Act requires a party asserting invalidity to engage in a form of judicial review of the Commissioner’s “decision” to grant an impugned patent. Furthermore, Lilly argues that deference is owed, and that the standard of reasonableness should apply.
 In Whirlpool, the Supreme Court of Canada put plainly the task faced by a party asserting invalidity: “The burden was on the appellants to prove on a balance of probabilities, that the patent was invalid” (para. 92). In so doing, the party attacking validity must establish that the patent, or claims within a patent, do not meet the requirements for patentability under the Patent Act (i.e. obviousness, utility, etc.). This requires one to examine the claims of a patent, properly constructed, against the requirements of the Patent Act (see Free World Trust at paras. 24-27).
 This is perfectly in line with the wording in s. 59 of the Patent Act which speaks of “any fact or default which by this Act or by law renders the patent void” and directs the Court to “take cognizance of that pleading and of the facts and decide accordingly.”
 The approach to validity, assessing claims against the requirements of the Patent Act, without reference to principles of administrative law, has been the standard judicial practice for more than a hundred years.
 It cannot be presumed that just two years after Free World Trust and Whirlpool, the Supreme Court of Canada sought to drastically modify the law with respect to invalidity in an implicit fashion with its decision in Wellcome (2002). One would expect such a shift to be done clearly and in express terms. The fact that the bulk of the jurisprudence since Wellcome (2002) has considered invalidity without resort to administrative law principles buttresses this conclusion. (See Laboratoires Servier, para. 225; M.K. Plastics Corp. v. Plasticair Inc., 2007 FC 574, 61 C.P.R. (4th) 1, para. 105.)
 Although it is clear that in Wellcome (2002), the Court was dealing with an action of infringement and a defence of invalidity in its administrative law analysis, the Supreme Court references s. 42 (now s. 41) of the Patent Act, which deals with the right to appeal from a decision of the Commissioner to refuse the grant of a patent to the Federal Court. The defence of invalidity and appeal from a refusal by the Commissioner to grant a patent implicates different actors (putative patentee v. alleged infringer) raising similar issues but in very different contexts.
 Furthermore, despite having imported administrative law principles into the invalidity analysis, neither Wellcome (2002) and Monsanto Canada Inc. actually applies concepts such as the degree of deference owed to the decision of the Commissioner to grant the patents at issue. In fact, notwithstanding the above referenced paragraphs of these decisions, the term “reasonableness” is not even used in assessing invalidity.
 A telling example of the unease created by those decisions can be found in Jay-Lor International Inc. v. Penta Farm Systems Ltd., 2007 FC 358, 59 C.P.R. (4th) 228, where Justice Snider was confronted with a patent infringement claim and defence of invalidity. In discussing the issue of validity, Justice Snider stated:
Once a patent is issued, there is a presumption that, in the absence of evidence to the contrary, the patent is valid (Patent Act, s. 43(2)). The onus is thus on the Defendants to show that the Commissioner of Patents erred in allowing the patent (Monsanto Canada Inc. v. Schmeiser, 2004 SCC 34 at para. 24,  1 S.C.R. 902; Apotex Inc. v. Wellcome Foundation Ltd., 2002 SCC 77,  4 S.C.R. 153 at paras. 43-44, 21 C.P.R. (4th) 499). In this case, the Defendants argue that the patent is invalid because it was both obvious and anticipated. I will consider each of these arguments.
Having made this observation, however, nowhere in her reasons does Justice Snider engage in anything resembling a reasonableness review akin to that which was set out in Dunsmuir v. New Brunswick, 2008 SCC 9,  1 S.C.R. 190 (Dunsmuir). In fact, the words “deference” and “reasonableness” (in an administrative law sense) appear nowhere in the decision, nor is there any reference (beyond the above quote) to the decision of the Commissioner to grant the patent at issue.
 Such an attitude is understandable for there are a number of reasons why an administrative law approach to invalidity is almost impossible to apply without further guidance from Canada’s highest Court.
 In effect, it is unclear what would be the subject of this judicial review. A decision by the Commissioner to grant a patent comes with no reasons, no explanation, and no context. Indeed, a patent’s prosecution history cannot be reviewed in construing the claims of a patent (Merck & Co. (FCA), para. 53).
 A reasonableness review involves determining whether a decision falls within a range of possible acceptable outcomes on the basis of the evidence before the original decision maker (Dunsmuir, para. 47). If, as Wellcome (2002) suggests, the Commissioner’s decision to grant a patent is owed some matter of deference, how would a reviewing court assess reasonableness without access to the material considered by the decision-maker? Although the Supreme Court of Canada left the door open in Free World Trust (para. 67) as to whether prosecution history can be relevant for a purpose other than defining the scope of the grant of the monopoly, it has never been used for the purpose of deciphering the Commissioner’s reasons for granting a patent.
 A court engaged in judicial review, regardless of the standard applied, is usually limited to only considering the evidence that was before the decision-maker (Gosselin v. Canada (Attorney General), 2006 FC 3, 289 F.T.R. 7, paras. 12-13). This has not been the case when courts are engaged in examining allegations of invalidity, with respect to a patent.
 There is no statutory requirement that the evidence before the Commissioner of Patents be provided to the Federal Court in the context of an infringement action. Furthermore, nothing in s. 59 of the Patent Act limits a party challenging the validity of a patent to the evidence that was put before the Commissioner of Patents.
 Parties challenging validity have always been free, subject to the applicable rules of evidence, to put forth any evidence that may serve to undermine the validity of a patent’s claims. Standards of review are neither useful nor designed to address situations where the evidentiary record before the Court is different than the one before another decision-maker.
 In the Harvard College (2000) decision, Chief Justice Isaac referred by analogy to appeals from decisions of the Registrar of Trade-Marks under s. 56 of the Trade-Marks Act, R.S.C. 1985, c. T-13. In such cases, standards of review only apply where there is no new evidence that could have affected the decision of the Registrar. If the Court concludes that there is such evidence, then the Court must exercise its discretion de novo. It should be noted that the Registrar of Trade-Marks must give reasons for his or her decision, which can then be the subject of an assessment by the Court.
 To be certain, administrative law principles have been applied to certain decisions of the Commissioner of Patents (See e.g. Genencor International, Inc. v. Canada (Commissioner of Patents), 2008 FC 608,  1 F.C.R. 361 (reviewing a decision of the Commissioner on a re-examination under ss. 48.1 – 48.5 of the Patent Act); Pason Systems Corp. v. Canada (Commissioner of Patents), 2006 FC 753,  2 F.C.R. 269 (reviewing a decision of the Commissioner in respect of alleged clerical corrections under s. 8 of the Patent Act); and, Dow Chemical Co. v. Canada (Attorney General), 2007 FC 1236, 63 C.P.R. (4th) 89).
 With respect of some of the decisions of the Commissioner, a statutory right of appeal to the Federal Court is provided (see s. 19.2, subs. 20(15) and s. 41 of the Patent Act). However, where administrative law principles have been applied to decisions of the Commissioner of Patents, it has been in the context where these are amenable to judicial review and not pursuant to s. 59 and subs. 60(1) of the Patent Act.
 It may very well be that the material effect or consequence of a finding of invalidity is that the Commissioner “erred” in granting a patent. But, in the context of an action for infringement where a defence of invalidity is raised, that is not the essential point of departure: the claims stand alone to determine if the monopoly granted meets the test set out in the Act, for example in respect of utility, novelty and inventiveness.
 In sum, the importation of administrative law principles into the assessment of invalidity has not been thoroughly canvassed by appellate authorities and would constitute a significant departure from the Supreme Court of Canada’s well-established jurisprudence concerning pleas of invalidity. Absent further clarification on how the concept of deference is to be integrated into the established invalidity analysis, the Court is reluctant to employ administrative law principles in its analytic framework in this regard.
 Thus, in these proceedings, the merits of Apotex’s defence will be assessed on the basis that the defendant must establish on a balance of probabilities any fact which by virtue of the Patent Act or by law renders invalid the patents at issue, keeping in mind the applicable presumption as to their validity.
7. Inherency and Lack of Subject Matter
7.1. Shionogi Patents
 Apotex argues that the Commissioner of Patents did not force Shionogi to file divisional applications during the prosecution of these patents. It also submits that the Shionogi patents lack subject matter and that if there is anything novel and inventive in the
original application, it would be the
overall synthetic pathway that was not claimed in any of the Shionogi patents
 However, during the final argument, Apotex’s counsel made it clear that if the Court concluded that as in Consolboard Inc. v. MacMillan Bloedel (Saskatchewan) Ltd.,  1 S.C.R. 504, 122 D.L.R. (3d) 203 (Consolboard (1981)), Shionogi was required by the Commissioner of Patents to divide this application, none of these divisional applications should be open to attack by reason only of the granting of the original patent, that is, for lack of subject matter for more than one patent (see Consolboard (1981), at pp. 536-537 of the S.C.R.).
 That said, it is not disputed that Shionogi’s patent agent received an Examiner’s Report (also referred to as an “Office Action”) dated February 28, 1979, from the Patent Office where the Examiner indicated that:
The claims of this application are directed to four possible different subject matters as follows:
(1) Claims 1 to 10, 13 to16, 21 to 23, 38, 39 and 54 to 73.
(2) Claims 11, 12, 31 to 34 and 45 to 53.
(3) Claims 17 to 20 and 40 to 44, and
(4) Claims 24 to 30, 35 and 36.
Applicant must restrict his claims to a single subject matter under section 38 of the Act.
Amendment is required.
 The exact wording of the Commissioner’s letter in Consolboard (1981) is not reproduced in the Supreme Court of Canada’s judgment. Apotex did bring to the Court’s attention that in the trial decision, Consolboard Inc. v. MacMillan Bloedel (Saskatchewan) Ltd. (1978), 39 C.P.R. (2d) 191,  F.C.J. No. 305 (QL) (Consolboard (1978)), the said letter is described as follows:
The Commissioner of Patents took the view the application described and claimed more than one invention. He directed the applicant limit the claims to one invention only. Accordingly, on February 25, 1957, a divisional application was filed.
 It is not
disputed that such description appears to support the view of Lilly’s expert, Mr.
Murphy, that like in the above case, the filing of divisional applications here
was made at the direction of the Commissioner of Patents. In his report, Mr.
Murphy also notes, at para. 37, that “[u]pon filing of a divisional
application, the application is checked in the Patent Office to ensure that it
is entitled to divisional status.”
The expert concluded from his review of the relevant patent files that the
Patent Office properly accepted the divisional status of these applications. (See
also para. 40 of Mr. Murphy’s affidavit (E-20))
 Apotex did
not file any expert affidavits on this subject and relies solely on its
cross-examination of Mr. Murphy. The Court has considered the said
and finds that there is insufficient evidence to conclude that this case is
distinguishable from the one before the Supreme Court of Canada in Consolboard
 Beyond the issue of whether or not the Shionogi applications resulted from a proper divisional, there was some dispute between the parties as to what it means for a patent to “lack subject matter”. Fox teaches that in a wider sense, the question of subject matter is directed to ascertaining whether a device or process “falls within those classes of things designed to be protected by the patent law.” (p. 15) This was the main issue faced by the Supreme Court of Canada, for example, in Harvard College. According to Lilly, this is the way it understood Apotex’s pleadings.
 However, Fox also speaks of a more restrictive meaning which in sum directs the inquiry as to whether the production of the device or process “was obvious or involved the exercise of the inventive faculty. […] This enquiry, in the English cases usually discussed under the heading of obviousness, is directed to ascertaining whether […] its production was sufficiently important and worthy to entitle it to the grant of monopoly rights.” (pp. 15-16) In that context, the Courts sometimes loosely refer to lack of subject matter when what was claimed was not inventive but the Court finds that this expression should now be avoided. Even though it may be correct, strictly speaking, to say that there is no patentable subject matter if there is no invention, it is better to address the following aspects of a patentable invention – novelty, inventiveness, utility – under more specific headings and to reserve “lack of subject matter” as the heading under which one deals with whether or not the invention falls between those classes of things designed to be protected by the patent law.
the heading which one chooses to present one’s argument cannot change the fact
that one cannot have “two kicks at the can” by simply presenting its position under
distinct headings. The Court has already reviewed the Apotex argument in
respect of obviousness.
As indicated when discussing obviousness, the Court is satisfied that there is
at least one valid (unobvious)
claim at issue in each patent that is infringed. Thus, in my opinion, there is
no need to say more here.
7.2. Lilly Patents
 Apotex argues that the Lilly process patents lack “subject matter” as they claim nothing more than the inherent properties of a known compound. Also, as the usefulness of the kinetic complex in cephalosporin chemistry was disclosed in detail in the ‘007 patent (disclosure or specification only), there is no distinct “subject matter” supporting these process patents.
of the first argument, having reviewed the case law submitted by Apotex, the Court has no hesitation to conclude
that it has no application whatsoever here. These cases were dealing with very
different sets of facts.
 Also, given that the only claim found valid in the ‘007 patent (claim 17) is a process claim, this argument appears to be moot.
 The second point is also unsound. In effect, as explained earlier, although Apotex uses the expression “subject matter”, to refer to the inventiveness, what Apotex is really saying is that there is only one invention, the allegedly new kinetic compound, and, by claiming it in the ‘007 patent, Lilly was not entitled to the Lilly process patents. In short, it should have put all the claims in a single patent. As mentioned, it is clear that the discovery of the kinetic complex itself is not the invention in any of the process patents.
 In any event, the Court agrees with Lilly that this sounds like a modified double patenting argument coupled with an improper divisional argument. In my view, it also calls into question longstanding Patent Office practices.
 I say “modified double patenting” because Apotex ought to know that the ‘007 patent application, which was filed on the same day as the applications for the process patents (presumed date of the invention claimed given the absence of evidence in respect of an earlier date), is not prior art that can be used to support an argument of double patenting (obviousness). The defendant also ought to know that, as indicated by the Supreme Court of Canada in Whirlpool and Sanofi, the inquiry of double patenting is directed to the claims and not to the disclosure of the various patents under review. Comparing the claims of all the Lilly patents, it is evident that they do not overlap (anticipation). It is also clear, in my opinion, based on the evidence before me, that the process covered by claim 17 in the ‘007 patent (the only valid claim) does not render the use of the kinetic complex in each of the reactions claimed in the Lilly process patent obvious, nor, as mentioned in discussing obviousness, does the fact that the kinetic complex can be used for any one such reaction make it obvious that it can be used for the other two, or in “one pot”.
 There is uncontradicted expert evidence (Affidavit of Mr. Murphy (E-20)) to the effect that Lilly could not have included in a single patent, claim 17 (‘007 patent), a claim to a combination of steps and claims to the individual steps covered in the ‘725, ‘468 and ‘536 patents. This would have been contrary to the unity of invention rule as defined and described in the MOPOP. Thus to accept Apotex’s argument would mean that, because Lilly complied with this practice, instead of filing an application that would necessarily raise an objection and result in a request for amendment – the filing of divisional applications, its process patents can now be challenged on a basis that would not have otherwise been open to Apotex (Consolboard (1981)).
 The Court notes that in Merck & Co. (FCA), the Federal Court of Appeal reviewed, albeit in a different context, the question of an improper divisional and its consequences at paras. 40-50, and noted that such a divisional would not necessarily result in the loss of patent rights. In fact, it found that the concept of double patenting provides for an adequate remedy in the event that more than one patent is issued for the same invention.
 At trial, Apotex confirmed that it was not arguing that there was double patenting in this case.
 There is no good reason why there should be a different remedy against patents issued following the Patent Office practices than when there is an improper divisional as is examined in Merck (2006).
 The valid claims of these patents do not overlap and as discussed under obviousness, there is at least one unobvious claim at issue in each of them.
8.1. The Legal Test
 The law in respect of anticipation has been recently clarified by the Supreme Court of Canada in Sanofi, particularly at paras. 18 to 50.
 In order to anticipate, a prior art document that is considered must meet both the requirements of disclosure and enablement. In that respect, the Supreme Court of Canada approved and endorsed the decision of the House of Lords in Synthon.
 With respect to disclosure, Justice Rothstein made it clear that the prior art document must disclose subject matter which, if performed, would necessarily result in infringement of the patent being challenged.
 That prior art document must be read by the person skilled in the art with an open mind, trying to understand what that prior art document meant. However, at this stage of the inquiry (disclosure), the skilled person is not allowed to conduct experimentation as there is no room for trial and error, the prior art is simply to be read for the purposes of understanding it. (see Sanofi at para. 25; Abbott Laboratories v. Canada (Minister of Health), 2008 FC 1359, 71 C.P.R. (4th) 237 (Abbott (2008)), para. 67).
 The Court also understands that the law, as discussed in Beloit Canada Ltd. v. Valmet Oy (1986), 64 N.R. 287, 7 C.I.P.R. 205 (Beloit), General Tire and Free World Trust is still relevant on the issue of disclosure, but the Beloit test has been refined in respect of enablement (see Sanofi paras. 20-22 and 28).
 Surprisingly, there was a controversy at trial as to what exactly the prior art document must disclose. Must it reveal all the advantages or the details as to how to best use the patented invention disclosed in the patent or should it only describe the claimed invention? If the latter, should the prior disclosure include only the essential elements of the claim at issue or all of the elements described in the said claim? The parties wrote detailed submissions on this particular issue. Although these were duly considered, there is no need for a lengthy review of the authorities cited therein.
 As mentioned, the inquiry the Court must carry out seeks to determine whether or not the matter performed in the prior art would necessarily constitute infringement. Such inquiry is thus necessarily directed at the invention as claimed, and only to the essential elements of the claim, properly construed. In that respect, the Court notes that this also appears to be the understanding of Justice Hughes in Abbott (2008), at para. 76.
 In line with its argument that the inquiry is directed to the patented invention only, Apotex also argued that once the patented invention (distinct from what is claimed) is disclosed in the prior art, all claims in the patent must fall for there is only one such invention and if it is not novel, there should be no patent. This argument must also be rejected, not only because it is not in line with the inquiry at hand, but also because it leads to an absurd result. For example, if the broadest claim (such as claim 1) is invalid because it is too broad, having included a specific embodiment that has been made in the prior art, the inventor would not be entitled to claim another aspect of the invention in a dependent claim which covers only a compound that has never been disclosed or made. This would render obsolete what has been described as “the art of claiming” (see Hayhurst) and is also contrary to the approach now mandated by subs. 27(5) of the Patent Act as amended.
8.2. The ‘007 Patent
 The Court is satisfied that Apotex has established on a balance of probabilities that when one carries out the process disclosed at p. 3053 (triphenoxy-dichlorides (b)) of Rydon (Example B) which expressly provides for reacting TPP with Cl in hexane (an anhydrous inert solvent) in equimolar proportions, one would necessarily make a compound within the formula described in claim 1 and would thus infringe. The process would also necessarily infringe claim 8 (a process claim), which does not provide for a particular order of addition of the Cl and the TPP.
 By the end of the trial, this fact was no longer disputed by Lilly. It was admitted by Dr. Baldwin quite early in his testimony that the kinetic complex would necessarily have been formed when Rydon did this particular experiment.
 Whether one knew that the kinetic compound was formed or not is irrelevant, as is the fact that this compound would disappear if not stabilized or used quickly. This is a perfect analogy and direct application of the principles established and applied by the Federal Court of Appeal in Abbott (2006)  at para. 22 and Merrell Dow Pharmaceuticals Inc. mentioned above.
 There was a debate as to whether or not the claims could be anticipated if the prior art did not clearly disclose the fact that the fastest forming compound of this reaction was a halogenating compound. As mentioned, I do not construe claim 1 as a “use claim”. But even if I were wrong in this regard, I would apply the principles stated and applied by my colleague Justice Hughes in Abbott (2008) at paras. 71-75, and conclude that claims 1 and 8 are nevertheless anticipated.
 It is also relevant to further discuss what is disclosed in Coe and in Rydon in respect of halogenation. The Court finds that on the whole of the evidence (with particular consideration of the testimony of Dr. Baldwin), Apotex has not established that a compound covered by the claims of the ‘007 patent would necessarily participate in the halogenation process described in this prior art (particularly at p. 2285 of Coe and at p. 3049 of Rydon) if one were to follow the instructions given in those documents to prepare alkyl halides from the reaction of TPP, Cl and alcohol without solution (neat) and this even if the reaction was carried out in situ.
 Despite this, the Court is also convinced that the kinetic complex formed using the process described in Rydon at p. 3053 (Example B), is as a matter of fact a halogenating compound.
 The Court notes that in Abbott (2006), the claims under review also described the compound found to have been anticipated as an antibiotic. This was not viewed as sufficient to save the claim. This, I believe, is because the claims in Abbott (2006), like the claim here, are not “use” claims and the reference to halogen compounds or antibiotics is simply descriptive of the claimed compound.
 The parties are agreed that if claims 1 and 8 are anticipated, the only other claim of the ‘007 patent which requires a determination is claim 17. I do not believe that Apotex disputes the fact that neither Coe nor Rydon disclose subject matter, which if performed, would infringe claim 17. In effect, it appears undisputable that one could not infringe that particular claim without using an aromatic or halogenated hydrocarbon solvent.
 There is only one experiment in Rydon (at p. 3052) where chlorobenzene (an aromatic or halogenated hydrocarbon solvent) is used to carry out a reaction between Cl and TPP. However, in that experiment, the ratio of Cl to TPP was 1:2, and as such this process could not infringe the process described in claim 17, which requires the use of equivalent amounts of those two substances.
 Apotex argued that the use of an aromatic of halogenated solvent is not inventive and that therefore, “there is no distinct patentable subject matter.” It may well be that this essential element of claim 17 is not inventive, but that inquiry is distinct from the one being carried out to determine if the invention as claimed therein is novel. I conclude that this claim is not anticipated by what is disclosed in Coe or Rydon.
8.3. The Lilly Process Patents
 In its memorandum on invalidity, at p. 57, Apotex appears to argue that the Lilly process patents were anticipated simply because the triaryl phosphite-halogen compound, which is one of the essential elements in all the claims in these patents, was not novel. However, in its additional submissions dealing specifically with the implications of Sanofi, Apotex does not discuss at all these patents under the heading of anticipation. The Court understands from this that the argument that these process patents were anticipated has been abandoned.
 In the event that this is not so, the Court has carefully reviewed all of the prior art cited in respect of the Lilly process patents as well as Apotex’s expert reports and finds that there is not one single prior art document that discloses all the essential elements of the claims at issue in these process patents. Thus, none of the subject matter disclosed in any one single document, if performed, would necessarily infringe these patents.
8.4. The Shionogi Patents
 Apotex has not argued that the Shionogi patents are not novel. It is acknowledged that the compound by process claims in three of those patents are indeed novel and that none of the processes described therein were ever carried out on the specific compounds described in the claims.
9.1. The Legal Test
 We are dealing with patents subject to the pre-October 1, 1989 version of the Patent Act, in which there was no express statutory test for obviousness. Rather, as noted by Justice Rothstein in Sanofi, this doctrine was developed by necessary implication based on the requirement for an “invention” as defined in s. 2 of the Patent Act.
 In Sanofi, the Supreme Court of Canada reviewed the legal principles applicable to obviousness and took the opportunity to provide practical guidelines as to the approach that should be adopted in an obviousness inquiry. At para. 67, Justice Rothstein explains that:
It will be useful in an obviousness inquiry to follow the four-step approach first outlined by Oliver L.J. in Windsurfing International Inc. v. Tabur Marine (Great Britain) Ltd.,  R.P.C. 59 (C.A.). This approach should bring better structure to the obviousness inquiry and more objectivity and clarity to the analysis. The Windsurfing approach was recently updated by Jacob L.J. in Pozzoli SPA v. BDMO SA,  F.S.R. 37,  EWCA Civ 588, at para. 23:
In the result I would restate the Windsurfing questions thus:
(1) (a) Identify the notional
"person skilled in the art";
(b) Identify the relevant common
general knowledge of that person;
(2) Identify the inventive concept
of the claim in question or if that cannot readily be done, construe it;
(3) Identify what, if any, differences
exist between the matter cited as forming part of the "state of the
art" and the inventive concept of the claim or the claim as construed;
(4) Viewed without any knowledge of the alleged invention as claimed, do those differences constitute steps which would have been obvious to the person skilled in the art or do they require any degree of invention? […]
It will be at the fourth step of the Windsurfing/Pozzoli approach to obviousness that the issue of “obvious to try” will arise.
[Emphasis in the original.]
When there is some difficulty in identifying the inventive concept or step, the English Court of Appeal’s comments in Pozzoli SPA v. BDMO SA,  EWCA Civ 588 are useful, particularly at paras. 19-21:
19. In some cases the parties cannot agree on what the concept is. If one is not careful such a disagreement can develop into an unnecessary satellite debate. In the end what matters is/are the difference(s) between what is claimed and the prior art. It is those differences which form the ‘step’ to be considered at stage (4). So if a disagreement about the inventive concept of a claim starts getting too involved, the sensible way to proceed is to forget it and simply to work on the features of the claim.
20. In other cases, however, one need not get into finer points of construction – even without them the concept is fairly apparent – in Windsurfing, for instance, it was the ‘free sail’ concept. In yet other cases it is not even practical to try to identify a concept – a chemical class claim would often be a good example of this.
21. There is one other point to note. Identification of the concept is not the place where one takes into account the prior art. You are not at this point asking what was new. Of course the claim may identify that which was old (often by a pre-characterising clause) and what the patentee thinks is new (if there is characterising clause) but that does not matter at this point.
 In Sanofi, the Supreme Court of Canada also closed the debate as to whether the “obvious to try” test should be applied in Canada and if so, in what circumstances (generally paras. 62-66 and 68). The Court will be guided in that respect by the principles set out in paras. 69-71 of the decision, which are relevant when one reaches the fourth step of the obviousness inquiry.
 The Court has already discussed the concept of common general knowledge which is relevant to the construction of the claim as well as to the obviousness inquiry. A claim can be obvious based on common general knowledge alone or by a publication read by a posita in the light of the common general knowledge.
 Before turning to the application of the law to the patents at issue, it is worth saying a few words about “mosaicing” as this illustrates what one needs to establish before the Court can consider together individual prior art publications that are not necessarily part of the common general knowledge.
 In Terrell, at 7-62, the authors note that:
The “mosaicing” of individual documents or prior uses is not permissible, unless it can be shown that the skilled person, confronted with a particular citation, would turn to some other citation to supplement the information provided by the first. Whether he would do so is a question of fact.
 It is also worth reproducing Justice Hugh Laddie’s comment in Lilly ICOS LLC v. Pfizer Ltd. (2000), 59 BMLR 123 (Ch. Pat.),  F.S.R. 16 at para. 66:
When any piece of prior art is considered for the purposes of an obviousness attack, the question asked is ‘what would the skilled addressee think and do on the basis of this disclosure’?’ He will consider the disclosure in the light of the common general knowledge and it may be that in some cases he will also think it obvious to supplement the disclosure by consulting other readily accessible publicly available information. This will be particularly likely where the pleaded prior art encourages him to do so because it expressly cross-refers to other material. However, I do not think it is limited to cases where there is an express cross-reference. For example, if a piece of prior art directs the skilled worker to use a member of a class of ingredients for a particular purpose and it would be obvious to him where and how to find details of members of that class, then he will do so and that act of pulling in other information is itself an obvious consequence of the disclosure in the prior art.
 More recently, Justice David Kitchin, who was twice cited by the Supreme Court of Canada in Sanofi, said, at paras. 83 and 84 of Scinopharm Taiwan Ltd v. Eli Lilly & Co.,  EWHC 631 (Pat.),  All ER (D) 282 (Mar):
83. There is one other matter it is convenient to mention at this stage. Scinopharm's case depends, in part, upon reading various items of prior art together. It contends it is permissible to do this if they are in the same technical field. I do not agree. In my judgment it is only permissible to read two documents together if it is obvious to do so, as the Court of Appeal made clear in Smithkline Beecham v Apotex Europe  FSR 23 at :
"96. I think the Judge erred in principle here. The skilled man has his common general knowledge — the mental tools of his trade — but no more. The law of obviousness supposes that he can be given any individual piece of prior art and read it with that knowledge. The piece of prior art forms part of the "state of the art". What he cannot do is to just link one piece of prior art with another, unless so to do would itself be uninventive. No-one disputes what Lord Reid said in Technograph v Mills & Rockley  RPC 346 at p. 355:
"In dealing with obviousness, unlike novelty, it is permissible to make a 'mosaic' out of the relevant documents, but it must be a mosaic which can be put together by an unimaginative man with no inventive capacity.""
84. The question whether it is obvious to read two documents together is one to be considered in the light of the particular circumstances of each case. Relevant factors may include whether one document refers to the other or whether one or both documents would be found on a literature search of the kind the skilled person would routinely carry out before attempting to find a solution to the problem the patent addresses.
 There was also some debate as to the use of post art, which warrants some comments.
 It is evident that in certain specific circumstances, literature published after the filing date can be considered as evidence of what was commonly known or what was part of the state of the art at the relevant time. For instance, the Sammes article, which purports to review recent chemistry of the β-lactam antibiotics, though published after the relevant date, could be used to establish what a diligent search in the relevant field would have uncovered. In effect, it expressly states that the literature discussed therein was selected from what was published up to the beginning of 1974 and was intended to complement recent books and reviews that were published well before the filing date (which were not all discussed by the experts). At the end of the trial, the parties were agreed that the literature referred therein would be part of the common general knowledge of the addressee of all the process patents.
 Apotex argues that Tseng and Michalski can be used to show what the posita would have learned from reproducing the experiments set out in Rydon and in Coe, with the benefit of 31P NMR spectroscopy.
 The Court agrees that this may constitute admissible evidence if introduced by an expert, but one must be careful not to cross the line and treat such art on the same footing as prior art. For example, one cannot simply assume that because there is no mention of the invention under review in the article, its author was unaware of such developments. Once a patent application is filed, inventors will often more freely discuss their findings with colleagues and friends outside of their institution and not necessarily in the context of public conferences. Thus, it may be very difficult to ascertain if indeed the author of a post art publication really did his work without knowledge of the invention. This was obviously one of the main considerations for setting the date of the invention as the relevant date for the obviousness inquiry in the pre-1989 era.
 Also, in the absence of evidence from or about the authors, how is the Court to know whether what they did was what a posita (objective test) would have done before the filing date? Were the authors super skilled? Were they inventive? Did they go beyond what would be routinely done by a posita? Did they have a special motivation to do the things they did? All this to say that the probative weight of this evidence will depend on the circumstances, particularly on the evidence of the expert using it and often on whether it is used simply to corroborate an opinion reached independently by an expert available for cross-examination by the other party.
 The Court will now apply these principles to the patents under review.
9.2. The ‘007 Patent (Claim 17)
 Apotex submits that it has established that the kinetic complex would necessarily be produced using the method described in Rydon, reacting one to one equivalents of Cl and TPP. Thus, a posita practising the method of the prior art or routine variations of it with the benefit of 31P NMR spectroscopy would easily discover that it produces the so-called kinetic product.
 Apotex adds that it would be more or less self-evident to a posita that aromatic or halogenated hydrocarbon solvents (such as methylene chloride or chlorobenzene) could successfully be used in such a process.
9.2.1. The Person Skilled in the Art
 I shall use the definition of the posita found at para. 92.
9.2.2. Relevant Common General Knowledge
 The Court is satisfied that it has been established that the posita would be familiar with the aromatic and hydrocarbon solvents discussed in claim 17, including methylene chloride and chlorobenzene. The posita would equally be aware of the properties of such solvents.
 A posita would also be familiar with 31P NMR spectroscopy and would have a working knowledge of how to use it to identify phosphorus compounds, if and when necessary.
 Disproportionation is a general type of chemical process which would be known to the posita.
9.2.3. Rydon, Coe and Ramirez
 It is clear that Rydon and Coe are part of the relevant prior art, for these publications are expressly acknowledged as such in the patent. Lilly, however, contests that they form part of the posita’s common general knowledge because of the differences of opinion between the experts as to their meaning and exactly what they teach. The plaintiffs also argued that Apotex failed to provide any direct evidence in that respect. Given the admission contained in the patent, such debate is futile and it can have no impact on my conclusion regarding the obviousness inquiry.
 Apotex and its experts spent much time explaining why they believe that what is called the thermodynamic product and described as a dihalide ((PhO)3PCl2) in the ‘007 patent is in fact, in their view, the monohalide ((PhO)4PCl) discussed in Rydon, while the kinetic compound would be the dihalide. Drs. Modro and Olah also explained how they understood the various reactions taking place including how, in their view, the thermodynamic product resulted from a disproportionation of the kinetic product.
 For our purposes, determining the stoichiometry of the thermodynamic product is a debate that need not be settled, especially when one considers that Dr. McClelland did not appear to agree with the views of Drs. Modro, Chivers and Olah and testified during his cross-examination that in any event, the nature of the thermodynamic is still not well understood today. Dr. Chivers also acknowledged that two experts could read Rydon differently. In that respect, Dr. Baldwin wisely said that he did not really know the answer. For him, these publications were difficult to read and understand and there is no indication that the authors recognized the significance of “first formed intermediate”.
 It is acknowledged by all that Rydon, Coe, Ramirez or any other publication that will be discussed in relation to the ‘007 patent, do not refer to, or even mention, disproportionation to explain the relationship between the monohalide and the dihalide described in Rydon. With respect to the various mechanisms at play, including the reaction between Cl and TPP, Dr. Hunter noted that one would need to do a Ph.D. on the subject to fully understand them.
 For our purposes, it is sufficient to say that Rydon and Coe teach at least the following:
- The reaction between Cl and TPP is quite complex and some mechanisms are still regarded as obscure or not well understood. (Rydon, p. 3044)
- Theoretically,  the system may contain as many as 45 species, most of which would be in equilibrium (covalent form/ionic form). Depending on the conditions used for the reaction, including temperature, concentration and solvents, different species will be produced “while solubility will play a major role in determining the nature of the solid phase separating from solution.” (Rydon, p. 3045)
- The authors reported on and tested nine crystalline solids, six of which were described in Coe as dihalides (see Rydon, p. 3043). Certain compounds prepared by the authors could not be prepared as purified specimens.
- Whatever their true nature or stoichiometry, Rydon indicates that:
- The reaction of Cl/TPP in a ratio of 1 to 2 in chlorobenzene produces tetraphenoxy-chloride – a monohalide (p. 3052).
- The reaction of Cl/TPP in a ratio of 1 to 1 without solvent produces triphenoxy-dichloride – a dihalide. (p. 3053, Triphenoxy-dichlorides A)
- The reaction of Cl/TPP in a ratio of 1 to 1 in hexane produces triphenoxy-dichloride – a dihalide. (p. 3053, Example B)
- The reaction of Cl/TPP in a 1 to 1 ratio in acetonitrite produces triphenoxy-dichloride – a dihalide. (p. 3053, Triphenoxy-dichlorides C)
- With respect to halogenation, Coe only tested the product(s) from the reaction of Cl and TPP without solvent. Rydon notes that the “monohalides may have some advantages over the dihalides previously employed for the preparation of alkyl halides.” (Footnote omitted, p. 3044)
 I turn now to the article by Ramirez, who was described by Dr. Olah as a pioneer in 31P NMR spectroscopy. In that article, it appears that the authors were trying to obtain an authentic sample of pentaphenoxyphosphorane and analyze it. In that respect, they were following work that started in 1927 and was pursued by other authors in 1959. Apparently, these attempts produced mixtures of dichlorotriphenoxyphosphorane and other materials, leading the authors to reinvestigate the previously reported mechanisms in Rydon. Though they give few details about their experiments, the Court finds that one can reasonably infer from the reference to the addition of Cl to TPP in hexane solution for the purpose of reinvestigating previously reported synthesis of a triphenylphosphite dichloride (dichlorotriphenoxyphosphorane) that they followed the procedure of Example B on p. 3053 of Rydon, which is the only synthesis known in hexane in evidence before the Court. The authors dried the precipitate obtained and tried in vain to purify it (not part of procedure in Example B). They note that:
All that can be said about this substance is that, in CH2Cl2 solution, it gives only one signal in the 31P nmr spectrum. The chemical shift does not vary significantly in several solvents.
9.2.4. The Inventive Concept
 The inventive concept of claim 17 is that the reaction of equimolar amounts of triaryl phosphate and Cl or Br in a halogenated or aromatic hydrocarbon solvent produces an intermediate that is the faster forming product of the reaction: the so-called kinetic complex.
9.2.5. The Differences between the Common General Knowledge and the above-mentioned Publications and the Inventive Concept
 In respect of equimolar quantities of Cl and TPP, the only solvent used in Rydon and Coe was hexane, which is not an aromatic or halogenated hydrocarbon solvent.
 Although, as mentioned, it is evident that the reaction performed in Rydon and Ramirez produced a first formed intermediate, there is no recognition therein that the above-mentioned reaction produces such an intermediate or that such intermediate (first compound) will transform over time into a second compound (final compound).
9.2.6. Would These Differences be Obvious to the Person Skilled in the Art?
 Apotex argues that the use of chlorobenzene or methylene chloride (aromatic or halogenated hydrocarbon solvent) was a worthwhile option and that it was self-evident that it ought to work, particularly to perform chemistry on cephalosporins.
 According to the defendant, Rydon taught the use of chlorobenzene and the fact that the method used involved non-equivalent amounts of the reactants (a 2:1 ratio) is irrelevant. Choosing a particular solubilizing solvent is not inventive.
 At first, the Court was sympathetic to this argument, but on a closer review of the evidence, the Court realized that it may well have been influenced by knowledge gained from the ‘007 patent. Hindsight is the one thing that is particularly important to avoid at this stage of the inquiry.
 Uncharacteristically, Apotex’s oral and written arguments were extremely brief on this point (see para. 112 of their memorandum on validity; p. 7 of their representations on reply; and, paras. 60-62 of the submissions on the implications of Sanofi).
 They rely essentially on their cross-examination of Dr. Baldwin, who said that one would know the solubility properties required for the use of solvents in cephalosporin chemistry. Also, Apotex’s counsel noted that in Ramirez, whatever product was in the sample used for the 31P NMR analysis was soluble in methylene chloride.
 First, with respect to the skilled addressee’s knowledge of solvents suitable for cephalosporin chemistry, given the definition of the skilled addressee in the ‘007 patent, it is not clear how this evidence would be relevant. How and why would a posita, as defined, would come to use the kinetic product to perform chemistry on cephalosporins? Such use, according to the evidence of Dr. Baldwin, was inventive (see below discussion of Lilly process patents).
 One would think that, if a solvent is obvious for any reason, it is sufficient to conclude the present inquiry in respect of this element of the inventive concept. Thus, Apotex did not need to show that the use of such solvents was obvious for this type of chemistry.
 With respect to the second argument based on Ramirez, the Court notes that the actual reaction between Cl and TPP was carried out in hexane and that none of the experts testified that this publication taught them that the dihalide discussed in Rydon would be produced by carrying out the reaction in methylene chloride.
 Apotex certainly did not explain how the Court should deal with the evidence of Dr. Modro, who commented on claim 17 in a manner that appears to contradict Apotex’s current argument that Rydon taught the use of chlorobenzene or an aromatic hydrocarbon solvent to prepare a dihalide. In effect, with full knowledge of what was disclosed in Ramirez and Tseng, Dr. Modro said, at paras. 76 and 77 of his report (A-13), that based on the statement found at p. 3044 of Rydon and the fact that the actual reaction carried out therein resulted in the formation a monohalide (tetraphenoxyphosphorus chloride), this art taught that the use of chlorobenzene does not produce the kinetic product claimed in the ‘007 patent.
 Having carefully examined the evidence and considered the motivation for as well as the details of how the inventors made their discovery, the Court concludes that Apotex has not established on a balance of probabilities that it would be more or less self-evident that the use of an aromatic or halogenated hydrocarbon solvent to carry out the reaction described in at p. 3053 of Rydon (Example B) ought to produce the same compound as when done in hexane, particularly that it would produce the dihalide described in Rydon.
 In my view, this is sufficient to conclude that claim 17 is not obvious. For whether or not one could actually identify the compound formed through the use of 31P NMR spectroscopy is irrelevant if Rydon in fact taught away from the use of the claimed solvent.
 However, as this matter may go further, it is worth reviewing the evidence in respect of what the posita would learn through the allegedly routine use of such technology. This is especially so considering that this evidence and my findings in this respect will be relevant to the inquiry into the obviousness of the Lilly process patents, particularly the aspect of the claimed invention relating to the stabilization of the kinetic product through the use of a tertiary base.
 Obviously, Apotex’s first hurdle is to explain the conclusion in Ramirez, which contradicts their argument that one could quickly identify the first formed intermediate of the reaction simply by using the 31P NMR technology.
 For that purpose, they rely on the experiments carried out by Dr. Modro, as well as the experiments carried out in Tseng and Michalski.
 To determine what weight should be attributed to such evidence (particularly the post art) the Court will quickly review how Apotex’s experts used this information.
 Dr. Chivers concluded that a posita would be able to understand and identify the kinetic compound on the basis of the experiments done by Dr. Modro, who performed 31P NMR tests and analyzed the evolution of the spectral information about the products in solution over 23 hours (see A-18, paras. 29-32). Dr. Chivers only referred to Tseng and Michalski to support his view that the thermodynamic compound has the empirical formula of (PhO)4PCl (monohalide). Surprisingly, Dr. Chivers does not discuss the impact of Ramirez at all, even though it would have been part of the prior art available to the posita.
 Dr. Modro uses Tseng to confirm his view that: 1) the tetraphenoxyphosphorane (monochloride) is the thermodynamic product described in the ‘007 patent (by comparing the ppm shift obtained by Tseng and the ppm shift disclosed in the ‘007 patent for the thermodynamic product); and, 2) the equilibrium mechanism involved (ionic form versus covalent form which is quite distinct from the disproportionation mechanism discussed earlier). He refers to neither Michalski nor Ramirez.
 Dr. Olah is the only expert who refers to Ramirez. He affirms that based on the conclusion of Tseng and Michalski the authors of Ramirez were wrong. Dr. Olah does not explain why, without using the knowledge gained from the ‘007 patent, it would be so evident that both Rydon and Ramirez were wrong in identifying the product of the experiment described at p. 3053 of Rydon (Example B) as a dihalide. As I said, in any event, the stoichiometry of the compounds is not particularly relevant here.
 Dr. McClelland refers to the rapid equilibrium phenomenon which was disclosed in Rydon, further explained in Tseng and perfected in Michalski. This phenomenon explains, in his view, the difference in ppm shifts reported for the kinetic product. Again, this relates to the equilibrium between the ionic and the covalent form of the kinetic product, not to its transition to the thermodynamic form (disproportionation).
 This evidence is not particularly helpful to determine if, through the use of this technology and by simply repeating the process set out in Rydon (Example B, p. 3053), one would have come to the conclusion that the reaction produces two products (a first, faster forming intermediate and a final product).
 Dr. McClelland did say on cross-examination that reversing the order of addition of the reactants, as was done by Tseng, was a routine variation of Rydon’s method (Example B, at p. 3053). The Court accepts this evidence and notes that it is somewhat corroborated by Dr. Blaszczak’s evidence on discovery, when he discusses what was done by Mr. Fisher.
 However, there is no similar evidence in respect of the method and the temperature used by the authors of Michalski when they reacted the TPP with the halogen. This was clearly very different from the process disclosed in Rydon and there is no evidence that it was simply a variation that would routinely be carried out by a posita before the date of filing. The Court is not prepared to assume that what was done in Michalski was what a posita would be expected to do if he simply wanted to identify the product formed by the Rydon method, as opposed to embarking on a full research project to elucidate the reaction mechanism of TPP and halogen.
 That said, there is no evidence that the method used (31P NMR) for the experiments performed in Ramirez was not in accordance with the practice of positas as of the filing date. In fact, there is no evidence that there was any accepted practice as to when a spectra should be taken – such as before or after attempts to purify a product or within a certain time of having prepared a product.
 Certainly, there is no evidence that a posita would, as a matter of routine, take and analyze 31P NMR spectras of the product of the reaction over a period of 23 hours. In fact, this was not done in any of the publications before the Court.
 As mentioned earlier, Dr. Modro did carry out this type of experiment on behalf of Apotex. These were done with full knowledge of the teachings of the ‘007 patent. The Court does not accept these experiments as proof of what a posita carrying out routine experimentation at the relevant time would have done.
 In fact, it appears that, to attribute a particular ppm shift to a specific compound, one needs to know with some certainty what species is in the sample being tested.
 Ramirez, having failed to obtain a purified specimen, tentatively attributed the shift of -22.8 (CH2Cl2) to the product that was “regarded as” dichlorotriphenoxyphosphorane (triphenoxy-dichlorides in Rydon). Meanwhile, Tseng said that the -22.5 ppm shift (in deuterated chloroform) he obtained from the reaction of Cl and TPP without solvent was “likely to be” that of tetraphenoxyphosphorane because it was similar to the shift reported for that substance by Nesterov in what Dr. Baldwin described as an obscure Russian publication. In fact, Dr. Baldwin said that this method was quite suspect. Tseng certainly came to a conclusion in this respect that runs contrary to the teaching of Rydon.
 There is also no evidence that Ramirez or Tseng discuss the disproportionation mechanism referred to by Drs. Modro and Olah. There is no indication that they clearly and easily understood what these two experts suggested was obvious.
 In fact, it is telling that Tseng, who reported a shift of +7.7 ppm for the compound resulting from the reaction of equivalent amounts of TPP and Cl, attributed the other two shifts he obtained (one of which was the -22.5 ppm shift) to “impurities,” and not to a more stable form of the first compound he obtained.
 With respect to motivation, although the work of Ramirez, Tseng and Michalski do support the view that there was an interest in identifying the compounds reported in Rydon, it is not clear that these authors were looking for a halogenating compound. None of their experiments are directed to halogenation or to the properties of the Rydon compounds as halogenating reagents. They more likely resemble those carried out by theoretical chemists interested in the mechanistical reaction of Cl and TPP reported in Coe and Rydon. That said, the Court is ready to assume a certain degree of motivation.
 Sanofi teaches that in some circumstances, the means by which the inventor reached the invention may provide evidence in support of a particular conclusion on obviousness.
 Such a review will indeed be useful when inquiring into the obviousness of the Lilly process patents. However, the path followed by the inventor does not shed much new light in respect of claim 17 of the ‘007 patent. It mostly corroborates Dr. Baldwin’s view that, contrary to theoretical chemists, practicing synthesis chemists are more interested in the reactivity of compounds than using techniques such as 31P NMR spectroscopy to characterize and identify compounds unless they are motivated to do so by reasons other than just looking for a halogenating compound.
 In effect, it appears the inventors were not motivated to use 31P NMR spectroscopy to characterize the products of the reaction of TPP and Cl until they encountered a problem reproducing the experiment where they had successfully chlorinated the enol on which they were working. Until then, they were satisfied to work with whatever product resulted from reacting equivalent amounts of TPP and Cl in the solvent in which they were working on their cephalosporin substrate. Thus, it is the discovery that in certain circumstances the reagent produced by the reaction worked while it was inactive in others, which led to an in-depth study of the products, their stability, method of formation and structure-activity relationship.
 Moreover, the use of TPP and Cl was not a step undertaken on the basis of knowledge gained from Coe and Rydon. In effect, the idea to try phosphite as a possible reagent came to a Lilly chemist working in a different department after a discussion with a graduate student at Harvard, who was working on a totally different project but had noted that phosphites were more reactive than phosphines in his hands.
 In view of the foregoing, Apotex has not established that by practicing the method described in Example B, p. 3053 of Rydon with the benefit of 31P NMR spectroscopy, it would be more or less evident that the faster forming product of the reaction was an intermediate (of transient nature). It would thus not be more or less evident to the posita that it would be beneficial to stabilize this compound by using a tertiary base.
9.3. The Lilly Process Patents
9.3.1. Identify the Skilled Addressee
 I shall use the definition of the posita found at para. 92.
9.3.2. The Relevant Common General Knowledge
 The common general knowledge described in respect of the ‘007 patent would be available to the skilled addressee of the Lilly process patents.
 The disclosures of these process patents make it very clear that the particular steps or chemistry intended to be performed, i.e. the cephalosporin sulfoxide reduction, the enol chlorination and the imino halide formation were known in the prior art but were performed using other reagents.
 It was also known in 1978 that various phosphorus compounds (including PCl5) could reduce sulfoxides in general (as opposed to the more complex cephem cephalosporin sulfoxides under review).
 There was a known reagent called the Vilsmeier reagent which was typically made by using PCl3 to transform dimethylformamide. It was also known that PCl5 as well as other compounds such as phosphine, oxalyl chloride and thionyl chloride could be used with dimethylformamide to generate the Vilsmeier reagent. The Vilsmeier reagent is a non phosphorus reagent.
 In respect of cephalosporin synthesis, the posita generally knew how to change an OH at the 3-position to a Cl using the Vilsmeier reagent. It was known that this reagent could chlorinate an enol and reduce a sulfoxide. PCl5 could then be used as reagent to cleave the 7-amino side chain. However, PCl3 could not be used alone to perform such cleavage.
 The Court is also satisfied that at the relevant time, the posita would naturally view non-cephalosporin publications with some caution. He or she would not simply accept chemical reactions or reagents used in other fields and on less complex molecules as being directly applicable.
 With respect to sulfoxide reduction in particular, the natural caution described in Dr. Baldwin’s affidavit would be heightened by the fact that the literature reported that usual methods for reducing sulfoxides would not work with cephalosporins. Dr. Baldwin’s views in that respect are corroborated by a statement found in U.S. Patent No. 3,641,014. This document indicates that:
[t]here is a claim in the literature (J. Chem. Soc. (C), 1966, No. 13, p. 1142) that the usual methods for reducing sulfoxides will not reduce ∆3 –cephalosporin sulfoxides to the ∆3 –cephalosporin sulfides. We have corroborated this observation.
[p. 2, lines 47-51]
9.3.3. The Dreux Article and Other Prior Art
 This article, entitled “Deoxygenation of Sulfoxides under Mild Conditions with a New Reducing Agent: 2-phenoxy-1, 3, 2-benzo-dioxaphosphole” by M. Dreux, Y. Leroux and Ph. Savignac, published in Synthesis, 1974 at 506 (TX-1601, Dreux) is referred to in Drabowicz’s “Deoxygenation of Sulfoxide. A Review.” published in Organic Preparations and Procedures Int., 1977 (TX-1602, Drabowicz). There was some debate as to whether or not these would be part of the common general knowledge of the posita at the relevant time or even of the state of the art, given that they are not part of the cephalosporin or β-lactam literature.
 Having carefully considered the content of these publications, the Court need not deal with this particular issue further, given that even if they were part of the common general knowledge, it would have no impact whatsoever on the final determination of the issue of obviousness as the Court accepts Dr. Baldwin’s testimony regarding how it would be understood and used by the posita at the time.
 As mentioned in Drabowicz, Dreux shows that dialkyl, alkyl, aryl and diaryl sulfoxides can be reduced with cyclic phospholane used with a catalytic amount of iodine.
 It is worth noting that Dreux specifically mentions that the cyclic phospholane “seems to be a better reducing agent than triphenyl phosphite, which according to the available data,[] is itself an efficient reducing agent.” (p. 506)
 With respect to Drabowicz, it is acknowledged that the only method described therein that applied directly to penicillins or cephalosporins is found at p. 78. It refers to a then-recent publication by R.G. Micetich. Although it appears at first sight that the reduction of the sulfoxide was done with a phosphorus pentasulfide-pyridine system, Dr. Baldwin explained during his cross-examination that the reduction of the sulfoxide in such a case was not done by the phosphorus compound, but by the sulfur. According to him, it was known that sulfur compounds of this valent state were good reducing agents for such sulfoxides. The phosphorus only acts as a way of conveying the sulfur to the sulfoxide.
9.3.4. The Inventive Concept
 The inventive concept in each of the claims at issue was the use of the kinetic complex – the fastest forming intermediate of the reaction of equivalent amounts of triaryl phosphite and Cl or Br – to execute the steps described in these various patents, i.e. the cephalosporin sulfoxide reduction, enol chlorination and imino halide formation.
 In addition to this, some of the claims of the ‘468 patent (for example, claim 20) and the ‘536 patent (for example, claim 14), include the use of a tertiary amine base (including pyridine) to stabilize the kinetic complex. Also, with respect to the claims of the ‘536 patent, the inventive concept includes the use of a halogen scavenger to dispose of the halogen released during the formation of the kinetic complex to allow the reduction to take place.
9.3.5. The Differences between the Prior Art Including Common General Knowledge and the Inventive Concept of the Claims
 There is no disclosure that any compound resulting from the reaction of equivalent amounts of TPP (or any other triaryl phosphite) and Cl or Br in a solvent – let alone the first formed intermediate compound – is or would be useful in cephalosporin chemistry, including particularly cephalosporin enol halogenation.
 There is no disclosure in the prior art that a phosphorus containing reagent will halogenate a cephalosporin enol (the ‘725 patent), nor is there prior disclosure of the use of a pentavalent phosphorus reagent to effect sulfoxide reduction in cephalosporins (the ‘536 patent).
 There is no prior disclosure of the use of the kinetic complex in sulfoxide reduction requiring concomitant use of a halogen scavenger.
 There was no known or disclosed reagent that could perform all the steps described in the ‘536 patent – separately or in one pot (without the need to isolate).
 There was no disclosure of the value of stabilizing or maintaining the first formed product of the above-mentioned reaction or of the means to do so, in order to facilitate their use in chemistry, including, in particular, cephalosporin chemistry.
9.3.6. Do these Differences Constitute Steps which would have been Obvious or Do they Require Any Degree of Invention?
 It is here, according to Sanofi, that the “obvious to try” test might be appropriate. Apotex argues that, having regard to the type of reagent used to execute those transformations in the past, either in cephalosporin chemistry or in general organic chemistry, it would have been obvious to the posita to try the pentavalent phosphorus compound resulting from the reaction of TPP and Br or Cl disclosed in Rydon. It would have been more or less self-evident that it ought to work to perform the claimed chemical processes.
 As noted by Dr. McClelland during one of his cross-examinations, generally, the less one knows about a reagent, the more difficult it is to predict if it can be used successfully in synthesis chemistry.
 Here again, the expert evidence adduced by Apotex to support its position in respect of the Lilly process patents has very little probative value, given that none of the experts who opined on these patents were qualified to discuss what a posita would have found obvious to try.
 As noted previously when discussing Rydon, Coe, Ramirez and what one would learn through the use of 31P NMR spectroscopy, the Court is not persuaded that the posita would know that the first formed product of the reaction disclosed in Rydon is an intermediate that transforms over time. The stabilization of the kinetic complex through the use of a tertiary base could not be self-evident to a posita who did not first appreciate the transient nature of the first formed product of the reaction of TPP and Cl in the claimed solvent.
 Dr. Modro, when discussing the ‘007 patent observed that Rydon expressly taught the contrary (see para. 24(3) of his affidavit, A-13). There is no evidence as to why one would know or find it evident to use the (first formed) kinetic complex instead of the thermodynamic compound (final compound).
 The Court has very carefully considered Dr. Baldwin’s cross-examination as Apotex’s counsel tried very hard to obtain some useful admissions from this key witness to support their position. In my view, Dr. Baldwin’s evidence was quite clear. None of the prior art (including the common general knowledge alone or considered with the prior art), would lead a posita to the use of the kinetic complex to effect any of the processes claimed in the Lilly process patents.
 The Court was not persuaded by the expert evidence that either the thermodynamic or the kinetic product would be on the list of possible reagents to try.
 The Court has assumed here that there was motivation to find an appropriate reagent to execute those steps given that there was vigorous research in the relevant field (β-lactam and cephalosporin chemistry) at the time.
 Certainly, Lilly was particularly motivated to find such a reagent, given that it wanted to commercialize cefaclor.
 As mentioned, despite this, Dr. Hatfield and his team (particularly his lab technician, Mr. Fisher), who were actively trying to improve the Chauvette process (particularly the chlorination of the enol), after trying several potential candidates on what Dr. Blaszczak called their “laundry list” over a period of approximately two years, felt the need to send a general request to all research chemists in the β-lactam group at Lilly, seeking suggestions for reagents to be tried for the chlorination of the enol.
 As noted earlier, Dr. Blaszczak (one of the inventors) conceived the idea of trying “phosphite” after a discussion with a Harvard graduate student who was experimenting with them in a completely different context. The idea did not come to him because of what was generally known or disclosed in the literature.
 When he mentioned it to Dr. Hatfield and Mr. Fisher, they were experimenting with triphenyl phosphine in carbon tetrachloride and triphenyl phosphine in chloride. This suggestion led them to change the phosphine in the reactions they were testing for a phosphite to see what would happen.
 Again, it is worth noting that the inventor of the ‘536 patent (sulfoxide reduction and the 3-step process) is not one of the inventors of the ‘468 and ‘725 patents. In effect, the inventors of the latter two patents did not appreciate that the kinetic complex could also be used to effect sulfoxide reduction. This is particularly significant when one considers that these inventors knew what the posita did not know at that time – that the kinetic complex could effect the enol halogenation and the imino halide formation. Clearly, they also did not appreciate that such reduction could only work in the presence of a halogen scavenger.
 As mentioned, given that there was no other reagent known to be efficient enough to perform all three of these steps let alone in one pot, the Court is at a loss to understand how Apotex could say that the posita ought to expect that the said reagent would work to perform those three chemical reactions, that there is no synergistic result flowing from the possibility of carrying them all in one pot and that it was a mere aggregation of known steps. None of the experts contested the added value of being able to perform those three reactions in one pot. This evidently improved the cost and yields obtained. Even Dr. Hanessian referred to the kinetic complex as the “magic reagent.” This echoed the comments of Dr. Baldwin, who noted that he had many ways of listing new discoveries and this one was in the highest category; the one that he wishes he had thought of.
 What happened at Lilly in reality certainly supports Dr. Baldwin’s opinion. It points to a conclusion that: i) it was not obvious to try the product of the reaction of TPP and Cl, let alone the first formed intermediate; and, ii) it was not self-evident that such reagent would indeed be useful in one or more of the steps covered by the Lilly process patents.
 In view of the foregoing, Apotex has failed to persuade the Court that the claims at issue were obvious.
9.4. The Shionogi Patents
experts (Drs. Hanessian, Martin and McClelland) relied on various publications
to opine that the chemistry disclosed in each of the Shionogi patents was well-known
acknowledges that the common general knowledge of organic chemists would be
part of the common general knowledge of the posita. It is in that respect only that
the evidence of Drs. McClelland and Martin was given weight. As noted earlier,
because of their lack of expertise, or even focus on β-lactams, these
experts were not qualified to opine on how a posita would read the prior art or
what common general knowledge (other than from his PhD formation in organic
chemistry) he would possess. However, their evidence in respect of the common
general knowledge of PhD in organic chemistry does not add anything to the
evidence of Dr. Hanessian in that respect for he also included in his report
the same general concepts.
 Hence, the Court will only comment here on the prior art and common general knowledge relied upon by Dr. Hanessian. These would include the following:
i. The ‘547 patent
a. Ricardo Scartazzini & Hans Bickel, “Neue β-Lactam-Antibiotika. Über Derivate der 3-Hydroxy-7-amino-ceph-3-em-4-carbonsäure. Modifikationer van Antibiotika, 10 Meitteilung” (1974) 57 Helvetica Chimica Acta 1919 (TX-1587, Scartazzini).
b. Robert R. Chauvette & Pamela A. Pennington, “Chemistry of Cephalosporin Antibiotics XXIX. 3-Halo- and 3-Methoxy-3-cephems” (1974) 96 Journal of the American Chemical Society 4986 (TX-1585, Chauvette).
c. R.D.G. Cooper, & F.L. José, “Structural Studies on Penicillin Derivatives. IX. Synthesis of Thiazoline-Azetidinones” (1972) 94 Journal of the American Chemical Society 1021 (TX-1581, Cooper 2).
ii. The ‘924 patent
a. Robert Thornton Morrison & Robert Neilson Boyd, Organic Chemistry, 2nd ed., (Boston: Allyn and Bacon, 1966) at 667. (TX-1606).
b. “7-Alpha-Aminoacyl-3-Halogencephalosporine und Verfahren Zu Deren Herstellung”, German Patent App. No. 2408698, published September 5, 1974 (Chauvette application).
iii. The ‘132 patent
a. “Delta-2 Cephalosporin Compounds”, U.S. Patent No. 3637678, (13 January 1969) (TX-1583, Webber).
b. Douglas O. Spry, “Synthesis of C-2—C-3-Tricyclic Cephalosporins” (1973) J.C.S. Chem. Comm. 671 (TX-1622, Spry).
iv. The ‘026 patent
a. R.B. Woodward et al., “The Total Synthesis of Cephalosporin C1” (1966) 88 Journal of the American Chemical Society 852 (TX-1578, Woodward).
b. “Antibiotika”, German Patent App. No. 2400165, published July 18, 1974 (TX-1586, Cocker).
c. W. Maas et al., “Mechanism of Enamine Reactions. IV. The Hydrolysis of Tertiary Enamines in Acidic Medium” (1959) 32 Journal of Organic Chemistry IIII 5089 (TX-1607).
9.4.1. The Person Skilled in the Art
 The posita to whom these patents are addressed was described earlier (see para 75).
9.4.2. Common General Knowledge
 The parties are agreed that all the publications discussed in Sammes were part of the literature that would have been commonly known to, and generally accepted by, the posita at the relevant time. This means that most of the above-mentioned publications (Scartazzini, Chauvette, Cooper 2, Spry, Webber, Woodward), as well as others discussed by Dr. Barrett (such as R.D.G. Cooper, “Structural Studies on Penicillin Derivatives VIII. A Possible Model Biosynthetic Route to Penams and Cephems” (1972) 94 Journal of the American Chemical Society 1018 (TX-1581, Cooper 1)), are part of the common general knowledge. However, the experts disagree as to what some of these publications taught the posita. This will be discussed later on.
 β-lactams and cephalosporins were known to be polyfunctional and sensitive molecules that raised many issues relating to selectivity and reactivity.
 It was known to the posita that the most advantageous and economical method for producing a cephalosporin was to synthesize it from penicillin.
 Such synthesis had been done for cephalexin, another cephalosporin antibiotic, which was a 3-methyl (CH3) analog of cefaclor. It was prepared using the Morin arrangement or chemistry (conversion of a penicillin sulfoxide ester). This Morin arrangement, discovered in the mid 1960’s, was the commonly used method to open the 5-membered ring of the penicillin molecule to transform it into a 6-membered ring cephalosporin.
 In the early 1970s, Dr. Cooper, building on the work of Dr. Morin, developed another method for opening the penicillin ring and made what has been referred to as the Cooper thiazoline compound. However, at the relevant date, this compound, which is a penicillin derivative, had never been converted to a 6-membered ring cephalosporin.
 The 3-hydroxy cephalosporin molecule, the target compound of the so-called Shionogi synthetic pathway, had been disclosed in two then relatively recent publications, Chauvette and Scartazzini. At the time of these publications the patent on cefaclor (product by process) had not yet been published, the only known way of making this 3-hydroxy compound was to functionalize an existing cephalosporin structure. As of February, 1975 no one had made the 3-hydroxy compound from a penicillin molecule.
 Ozonolysis, sulfonylations, aminations, allylic halogenations, acylations, hydrolysis and bonds forming through nucleophilic substitution were known chemical processes, commonly used in general organic chemistry in 1975.
 Both Drs. Chauvette and Scartazzini used ozonolysis on a cephalosporin compound (a fully cyclicized 6-member ring structure) when they made the 3-hydroxy cephalosporin molecule described above.
 In Cooper 1 at p. 1019, Dr. Cooper indicates that ring closure to a cephem from his thiazoline azetidinone would involve an oxidative cyclization. Consequently, he had investigated the oxidation of compound 4 (which is compound 7 in Cooper 2) under various conditions in an effort to chemically duplicate this biosynthetic postulate. He explicitly notes that “[t]he isopropenyl double bond of 4 is generally inert to electrophilic reagents, [] it being recovered in high yield from reactions with bromine and permaleic acid.” He then went on to report on the isomerisation of the double bond of the Cooper thiazoline compound, followed by ozonolysis, which resulted in the formation of a new compound described therein.
 In Cooper 2, (the reference used by Dr. Hanessian), Drs. Cooper and José discussed other chemistry but refer to their earlier reported ozonolysis of the isomerized version of the Cooper thiazoline.
 There is no evidence from Dr. Hanessian on how a posita would construe the comment found in Cooper 1 with respect to the isopropenyl double bond. There is in fact no evidence that this expert was even aware of, or remembered (assuming he had read it sometime before in his career), this comment given that the article he uses in his report was provided to him by Apotex’s counsel (see A-15, para 5(f)(3)).
 Having carefully considered the extensive cross-examination of Dr. Barrett, the Court accepts Dr. Barrett’s views as to how a posita would understand Dr. Cooper’s comment in respect of the isopropenyl double bond. Among other things, the posita would understand that the reactivity of the thiazoline compound had far from normal reactivities associated with an alkene and was quite different from the reactivity profile of the product obtained from the isomerisation discussed in Cooper 2. 
 It was also known that Dr. Spry used a 2-substituted cephem to generate novel tricyclic cephalosporins. In that context, he performed allylic bromination of a cephem. It is to be noted, however, that at p. 672 of Spry, the author makes the following comments: “[a]ttempts to functionalize C-3’ further via the allylic bromination of (4) resulted in C-2 derivatization giving the C-2 bromo-derivative.” Again, the Court accepts Dr. Barrett’s evidence as to how this would be understood by a posita.
 It was also known and generally accepted that, in the context of transforming a penicillin molecule into a cephalosporin, Dr. Webber performed an allylic bromination after migrating the double bond from ∆3 to ∆2. Dr. Webber worked on a compound with a methyl (CH3) at the 3-position.
 Also part of the common general knowledge was the fact that in 1966, Dr. Woodward had opened a thiazolidine ring through hydrolysis in an acid.
 Retrosynthesis was used in 1975 as a general method for planning chemical synthesis in general organic chemistry. The Court accepts Dr. Barrett’s evidence that this was not commonly used in the field of cephalosporin chemistry and research related thereto at the relevant time.
9.4.3. Contested Art
 Lilly disputes the assertion that the three following publications would have been found by a diligent posita. It contends that these were not part of the common general knowledge and that no evidence was presented as to why they would be considered either alone or together by a posita, when faced with the problem solved in the Shionogi patents.
 This document is a German patent application, of which there was no available English translation at the relevant time. However, it was established that a short English abstract (number 120652H) was published in volume 81 of the 1974 Chemical Abstracts.
 Lilly notes that Cocker is not described in the Sammes review, despite the fact that it was published in July, 1974 with the abstract being published sometime in December, 1974. As the Sammes review refers to some patents, this could indeed indicate that this was not considered to be part of the relevant art; however, it may also be that it was simply not reviewed because of the language of the original and the fact that the English abstract was published at a date which was too close to the date on which the revised draft was submitted for publishing.
 Also, Lilly submits that the compound described in Cocker is not a cephalosporin (it lacks the 4-carboxylic function) and one would thus have had to search all β-lactam references to locate it. There is little evidence that such an extensive search would be undertaken by a posita, especially considering that there was no motivation to carry out the reaction, given that the compound in the Shionogi patent on which it is carried out was not known. It was also not known that this could be useful in the overall Shionogi process.
 As mentioned earlier, the lack of evidence on Apotex’s part as to how, and through what means, this document was found is troubling. However, the Court is prepared to consider that at least what was described in the abstract was part of the relevant state of the art. That said, it has not been established that this would be part of the common general knowledge.
 The Court will consider that a posita reviewing Cocker would understand that its author performed a hydrolysis of a thiazoline ring in acidic conditions with the resulting compound being transformed into a cephem derivative through a nucleophilic substitution where the sulfur attacks the 3-membered oxirane (a different group than in the ‘026 patent) to form a new carbon sulfur bond.
126.96.36.199. Chauvette application
 This is another German patent application that was allegedly published in September, 1974 with no English version being provided to the Court. Although Apotex tried to establish through cross-examination that an abstract could have been published in Chemical Abstracts, its failure to refer to such an abstract in the evidence of its experts raises a reasonable inference that it was not so-published at the relevant time. It has not been established that it would be part of the common general knowledge. The Court also notes that Dr. Martin indicated in his cross-examination that he had not been able to find one of the two German patent applications he referred to. The Court will not consider the evidence based on this document as there is insufficient evidence that it would even have been available to the posita at the relevant time. In any event, having carefully examined this art and the conflicting expert evidence related thereto, the Court does not believe that consideration of this publication would have altered the overall conclusion on the obviousness of the claims at issue in the ‘924 patent.
24-28, 1974 Dr. Kishi made a presentation at the 9th International
Conference on the Chemistry of Natural Products in Ottawa, Canada and another at International Union of Pure and Applied
Chemistry (IUPAC) conference on organic synthesis on August 26-30, 1974 in Louvain-la-Neuve, Belgium. A paper was later published in
the Journal of the American Chemical Society in 1975 as well as in two
IUPAC publications, also in 1975. It was admitted by Dr. Martin, who was
asked to find details of the presentation given at the conference, that the
above mentioned publications could not have been found at the relevant time.
The particular sections used by Apotex’s experts as a basis for their opinions
are found well into the paper (drawings relating to the allylic bromination of
compound 54 as well as the conversion of compounds 67 to 72).
experts who commented on the Shionogi patents initially relied on the work of
Dr. Yoshito Kishi described above to conclude that the claims of the ‘132
patent and the ‘026 patent were obvious.
Hanessian testified, the paragraphs dealing with this art were deleted and he
indicated that this deletion had no impact on his conclusion. Given that I have
found the evidence of Drs. McClelland and Martin in respect of the Lilly
process patents to be of little weight given their lack of experience in β-lactam
or cephalosporin chemistry, it is almost superfluous to discuss this
publication, which they alone discuss. Nevertheless, to avoid further debate I
will simply comment as follows:
cross-examination, Dr. Martin admitted that ordinarily presenters did not read
the paper that was later published. There is absolutely no evidence that the
particular segments or reactions used by these experts to support their
opinions were shown or mentioned by Dr. Kishi during his presentations. None of Apotex’s experts attended those
conferences or reviewed slides, (if any were actually used at the conferences)
or other information.
 In the circumstances, the Court is not satisfied that Apotex has established that the information used by its experts was indeed available to the public at the relevant time and should be considered for the purpose of assessing the obviousness of the Shionogi patents.
9.4.4. The Inventive Concept
 Although it is very clear that the inventive concept is to be assessed in respect of each claim at issue for each patent under review, the Court is satisfied that the issues raised by Apotex can be properly addressed without a full description of the inventive concept of each of the claims. It suffices to describe the relevant elements of the inventive concept of most of the claims at issue in each patent. As mentioned, infringement of one valid claim is sufficient for Lilly to succeed in this action.
 Apotex agreed that if there is any inventive concept in these patents (which it denied), it would be the overall synthetic pathway which is not claimed per se. However, even if it is clear from the disclosure of each patent that the overall synthetic pathway, which enables the addressee of each patent to cyclicize a penicillin derivative compound (the Cooper thiazoline compound) into a 6-membered ring cephalosporin, where a hydroxyl is already in place at the 3-position, is included in the inventive concept of at least one claim at issue in each patent; it is not the only relevant element thereof.
 In effect, the inventive concept of the claims at issue in the following patents also includes:
i. The ‘547 patent
a. The conversion of the Cooper thiazoline compound (an exomethylene compound) to new hydroxyl derivatives through ozonolysis.
ii. The ‘924 patent
a. That the new hydroxyl derivatives described therein can be activated (in claims 8 and 9, this is done by sulfonylation), that this process can be followed by amination (in claims 12 and 37, the amine is morpholino) to produce useful novel compounds.
iii. The ‘132 patent
a. That the new compounds described therein can be halogenated to produce other new useful compounds.
iv. The ‘026 patent
a. That the new halogenated compounds described therein (still penicillin derivatives) can be deprotected (hydrolysis) to form an azetidinone enol (or its ketotautomer) and that the new compounds can be cyclicized to form a 3-hydroxy-3-cephem (or its ketotautomer), this enabling the production of the desired antibiotics referred to in the disclosure, which include cefaclor.
9.4.5. The Differences between the Prior Art and the Inventive Concept
188.8.131.52. The ‘547 Patent
 There was no prior disclosure as to how the claimed reaction or process and the resulting compounds are useful in the synthesis of the desired 3-hydroxy cephalosporin.
 There is no prior disclosure of the ozonolysis of the isopropenyl bond in the Cooper thiazoline, which is one of the main starting compounds of the Shionogi process.
184.108.40.206. The ‘924 Patent
 With respect to the ‘924 patent, both the starting material and the final product of the claimed reaction were unknown.
 There was no prior disclosure as to how the claimed transformation could be useful in the synthesis of 3-hydroxy cephalosporins.
 There was no prior disclosure of a 2-step reaction involving sulfonylation of a hydroxyl group followed by amination of the sulfonylated product in penicillin derivative compounds (open ring structure).
220.127.116.11. The ‘132 Patent
 With respect to the ‘132 patent, there was no prior disclosure of the starting material or the final product of the claimed reaction.
 There was no prior disclosure as to how the claimed reaction could be useful in the synthesis of 3-hydroxy cephalosporin.
18.104.22.168. The ‘026 Patent
 With respect to the ‘026 patent, there was no disclosure of the starting material of the claimed reaction or the intermediate species formed after the first step.
 There was no prior disclosure of the ring closure of a thiazoline to form a cephalosporin (a β-lactam having 4-carboxylic acid function); there was no prior disclosure of how the new starting compound could be converted to give a 3-hydroxy cephalosporin or a compound which could be converted to such a compound.
 There was no prior disclosure of a 2-step reaction of a thiazoline having substituents similar to those used in the ‘026 patent or where an enamine is converted in situ to the desired functional group, that is hydroxy.
9.4.6. Are these Differences Inventive?
 I will first deal with the inventiveness of at least one of the claims at issue in each patent, based on the idea of the overall Shionogi synthetic process described in the disclosure. Apotex has not met its burden of establishing that this overall pathway was obvious. Dr. Hanessian, the only expert Apotex qualified to comment on what a posita would have known or would have found self-evident at the relevant time, did not opine at all on this point. He simply looked at each individual step; never considering the global process per se. Dr. Martin (though he was not really qualified to discuss this issue) submits that the one “invention” in all these patents is the overall process. In the context of his report this can only mean that, in his opinion, this overall process was not something that a posita as a matter of fact would have known or have found a trivial variation of what was known.
 Only Dr. McClelland, who, as mentioned earlier, outside of the present proceedings has no real experience, focus or particular interest with regard to β-lactam, let alone cephalosporin, chemistry, made the point in the two last paragraphs of his report (A-12, paras. 209-210) that the Shionogi pathway would have been self-evident if one used retrosynthesis.
 As mentioned, the opinion of Dr. McClelland has no probative weight in order to establish that a posita would have used retrosynthesis for this purpose in 1975.
 Furthermore, Dr. McClelland’s discussion of retrosynthesis is based on the premise that the posita would know that the process should go from the target 3-hydroxy compound (compound D) to the Cooper compound (compound B) in order to get to a penicillin, the desired starting compound (compound A). There is no doubt that the 3-hydroxy compound would be a self-evident target compound, if the problem to be solved was to find a way to make cefaclor from penicillin. Indeed, there was no way to make cefaclor without going through this specific intermediate.
 However, here again, Dr. McClelland was not qualified to say that the Cooper compound (compound B) would be the obvious way to get from compound D to compound A. This is especially so when one considers that at that time, the only known method to make the 3-hydroxy compound was through the 3-methylene cephalosporin, a pathway which leads away from the Shionogi process and the use of the Cooper compound.
 Dr. Barrett testified that, at the relevant time, it was more likely that the posita would start with, or go through, the Morin arrangement, which was the reliable method used for opening the penicillin ring to make a cephalosporin.
 That one could go through the exomethylene (compound 4 in W-17), to go back to compound A (which would include a penicillin sulfoxide) is corroborated by what Dr. Kukolja (another Lilly chemist) did when he discovered another process to make the 3-hydroxy from penicillin after 1975.
 Retrosynthesis is a purely visual thought process which would have produced many possible pathways. Although the fact that very many options were open is obviously not in and of itself sufficient to conclude that an invention is not obvious. It is still an element to consider in the overall analysis. In his cross-examination, Dr. Hanessian agreed that all the pathways proposed by Dr. Barrett in his report were reasonable, even if some appear to have a better chance of success than others. Interestingly, he added that “[t]here may be even more.” 
 Moreover, retrosynthesis does nothing more than provide a list of avenues to try. Execution, that is testing, is the next step. Thus, as noted in Sanofi, Apotex also had to establish that it would be more or less evident to the posita that the overall Shionogi pathway (assuming here that it would be part of the various retrosynthesis pathways one would have thought of) ought to work. The Defendant has simply not met its burden in this respect either, which is especially evident when one considers other factors relevant to the obviousness inquiry.
 There is little doubt that there was a general motivation in the industry to find methods to make cephalosporins from penicillin. Lilly chemists were particularly motivated to find a synthetic pathway that would enable them to make cefaclor from penicillin. As of February, 1975, Lilly had yet to find a way to efficiently produce its new antibiotic on a large scale.
 Dr. Cooper, one of the most prominent chemists in the field of cephalosporins and the inventor of the compound used as starting material for the Shionogi process, testified that he tried in earnest to close the ring of this thiazoline but simply could not do it. Thus, the Cooper compound was at the bottom of the list when looking for a way to make cefaclor from penicillin.
 Apotex argued that this evidence has little weight because Dr. Cooper’s job at Lilly was to find new compounds (he was on the β-lactam research team as opposed to the process team). The defendant also suggested, based on Kukolja, that one could assume that the Lilly chemists were busy looking at other avenues.
 Despite these arguments and an effort to challenge Dr. Cooper’s credibility in the course of his cross-examination, the Court finds his evidence credible. It only made good sense that he would try to find such a use for “his” compound. Although this evidence is not determinative per se, it certainly supports Dr. Barrett’s conclusion that the solution (overall pathway) proposed by Shionogi was not self-evident to the posita.
 Although there is no evidence on which the Court could conclude that cefaclor was “the” priority at Lilly, it was certainly important enough for Lilly to go to Shionogi for help. Lilly was willing to pay for this research and to disclose its private information. Dr. Cooper met with Shionogi scientists; this provided him with another opportunity to turn his skilled mind to the problem. There is no evidence that the solution disclosed in the Shionogi patents became evident to him during that process.
 In view of the foregoing, and having considered all the evidence presented, the Court concludes that the Shionogi synthetic pathway was not obvious.
 It is not disputed that the compounds by process claims in the various Shionogi patents constitute an invention, only if their utility was disclosed in the patent. In that respect, the overall Shionogi process provides the inventiveness supporting at least one such claim in each patent (except the ‘026 patent which contains no such claim). The case law is clear that in such a case, there is no need to claim the utility of the compounds in the claims.
 Here, the overall Shionogi process also provides inventiveness to at least one process claim at issue in each of the patents. The concept that an idea (overall synthetic pathway) can provide inventiveness to a claimed process or claimed product is not new. It is a basic tenet of patent law. (See Terrell, at paras. 7-8, on p. 276) There is no legal requirement that it be included in the said claims.
 That said, it is worth mentioning that in any event, Apotex has not met its burden of establishing that each individual step disclosed in the patent was obvious per se.
 It is here that Dr. Barrett and Dr. Hanessian are at opposite ends. Dr. Hanessian’s approach is quite simple – Lilly referred to it as simplistic. Reduced to its most basic expression, Dr. Hanessian’s position can be summarized as follows: the chemical reactions claimed in the Shionogi patents were generally known in organic chemistry. They each had been used at least once on similar compounds without destroying the β-lactam molecule (although the yields may have been very low). Thus, a posita would expect them to successfully work on the compounds described in the patents at issue even those that had never been made before.
 Dr. Barrett also acknowledges that these generic reactions (except maybe for one) were known and often used in general organic chemistry but he says that this would provide no comfort to the posita because of the delicate nature of the compounds at issue and the serious issues of selectivity they raised. Also, for Dr. Barrett to focus on some isolated examples which involved, according to him, compounds quite different from the ones at issue, ignores all the prior art references dealing with failures or unsatisfactory results obtained in other so-called similar compounds. Thus, in his view, it would not be plain nor self-evident at the relevant time to a posita that these reactions ought to work on penicillin derivatives, especially those that were not even known to exist.
 As mentioned earlier, Dr. Hanessian was a credible witness but the weight of his evidence was diminished by the fact that his opinion only refers to publications given to him by Apotex’s counsel. There is no specific reference or mention in his opinion of any bias or beliefs held at the time by the posita. There is no reference to the well-known literature of the time which summarized the advances in the field like the articles of Dr. Flynn or Sammes. In fact, there is no real evidence that he took into account any art outside that which was provided to him. It appears that he was given no specific instructions in this case against the use of hindsight and despite him mentioning that he had heard of the concept in a previous case, the Court is uncertain about his methodology. In cross-examination, when asked about the difficulty of transforming an exomethylene cephem at the relevant time, Dr. Hanessian that this involved a simple allylic bromination where everything has to do with its timing. However, he had to acknowledge that there was nothing about this in the relevant literature and that it was fair to say that in 1975, there was no known method to do so.
 On the other hand, Dr. Barrett was subjected to more than one long and skilful cross-examination and the weight of his evidence was diminished by the fact that some of the points made in his report were shown to have been somewhat overstated (see for example the evidence in respect of para. 115 of E-14). However, the weight of his evidence was still such that the Court could not conclude that there was a preponderance of evidence in favour of Apotex.
 This is especially true when one considers that the common general knowledge – Cooper 1, properly understood by the posita – would lead away from the process claimed in the ‘547 patent. Although the Court acknowledges that this paper shows that the Cooper thiazoline was stable in the conditions described therein, the Court does not agree that this would have been the only concern for the skilled person. The Court is simply not persuaded by Apotex’s evidence that the posita would be motivated to try this process on the Cooper compound and certainly not that the ozonolysis of this open-ring structure would be expected to work.
 In respect of the ‘924 and the ‘132 patents, none of Apotex’s experts explained how one would be motivated to even try such a process given that all the compounds involved were not known. It is also difficult to accept the proposition that these chemical reactions would be expected to work on compounds that were not even known.
 Apotex argued that the Court must assume that the posita knows of the overall Shionogi process so that it is placed in the same position as the inventor. I disagree. When considering obviousness, the posita is only assumed to possess common general knowledge and the public information disclosed in the prior art. The Shionogi process was not part of this. It was a solution only known to the inventors.
 In respect of the ‘026 patent, after reviewing the evidence several times, the Court had to conclude that it was equally unconvinced by both sides. The Court is simply not persuaded that even if a posita had been motivated to carry out this process (which is doubtful given that the starting compound was not known) it would have been evident that it would succeed. Thus the party bearing the burden on this issue fails.
10. Lack of Utility – Sound Prediction – Inoperability
 Apotex argues
that several of the claims in the patents at issue are overbroad; they
allegedly include claimed embodiments that are inoperable. Although the
defendant argues in its memorandum that the patentee had to establish utility
at the relevant time or that he could soundly predict that all the embodiments
claimed would be useful, it is evident that, as with any other arguments
presented to invalidate the patents, the burden of proof here is on the
 With respect
to sound prediction, the tripartite test to be applied was set out by the
Supreme Court of Canada in Wellcome (2002), at para. 70. More
particularly there must be: i) a factual basis for the prediction; ii) an
articulable sound line of reasoning; and, iii) proper disclosure.
10.1. The Lilly Patents
 In their
affidavits, Drs. Modro and McClelland stated that the ‘007 patent discloses
and claims reaction conditions for the formation of a kinetic complex of the
general formula where X is Cl or Br and Z is hydrogen, halo, C1-C4
alkyl or C1-C4 alkoxy. As there are no restrictions on the
position of the Z substituent on the benzene ring [ortho (-o-), meta (-meta-),
or para (-p-)],
they say that some of the Z variants other than hydrogen, such as
tri-p-chlorophenyl phosphite and Cl and tri-p-methoxyphenyl
phosphite and Cl and other similar members would be inactive, thus not work as
claimed in the patent.
 Given that
many of the claims at issue are limited to Z = H, such as
claims 20, 21, 27, and 11 (the alternative based on claim 10) of the ‘536
patent, claims 16, 23, 26, 27 and 30 of the ‘725 patent, and claims 8, 17, 19 and
20 of the ‘468 patent, it was not clear at all how such argument could be
determinative. The Court sought Apotex’s counsel’s views on this point and as
appears from the transcript of November 11, 2008, after reflecting upon it for
quite some time, the said counsel advised the Court that “it is really complex
to try to discern if such argument could be determinative” and thus noted the
Court should decide the issue.
 In an
abundance of caution, the Court has thus decided to review the evidence on this
issue but this should not be taken as implying that such argument could be
determinative in any way of the findings in respect of all the claims which
were found to be infringed. In fact, I do not believe that it is.
 Apotex’s experts’ views are not based on any experiment done by Dr. Modro or anybody else on behalf of Apotex. Except in respect of variants at the ortho position, these views are mostly based on what was reported in TX-211, a 1978 progress report which states:
The complexes formed from triphenyl phosphite and tri-o-tolyl phosphite behave identically, but the compound from tri-p-chlorophenyl phosphite and chlorine is inactive. This suggests that even small electronic factors are very important in order to obtain the correct compound. These data prompted speculation that the ionic complex, (ArO)3P±Cl Cl¯, was in fact the active complex and therefore substitution on the aromatic ring that would stabilize the positive charge on phosphorus should in turn provide a more stable, active reagent. With this in mind tri-p-methoxyphenyl phosphite was prepared and reacted with chlorine in methylene chloride at -15º. However, the compound was just too reactive with chlorine, either because of decomposition or aromatic ring chlorination, such that the endpoint in complex formation was extremely difficult to determine. The complex that did form was active in both chlorination and cleavage but low yields were obtained. A more extensive series of phosphites and resulting complexes with chlorine will be prepared.
[Emphasis added pp. 7-8.]
 As mentioned, TX-211 was introduced during the testimony of Dr. Blaszczak, who had read that report at the time it was circulated. Although he indicated that he had no reason to believe that the results reported therein were not accurate, it is clear that he was not
personally involved in the experiments
discussed, particularly those at the passages referred to by Apotex’s experts.
 The ‘007
patent, as well as the Lilly process patents, do contain examples where the
tri-p-chlorophenyl phosphite and chlorine complex was used to perform chemistry
on a cephalosporin substrate (see examples 9 and 10 in the ‘007 patent, example
48 in the ‘725 patent, example 27 in the ‘468 patent, and examples 72 and 89 in
the ‘536 patent). There are also many examples where a kinetic complex formed
from tri-p-methoxyphenyl phosphite was used to perform the claimed reaction
(see examples 68, 75, 90, and 94 of the ‘536 patent, and example 7(G) of the
‘007 patent). The patent also contains examples where a Z substituent other
than H is used on the ortho position (see example 7(F) of the ‘007 patent).
 The weight of
Apotex’s experts’ opinions were greatly diminished by way of cross-examination. It
became clear that, in respect of the para and meta substituents, Dr. Modro was
expressing mere concerns as to the yields that would be obtained using some of
these substituents rather than the fact that said compounds would be inactive.
It also became clear that the said experts had no more reason to rely on what
was reported in TX-211 than what was reported in the various patents. Dr.
McClelland insinuated that he could not rely on the examples in the patents
because he had not seen the actual lab notebooks concerning these experiments.
However, it is clear that he had not seen any lab notes relating to the
experiments reported in TX-211 either.
 In his affidavit
(E-19, paras. 57-59), Dr. Baldwin indicates that, based on the examples of the
preparation and use of ortho and para derivatives, there was no reason to
believe that meta-substituted compounds could not also be similarly prepared
and used. He also noted that he would not be concerned about steric effects since
only a single, relatively small (C4 alkyl or alkoxy) substituent is
The Court prefers the evidence of Dr. Baldwin who, although he had not seen any
lab notebooks with respect to the examples, represents what a posita would have
expected based on the data disclosed in the patents.
 When Lilly attempted to introduce direct evidence of the work carried out in the patent in respect of example 9 of the ‘007 patent, Apotex objected to the evidence of Mr. Gardner on the basis that Lilly had refused to reply to questions relating to all the experiments disclosed in the patents based on Justice Hugessen’s decision in these proceedings dated August 9, 2000 reported in Eli Lilly (2000), particularly where he stated, at para. 4:
I equally accept the plaintiffs’ position with respect to the plea that there was no sound basis for prediction of utility of the claims or some of them as pleaded in the defence. Inutility as pleaded here is a form of overclaiming and, equally in my view, must be tested against an objective standard, namely do the claims go beyond what could have been predicted, thereby claiming more than what was invented; I accept that what was said by Mr. Justice MacGuigan in Merck v. Apotex:
... section 34 is not concerned with the sufficiency of the inventor’s knowledge. Rather, the issue is whether the information provided in the specification is sufficient to explain the functioning of the invention to a person skilled in the art. In other words, the analysis centres on what the inventor expressed in the specification, not on what the inventor knew.
[Footnote omitted; emphasis added.]
This description of the law was expressly confirmed by the Federal Court of Appeal in Eli Lilly (2001) where Justice Rothstein indicated that the Court was not persuaded of any error of law in his reasons.
 In my view,
there is no need to even rule on this objection for, after carefully reviewing
the evidence, the Court is simply not satisfied that Apotex has met its burden
of establishing on a balance of probability that any of the above mentioned
compounds were inactive or that their ability to perform the claimed reactions
could not be soundly predicted
based on the factual data (the examples) disclosed in the patents and the
common general knowledge of the posita at the relevant time.
 The Court finds that there was no positive burden on Lilly to independently prove the experiments disclosed in its patents for Apotex abandoned its challenge of their accuracy
pursuant to s. 53 of the Patent Act.
Obviously, the evidence of Mr. Gardner would have strengthened Lilly’s case but
it does not improve Apotex’s.
 This leaves two further issues
to be discussed – the orthomethoxy derivative and para. 111 of Dr. McClelland’s
affidavit (A-12). 
 Dr. McClelland indicates, at para. 111 of his affidavit (A-12) that, according to TX-211, the inventors knew that the triphenylphosphite-chlorine complex employed to perform sulfoxide reduction (‘536 patent), halogenation of the 3-OH to 3-Cl (‘725 patent), and the acylamino conversion (‘468 patent) must be formed at -10º Celsius or lower to work and must be used quickly. Nevertheless, the inventors claim the use of such complexes and included in their claims temperatures of up to 30º Celsius.
 In the course of cross-examination, Dr. McClelland admitted that the passage cited in his report was in fact missing a part which is essential to understanding the passage relied upon in his report. In effect, at p. 7 of TX-211 it is indicated that:
The complex must be formed at -10º or lower and used as quickly as possible, since it becomes essentially inactive after standing at room temperature for several hours.
 Dr. McClelland
agreed that, read in context, this sentence means simply that the kinetic
complex must be used before it transforms after sitting at room temperature for
Dr. McClelland acknowledged that it is clear that a kinetic complex can be formed
at room temperature but still questioned how it would react with cephalosporins
at such temperature. He noted that he didn’t know because there were no
experiments, at least that he recalled. In fact, example 8(B), on p. 27 at the
‘007 patent used a kinetic complex at room temperature to perform imino-halide
formation producing a yield of 85.4% (as compared to 91.6% at 10º to 15º
 Turning to the last argument, here again, it is to be noted that Dr. Modro does not opine on whether, based on the experiment disclosed in the ‘007 patent (7(F) using tri-o-tolyl to transform a cephalosporin substrate) the inventor could have soundly predicted the usefulness of these other Z substituents at the ortho position.
 Dr. Baldwin
indicated in his report that in an earlier article (exhibit E-19 G), Dr. Gloede
had clearly shown the formation of a kinetic complex. Although
this does not appear clearly from his affidavit as drafted, Dr. Modro said that
the issue was more precisely whether the kinetic complex – an intermediate which
by nature is unstable – would be able, for example, to chlorinate the enol
before it reacted further with the chlorine as described in Gloede. There is no
evidence before the Court that the allegedly competing reaction shown in Gloede
(OZ = OCH3) was known to the inventor or to a posita at the relevant
 In respect of both of these issues the following comments of Justice MacKay in Wellcome (1991) are particularly apposite:
The Defendant raises doubt about the operability of certain of the reactions when particular reactants are utilized; however, there is no clear proof that any of the reactions will not proceed. That might have been demonstrated by attempting to carry out the claimed processes for particular reactions and documenting those which were found inoperable. I appreciate that there is no obligation on the Defendant to undertake any such experimental work to support a submission that processes claimed are inoperable, but the Defendant does have the onus of establishing invalidity of a registered patent. Despite doubts the Defendant raises I am not persuaded that the onus on the Defendant is met. I find that the Defendant has not established that any of the process claims are simply inoperable.
 In this case
the Court is not satisfied that Apotex has provided evidence of sufficient
weight to support its allegation that the ‘007 patent or the Lilly process
patents contain embodiments that are not useful or whose usefulness could not
be soundly predicted by the inventor on the basis of the various experiments
described in the patents and the relevant common general knowledge. They have
simply not met their burden.
10.2. The Shionogi Patents
 Apotex raises
no issue under this heading with respect to the ‘547 patent. In respect of the
‘924 patent, Dr. McClelland raises certain issues with respect to some compounds
in which both A and B or R are hydrogen atoms. However,
this is only relevant to claims 3, 8, 9, and 27. Thus, even if the Court were
to accept Apotex’s point of view, this would not be sufficient to avoid the
findings of infringement made in respect of the Kyong Bo process.
 In respect of the ‘132 patent, Drs. McClelland and Martin (see paras. 94-95 of the affidavit of Dr. Martin (A-17); para. 168 of the affidavit of Dr. McClelland (A-12)) testified about issues including “difficulties” that would be encountered with compounds covered by claims 15, 22, 29, and 34 when Y is hydroxy (OH). Also in respect of other claims, such as 1 and 2, Apotex says that based on Drs. McClelland and Hanessian’s evidence, it appears that, as of 1975, there was no reliable method that allowed for allylic fluorination
reactions to occur and no reagents were
listed in the patent to assist the skilled person. Dr. McClelland also notes that
there are no examples of halogen in the patents other than Br.
 As noted above,
the Kyong Bo process infringes claims 38, 58 and 15, the validity of which
cannot be affected by these arguments.
 It is not
clear why Apotex’s counsel insisted on arguing all of the above mentioned issues
given that it was clear that certain claims at issue, which would obviously be
infringed if their argument with respect to importation was not accepted, would
not be affected by such arguments.
 This brings us to the last patent, the ‘026 patent where all the claims at issue would be affected by the matters raised by Drs. Hanessian (para. 120-123 of A-15) and McClelland (paras. 199-200 of A-12). This is dealt with in a single paragraph of Apotex’s memorandum (para. 365) where it is summarized as follows:
[W]hen “Hal” is equal to fluorine, the cyclization reaction (step two of the claimed process) will not occur since fluorine is a poor leaving group in all substitution reactions.
In that respect, both Drs. McClelland and
Hanessian rely on Jerry March’s 1968 book Advanced Organic Chemistry provided
to them by Apotex’s counsel.
During his testimony, Dr. Hanessian said that he himself had noted that the
patent contained only examples with Br and few with Cl but
that there were no examples where iodine or fluorine were used.
 Both experts
confirmed that Apotex never tried fluorine in the many experiments performed by
Dr. Modro or Dr. Chase. However, despite the lack of examples in respect of
iodine and fluorine and the lack of detailed information about chlorine, Dr.
McClelland indicated in the course of his cross-examination that one would
expect no problems with Cl or iodine as a leaving group.
 Although Dr.
indicated that the cyclization through substitution discussed in step two of
claim 1 was an easy reaction, Dr. Hanessian states in his affidavit that it
requires a good leaving group. In fact, it is on that basis and that Dr.
Hanessian concludes that fluorine, which is not a good leaving group, would not
work. Dr. Hanessian does not discuss why the use of a catalizer would not
assist cyclization in this case even if he found it doubtful that fluorine
alone would be an appropriate leaving group for this type of reaction.
 Dr. McClelland said “I can’t say unequivocally that it’s not going to work. I can say that it is not a reaction that a chemist would view as particularly facile.” At para. 154-156 of his report (E-14), Dr. Barrett indicates that fluorine is not the worst leaving group provided for in the table referred to by Dr. McClelland. He also notes that, although a posita would not likely choose fluorine because of the inherent danger linked to the use of such halogen, – “[y]ou might destroy your co-workers. It’s a dangerous element”  – in his view
a cyclicized 3-hydroxy cephalosporin would
be formed by the use of fluorine particularly where a catalyst is utilized.
carefully considered all of the evidence, the Court is not satisfied that
Apotex has established on a balance of probability that the use of fluorine in
claim 1, particularly with the use of a catalizer to
assist cyclization, would not work or that such process could not be soundly
predicted on the basis of the experiments described in the patent and the
common general knowledge about fluorine as a leaving group.
10.3. Deficiency of Specification and Ambiguity
 Under this
heading, Apotex raises several complaints to support its argument that the
disclosure of the ‘007 patent (the only patent to which this argument applies)
is deficient and does not contain all the information necessary to enable the
posita to practice and use the invention claimed. These complaints and all
the evidence on which Apotex relies are fully described in its memorandum on
validity at paras. 121-134.
 As the Court has already indicated that the only valid claim left at issue at this stage is claim 17, these arguments will only be considered in respect of the invention claimed
therein, that is, the process to make the
kinetic complex in an aromatic hydrocarbon or halogenated hydrocarbon solvent.
 The applicable
principles are well-known. Be it sufficient to say here that the then
applicable s. 34 of the Patent Act provided that the specification (the disclosure
and the claims) i) correctly and fully describe the invention, ii) set out
clearly the various steps of the process claimed at claim 17 in full, clear,
concise and exact terms so as to enable the posita to use the invention, and
iii) distinctly claim the “thing” that the inventor regards as his invention.
 The case law
(including those cases cited by Apotex at para. 122) is clear that the patent
must “disclose everything that is essential for the invention to
 In a
nutshell, Apotex argues that the ‘007 patent fails to disclose the need i) to
avoid excess TPP, ii) to make the kinetic complex or use it at -10 ºC, iii) to
use the kinetic complex quickly, and iv) that it fails to give sufficient
details about the particular species falling within the scope of the claims.
 During its final presentation, Apotex conceded that this line of defence is not a major argument. In fact, the Court is somewhat surprised that it was pursued given the paucity of the evidence supporting it and the fact that all the experts who tried to make the kinetic complex, following the instructions of the ‘007 patent, succeeded the very first time they
tried (such as Dr. Modro and Dr. Chase on
behalf of Apotex) and had no difficulty differentiating the kinetic complex
from the thermodynamic product.
 There is thus
no need to say much more than that Apotex has failed to convince the Court that
a posita armed with all the information contained in the ‘007 patent and its
common general knowledge would not be able to use the process described at
claim 17 successfully to make kinetic complexes. In other words, the evidence
relied upon is simply insufficient to meet that burden.
 For example,
the passage of TX-220 relied upon to support the view that it was essential to
instruct the posita not to use excess TPP was read out of context and without
full consideration of the information actually disclosed in the ’007 patent.
The passage reproduced in Tab 168 is from a paragraph starting with
“[i]nitially”. It describes, as I mentioned it earlier, the discovery process.
The inventors had difficulties reproducing their first successful experiment.
In their attempts to reproduce it, they noted that the reagent having stood
overnight at 0º C became inactive and that the addition of one equivalent of Cl
to two equivalents of TPP also produced a product that was inert – could not be
used to transform a cephalosporin substract. At that time, the inventors
clearly had little understanding of the product(s) made by the reaction of TPP
 The examples
3, 4, 5 and 8 do not teach the use of excess TPP of the magnitude discussed in
TX-220. In such experiments the two reactants are mixed together until a yellow
colour, indicative of excess Cl persisted, which colour is then
discharged by the addition of further TPP. This is in line with the
preferred mode described at p. 11, line 30 to p. 12, line 7. The ‘007 patent
makes it clear at p. 11, lines 23-27, that TPP itself reacts to some extent
with its kinetic reaction product with Cl or Br effectively increasing the rate
of conversion to the corresponding thermodynamic product (see also p. 6, lines
 Obviously one
must never lose sight of the fact that claim 17 expressly covers the use of equivalent
amounts of triaryl phosphite and Cl or Br and in one of its alternatives (claim
10) it covers wherein an excess of Cl is maintained during the reaction
of the triaryl phosphite and Cl.
Clearly, a posita using a 2(TPP):1(Cl) ratio or an excess of TPP of similar magnitude
would not be practicing the invention.
 With respect
to the need to use the kinetic complex quickly and to make it or use it at -10º
C or less, the Court has already reviewed, discussing the issue of utility, the
passages of TX-211 relied upon by Apotex, and Dr. McClelland’s views in that
 On p. 5, line 24 of the disclosure, the posita is told that:
To maximize the production and stability of the kinetically controlled product, reaction conditions are selected so as to minimize the potential for thermodynamic equilibrium of the initial product of the reaction. Most simply conditions for kinetic control are achieved both by lowering the reaction temperature and the temperature of the kinetic product after it is formed, and by minimizing [the] time allowed for thermodynamic equilibrium, such as by utilizing the kinetic product in a subsequent reaction immediately after it has been prepared.
It is difficult to see how a posita would not fully understand how to practice the invention.
 Finally, with respect to the need to further identify the kinetic complex by reference, for example, to a specific or more precise chemical formula. Given the construction adopted by the Court and the Court’s previous findings, the Court accepts Dr. Baldwin’s views on the matter. He was very clear that the specification easily provides sufficient chemical information to distinguish the kinetic complex from the latter formed product, that is, the thermodynamic product. The Court certainly agrees with Lilly’s submissions that there is a preponderance of evidence that with knowledge of what is disclosed in the ‘007 patent, it is relatively simple to observe the conversion of the kinetic complex to the thermodynamic product using 31P NMR analysis.
11. Remedies and Costs
11.1. Disentitlement and Set-off
 In its written submissions and at oral argument, Apotex argues that Lilly’s conduct in respect of the Shionogi patents should disentitle Lilly from any relief (equitable or otherwise) from its claim of infringement in respect of all the patents at issue. Apotex also argues that, even if its claims under the Competition Act, R.S.C. 1985, c. C-34, are time
barred, Lilly’s otherwise anticompetitive
acts should excuse Apotex from liability for patent infringement under the
doctrine of equitable set-off.
 First, it is
important to note that although the defence in the main action does include an
allegation with respect to disentitlement, there is no allegation with respect
to equitable set-off. Moreover, Apotex presented no evidence to establish a s.
45 offence in the main action. It did not agree with the plaintiffs (as
was done with respect to some evidence filed by consent in the counterclaim to
avoid repetition) that the evidence filed in the context of the counterclaim
would be entered by consent in the main action.
 When Lilly
raised the absence of such allegation in the defence, Apotex argued that this
was simply a procedural error which caused no prejudice to Lilly for they knew
from the allegation at para. 112 of the counterclaim that the
defendant was seeking set-off.
 That said, even if it were possible for the Court to import, as suggested, the evidence filed in the counterclaim, which includes evidence by Shionogi who is not a party to the main action, the Court is of the view that Apotex’s counterclaim is without merit because it is time-barred and Apotex failed to establish that it suffered a loss arising from the alleged anti-competitive conduct.
 If Apotex’s competition claim cannot stand in the context of its counterclaim, it cannot stand as a defence to Lilly’s claim in the main action.
 However, in the event I have erred with respect to the merits of Apotex’s counterclaim, but am correct in respect of my conclusion that the competition counterclaim is time-barred, it may be open to Apotex to introduce its competition counterclaim as a defence to Lilly’s infringement action. Defences raised under the doctrine of equitable set-off are not subject to the expiration of limitations periods (see Canada Trustco Mortgage Co. v. Pierce Estate; Pierce v. Canada Trustco Mortgage Co. (2005), 254 D.L.R. (4th) 79, 197 O.A.C. 369 (Trustco) at para. 4). No case law was provided on this point in respect of disentitlement.
 The assertion of equitable set-off and disentitlement by Apotex seeks to weigh Lilly’s conduct vis-à-vis Shionogi against Lilly’s claims for infringement under the Patent Act. For the reasons that follow, I am of the view that in this particular case, Apotex cannot invoke its allegations of anticompetitive behaviour to evade its liability for infringement through disentitlement or equitable set-off.
 The nature of disentitlement was discussed by Justice Sharlow in Volkswagen Canada Inc. v. Access International Automotive Ltd., 2001 FCA 79,  3 F.C. 311, where she concluded that, in order for disentitlement to be operative a defendant must establish a link between "the alleged unlawful behaviour and the equitable remedy sought by the patent holder that could support an unclean hands defence." (at para. 25; emphasis added, see also Sanofi-Aventis Canada Inc. v. Apotex Inc., 2008 FCA 175, 66 C.P.R. (4th) 6, paras. 14-16) A similar conclusion was reached by Justice Hugessen in Procter & Gamble Co. v. Kimberley-Clark of Canada Ltd. (1990), 29 C.P.R. (3d) 545,  F.C.J. No. 58 (QL) (F.C.A.):
For past conduct to be relevant to a refusal of equitable relief under the "clean hands" doctrine, relief to which the party would otherwise be entitled, such conduct must relate directly to the subject matter of the plaintiff's claim, in this case their patent.
[At 546; emphasis added.]
 Justice Rothstein (as he then was), framed the relevant inquiry into disentitlement as follows:
It is apparent that it is not any alleged inappropriate conduct of a party that may be relevant in the consideration of whether or not to grant equitable relief. The inappropriate conduct must relate directly to the subject matter of the plaintiff's claim.
[Visx Inc. v. Nidek Co., (1994), 87 F.T.R. 96, 58 C.P.R. (3d) 51 (F.C.) (Visx), para. 5, emphasis added.]
 Thus, the
Court cannot agree with Apotex that the defence of disentitlement could be a
total bar to the claim of Lilly given that its rights to sue for infringement
are based on a statute and not solely on equity. In my view, it could only be considered
in respect of Lilly’s right to elect as this is an equitable form of relief.
 In contrast, equitable set-off constitutes a substantive defence to a claim, and would (if successful) vitiate any relief, equitable or otherwise, sought by a plaintiff (see Trustco paras. 43-46, citing Henriksens Rederi A/S v. PHZ Rolimpex,  3 All E.R. 589 (C.A.) (per Lord Justice Denning)).
 The principles underlying equitable set-off, including relevant Canadian and English authorities, were canvassed by the Saskatchewan Court of Appeal in Saskatchewan Wheat Pool v. Feduk, 2003 SKCA 46,  2 W.W.R. 69:
The starting point is Holt v. Telford
where Wilson J., for the Court, quoted a statement of the applicable principles
for equitable set-off found in Coba Industries Ltd. v. Millie's Holdings
(Canada) Ltd. et al:
1. The party relying on a set-off must show some equitable ground for being protected against his adversary's demands: Rawson et al v. Samuel (1841), Cr. & Ph. 161, 41 E.R. 451.
2. The equitable ground must go to the very root of the plaintiff's claim before a set-off will be allowed: British Anzani.
3. A cross-claim must be so clearly connected with the demand of the plaintiff that it would be manifestly unjust to allow the plaintiff to enforce payment without taking into consideration the cross-claim: Federal Commerce & Navigation Ltd.
4. The plaintiff's claim and the cross-claim need not arise out of the same contract: Bankes v. Jarvis,  1 K.B. 549; British Anzani.
5. Unliquidated claims are on the same footing as liquidated claims: the Newfoundland case.
[Footnotes omitted, emphasis added.]
 The Saskatchewan Court of Appeal went on to cite Lord Justice Denning in Federal Commerce & Navigation Co. Ltd. v. Molena Alpha Inc.,  3 All E.R. 1066 (C.A.) (Federal Commerce), aff'd on other grounds  A.C. 757 (H.L.), where the following test was articulated in respect of claims of equitable set-off:
This question must be asked in each case as it arises for decision; and then, from case to case, we shall build up a series of precedents to guide those who come after us. But one thing is quite clear: it is not every cross-claim which can be deducted. It is only cross-claims that arise out of the same transaction or are closely connected with it. And it is only cross-claims which go directly to impeach the plaintiff's demands, that is, so closely connected with his demands that it would be manifestly unjust to allow him to enforce payment without taking into account the cross-claim.
(at 1078; see also Old Mac's Pty. Ltd. v. Cavallo Horse & Rider Inc., 2007 BCSC 726, 157 A.C.W.S. (3d) 944, para. 39; Cam-Net Communications v. Vancouver Telephone Co., 1999 BCCA 751, 182 D.L.R. (4th) 436, paras. 46-49).
 While the scope of disentitlement and equitable set-off are different, both defences ask a common question which both Federal Commerce and Visx frame in similar ways: does the unacceptable or unlawful conduct of Lilly go to the root or otherwise serve to impeach its claim and in such circumstances should the liability of Apotex be excused.
 There is no dispute in this litigation that Lilly is the owner of all eight patents at issue. Nothing in the Patent Act prevents a patent holder from assigning their rights to another party. While such an assignment can give rise to anti-competitive effects (see prior decision of the Federal Court of Appeal in this case on the summary judgment motions (2005 FCA 361,  2 F.C.R. 477), at para. 27), such an outcome does not otherwise impeach ownership rights in a patent. Put plainly, the anticompetitive consequences of an assignment of patent rights do not in and of themselves undermine or undo a lawful assignment of patent rights. Obviously, they can have no effect on the ownership of the Lilly patents.
 While Apotex’s allegations of anticompetitive behaviour against Lilly are related to the assignment of Shionogi’s patent rights, they do not in my view impeach Lilly’s title to any of these patents.
 The Court is convinced that there is no relationship between the infringing acts of Apotex, which are the subject of the main action, and the alleged unlawful behaviour. Apotex would have infringed the Shionogi patents, whoever owned them. This will be explained in more detail in my reasons dealing with the counterclaim.
 Even assuming that an anticompetitive act could go to the root of a patent infringement claim, I would decline in this case to exercise my discretion to allow Apotex access to the equitable set-off or disentitlement. First, because of the evidentiary issue discussed earlier. Second, because, as mentioned, in my view, it is most likely that Apotex would have infringed the Shionogi patents regardless of who owned them and it would not be unjust in this case to impose on Apotex the payment of the damages arising from its illegal actions.
 Thirdly, it
cannot go unstated that the Patent Act and the Competition Act are
distinct statutory regimes. What Apotex seeks to do vis-à-vis its
disentitlement and equitable set-off claims is resurrect its time-barred claim
under the Competition Act and give it new life in the context of a
patent infringement action. Such a result cannot be countenanced. It could
not have been Parliament’s intent in enacting the Competition Act that
its “special remedies” provisions would serve as a defence to a patent
infringement action or to otherwise interfere with the remedies flowing from a
finding of infringement.
 To reiterate, an assignment of patent rights may give rise to anti-competitive consequences. However, to the extent they do so, such claims must be adjudicated within the confines of the Competition Act. If judgment is obtained, it can then be set-off against any judgment dealing with infringement damages. To allow otherwise would allow for a fusion of two statutory regimes whose object and purpose are fundamentally distinct.
 I will now examine the appropriate remedy. Lilly has requested the following:
- An election between its damages or an accounting of Apotex’s profits
- Exemplary/punitive damages
- Pre and post judgment interest at a rate of 9% per year, compounded
 With regard
to the remedy of an accounting of profits, the Federal Court of Appeal has
recently reiterated the well established principle that “a trial judge has
complete discretion in deciding whether or not to grant this equitable remedy”
(Merck & Co. (FCA)). It is equally well established that a
successful plaintiff in a patent case does not automatically benefit from this
remedy. In AlliedSignal Inc. v. Du Pont Canada Inc. (1995), 95 F.T.R.
320 n, 184 N.R. 113 (F.C.A.), Justice Alice Desjardins held that “the choice
between the two remedies [damages or accounting of profits] cannot be left
entirely to the successful plaintiff.” (para. 77)
 In past cases, the right to elect has been denied for a variety of reasons; delay in bringing forward the action for infringement (Consolboard (1978)); “misconduct on the part of the patentee” and “the good faith of an infringer” (Beloit Canada Ltd. v. Valmet-Dominion Inc.,  3 F.C. 497, 214 N.R. 85 (F.C.A.), paras. 111 and 119); and, where “the Plaintiffs essentially threw in the towel and left this action to proceed in a leisurely fashion” (Merck & Co. v. Apotex Inc., 2006 FC 524, 282 F.T.R. 161, (Merck & Co. (FC)) para. 229). Obviously, all of these cases are very fact specific and quite distinguishable from the present situation. Still, they are useful with respect to factors to be considered in the course of the exercise of this Court’s discretion.
submits that Lilly does not come before this Court with clean hands, given the
evidence of its anti-competitive conduct in acquiring title to the Shionogi
patents and in attempting to prevent generic entry into the market for dosage
form cefaclor. Fundamentally, Apotex also argues that the right to elect should
be denied as Lilly has not diligently prosecuted this action, which took nearly
eleven years to come to trial and is inherently complex. Finally, Apotex
submits that the fact that the type of infringement, that is by importation,
should be considered by this Court and lead it to deny the right to elect.
 Apotex argues forcefully against the awarding of the right to elect and advocated that damages be assessed only in accordance with a reasonable royalty. Then Apotex performs an intellectual volte-face to argue that should the Court refuse to limit damages to the equivalent of a reasonable royalty, then Lilly should only be entitled to an accounting of profits, which represents less than the amount of general damages which would be payable.
 Although Apotex does not appear to make a distinction between the infringement of the Lilly and the Shionogi patents, the issue of royalties can only apply to the Shionogi patents. Also, a reasonable royalty is only acceptable as a measure of damages for sales made by the infringer that would not have been made by the plaintiff. Although Lilly was not practicing the Shionogi patents per say, it had a product on the market, the sale of which was allegedly harmed by Apotex’s entry with an infringing product.
 In such circumstances, the Court sees no good reason to limit Lilly’s damages to a reasonable royalty. Having considered and evaluated the circumstances of this case overall, the Court is satisfied that the proper exercise of its discretion is to afford Lilly the right to elect between an accounting of profits and damages. Should Lilly elect for damages, it should be clear that they will have to establish what sales were directly lost as a result of Apotex’s infringement.
 With respect to the alleged anti-competitive conduct, as mentioned above, the Court does not believe that in this case such allegations are valid basis for denying Lilly the right to elect.
 As for the alleged delay, while this action did indeed take nearly eleven years to get to trial, the Court is not of the opinion that this constitutes an excessive delay in the circumstances and does not find elements of misbehaviour in the course of the conduct of the action by Lilly that would justify denying the remedy sought. It should also be noted that in this case, the last of the patents at issue expired on July 26, 2000. As such, any delay in getting the present action to trial after this date is somewhat irrelevant for the purposes of an accounting for profits as no infringing act occurred thereafter.
 In addition, Apotex was aware that Lilly and Shionogi opposed the issuance of an NOC for Apo-cefaclor as soon as 1993, date at which the PM (NOC) proceedings were instituted against it. As soon as Apotex entered the market, Lilly instituted an action for infringement. While it was discontinued, the second action came shortly thereafter, in June, 1997. Apotex knew or ought to have known that Lilly would enforce its patent rights.
 Rather, Apotex’s insistence that the Court deny Lilly the right to elect and limit damages to a reasonable royalty is consistent with its assertion that it has the right to infringe at the lowest possible cost. As will be reiterated in the reasons dismissing Apotex’s counterclaim, the Court cannot endorse such an approach.
11.3. Exemplary/Punitive Damages
 In Lubrizol Corp. v. Imperial Oil Ltd.,  3 F.C. 40, 197 N.R. 241 the Federal Court of Appeal, citing the Supreme Court of Canada in Hill v. Church of Scientology of Toronto,  2 S.C.R. 1130, (1995), 24 O.R. (3d) 865, held that “the Court cannot decide whether exemplary damages are required until after it decides whether the general damages were insufficient for punishment and deterrent purposes. In other words, the Court must first assess the general damages.” (para. 36) Therefore, the Court cannot award punitive damages at this stage as the question of general damages has been bifurcated.
 However, the Court may rationally determine if the circumstances here “warrant the addition of punishment to compensation in a civil action” (Whiten v. Pilot Insurance Co., 2002 SCC 18,  1 S.C.R. 595, para. 67 (Whiten)). In this case, the addition of punishment is not warranted and punitive damages will not be awarded, irrespective of the result arrived at concerning the quantification of damages or the amount of profits.
 In crafting the appropriate remedy, Lord Diplock in Broome v. Cassell & Co.,  A.C. 1027 opined that Courts must strive to determine “how, in particular, an award would further one or other of the objectives of the law” (emphasis in the original, para. 71). The objectives of punitive damages have been established as “punishment (in the sense of retribution), deterrence of the wrongdoer and others, and denunciation” (Whiten, para. 68).
 Given that punitive damages are used to attain these objectives when general damages are insufficient to do so, the conduct which attracts such an award must be rationally connected to the conduct for which compensation is awarded. Lilly bases its claim for punitive damages on Apotex’s conduct in the course of the prosecution of this action. This has nothing to do with the conduct for which compensation is awarded, which is infringement. Applying these principles, the Court concludes that this conduct is more properly dealt with in the context of an award for costs.
 This position is consistent with that taken by Prothonotary Roza Aronovitch in a decision dealing with proposed amendments to Lilly’s statement of claim in 2003. At the time, Lilly sought to add allegations pertaining to Apotex’s conduct in prosecuting the action as a basis for its claim of punitive damages. Leave in this regard was denied as the conduct alleged in the amended plea, which is of the same nature than that which is advanced today, “is not conduct that can ground an award of punitive or exemplary damages.” (Eli Lilly and Co. v. Apotex Inc., 2003 FC 978,  1 F.C.R. 360, para. 14)
 In support of this conclusion, Prothonotary Aronovitch explains that:
The underlying action, is on account of patent infringement. Apotex’s alleged failure to disclose relevant documents such as to needlessly prolong the prosecution of this action and cause the plaintiffs to incur expense, is not a means, aggravation or continuation, of the alleged infringement. Any delay and additional expense Lilly incurred in prosecuting the action can be compensated by an award of costs.
 There is some basis for arguing that since Apotex had full knowledge of all the facts and nonetheless chose to engage in conduct which infringed on Lilly’s patent rights, its conduct is in fact particularly egregious, warranting an award of punitive damages. However, this element has already been weighted in affording Lilly with the right to elect for an accounting of Apotex’s profits. Thus, the comments of the Supreme Court of Canada in Whiten to the effect that “it is rational to use punitive damages to relieve a wrongdoer of its profit where compensatory damages would amount to nothing more than a licence fee to earn greater profits through outrageous disregard of the legal or equitable rights of others” (para. 72) do not apply to the case at bar.
 While the
awarding of punitive damages to Lilly was contested on the merits by Apotex, it
was also submitted that Lilly’s statement of claim did not adequately support
its claim in this respect. In order to remedy this situation, Lilly sought
leave to amend its statement of claim on December 19, 2008. Lilly’s motion
raises concerns with regards to whether it constitutes a collateral attack on
the 2003 decision of Prothonotary Aronovitch cited above. Despite this, the
Court has examined the merits of Lilly’s claim for punitive damages without
regard to the question as to whether or not such claim was properly pleaded.
Given the Court’s conclusion on the merits in this respect, Lilly’s motion is
entirely academic. The claim for punitive damages would fail irrespective of
whether leave to amend was granted or not.
 When a cause of action arises outside of, or in more than one, province, subs. 36(2) of the Federal Courts Act, R.S.C. 1985, c. F-7, applies, giving jurisdiction to this Court to include an award of prejudgment interest, at a rate it considers reasonable in the circumstances, on a sum of money representing damages. Unless the Court is awarding interest pursuant to para. 36(4)(f) of the Federal Courts Act (such as interest awarded in equity) or exercising its admiralty jurisdiction, Apotex’s position that pre-judgment interest awarded on an award for damages cannot be compounded is correct.
 By operation of para. 36(4)(b) of the Federal Courts Act, interest cannot be awarded by virtue of subs. 36(2) on interest accruing under s. 36. This, the Courts have determined, precludes prejudgment compound interest from being awarded on damages (Merck & Co. (FCA)).
 However, that is not to say that the reference which will deal with the quantification of damages or profits (depending on Lilly’s election) cannot award compounded pre-judgment interest (even at an elevated rate) as an element of compensation, provided it is adequately proven by Lilly. When so awarded, interest becomes part of a damage award and is not itself an award of interest.
 In Bank of America Canada v. Mutual Trust Co., 2002 SCC 43,  2 S.C.R. 601 (Bank of America Canada), Justice John Major held that “[c]ompound interest is now commonplace. […] It is for reasons such as these that the common law now incorporates the economic reality of compound interest. The restrictions of the past should not be used today to separate the legal system from the world at large.” (para. 44)
 Justice Major recognized that “the court has the jurisdiction to award compound interest under the court’s general equitable jurisdiction” (para. 42). This right is such as what is covered by para. 128(4)(g) of the Courts of Justice Act, R.S.O. 1990, c. C.43, the equivalent of para. 36(4)(f) of the Federal Courts Act, which is also mirrored at para. 2(2)(i) of Alberta’s Judgment Interest Act, R.S.A. 2000, c. J-1.
 Bank of America Canada is a contract case and on that basis the Ontario Court of Appeal had concluded that equity did not apply and thus there was no interest payable “by a right other than under [s. 128]” and the prohibition of an award of interest on interest provided for at para. 128(4)(b) of the Courts of Justice Act applied. However, the Supreme Court of Canada held that para. 128(4)(g) of the Courts of Justice Act does not exist purely to provide for the right to receive compound interest in equity. A common law right of interest can be an “other right” which avoids the application of the above-mentioned statutes. This decision has led the Courts to re-examine the issue of compound interest.
 For example, the Alberta Court of Appeal in Alberta (Minister of Infrastructure) v. Nilsson, 2002 ABCA 283, 220 D.L.R. (4th) 474 concluded that “Bank of America mandates a common law availability where compound interest is necessary to compensate accurately for the proven damages.” (para. 185) This is justified in its view as:
[N]otions of commercial fairness favoured an award of compound interest, as did the principle of restitutio in integrum. It recognized that if the plaintiffs were not awarded compound interest, they would suffer incompensable loss […]
 What is more, the reasoning of Bank of America Canada has even been applied in British Columbia, where the relevant legislation, the Court Order Interest Act, R.S.B.C. 1996, c. 79, s. 2, does not have a proviso for the exemption of the statute where interest is payable by virtue of an “other right”. For example, in Morriss v. British Columbia, 2007 BCCA 337, 281 D.L.R. (4th) 702, the British Columbia Court of Appeal held that “where compound interest is required to provide full compensation, an award of compound interest generally should not be discretionary. In that context, the plaintiff is entitled to compound interest as a matter of law.” (para. 37)
 In the present circumstances, the Court is not in a position to evaluate whether or not Lilly is entitled to pre-judgment interest as part of its damages for, as mentioned, “any question as to damages suffered by [Lilly]” has been bifurcated pursuant to the November 29, 1999 order of Justice Hugessen. Thus, in the course of the reference, Lilly has the opportunity to attempt to establish that an award of compound interest is required to provide full compensation, as well as the appropriate rate of interest to achieve this aim. If this is established, the interest so payable is by a right other than under subs. 36(2) of the Federal Courts Act and para. 36(4)(f) of this Act would prevent the Court from awarding pre-judgment interest under its subs. 36(2).
 There is not real doubt that pre-judgment interest can and should be awarded in this case but the Court is unable, for the reasons just explained, to determine which provision of the Federal Courts Act is applicable. Therefore, in order to ensure that a form of pre-judgment interest is awarded irrespective of the outcome of the reference, the Court will grant simple pre-judgment interest at the rate to be calculated separately for each year since the infringing activity began at the average annual bank rate established by the Bank of Canada as the minimum rate at which the Bank of Canada makes short-term advances to the banks listed in Schedule 1 of the Bank Act, R.S.C. 1985, c. B-1. However, this award is conditional upon the reference judge not awarding interest under para. 36(4)(f) of the Federal Courts Act.
 As for the question of post-judgment interest, it is well established that the appropriate rate is 5%, not compounded, as established by s. 4 of the Interest Act, R.S.C. c. I-15 (Janssen-Ortho (2006), para. 166; Merck & Co. (FC), para. 241; and, Laboratoires Servier, para. 513).
 Lilly made detailed representations seeking to establish that Apotex’s conduct in the course of this action warrants the grant of solicitor-client costs. Among these elements, Lilly cites the failure to provide proper documents relating to manufacturing processes, late discovery productions, wasteful experiments rendered necessary by Apotex’s failure to provide proper discovery, lack of notice for testing conducted by Apotex, deficient pleadings, lack of pre-trial cooperation, unnecessary duplication of expert’s evidence and especially the failure to disclose, even to the Court (Justice Hugessen), communications with Lupin concerning its manufacturing processes. The Court also notes that while hundreds of prior art references were initially mentioned, Apotex failed to include many of those which were relied upon by its own experts, forcing Apotex to seek leave to amend in the course of the trial.
 In respect of the failure to disclose Lupin information and communications, Apotex has chosen not to present any evidence as to how it happened and why this failure was not or could not have been discovered earlier. It is difficult to imagine that the file would not have been closely revised in preparation for trial, regardless of whether the July 4, 2000 letter from Lupin was inadvertently filed by a clerk without bringing it to the attention of the lawyers concerned. No good explanation was given as